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ABSTRACT OF THE DISSERTATION
Production of Medical Radioisotopes using Titanium Accelerator Targets
by
C. Shaun Loveless

Doctor of Philosophy in Chemistry
Washington University in St. Louis, 2020
Professor Suzanne E. Lapi, Co-Chair
Professor Lee G. Sobotka, Co-Chair

Theranostic radiopharmaceuticals enable diagnostic imaging and radionuclide therapy in patients
using a single molecular agent labeled with a diagnostic-therapeutic pair (e.g.,
theranostic radionuclide (e.g.,

131

68

Ga/177Lu) or a

I). This theranostic approach can help inform patient-specific

treatment plans and improve clinical outcomes. Radionuclide pairs used in theranostic agents fall
into two categories: pseudo matched-pairs (e.g.,

68

Ga/177Lu) and matched-pairs (e.g.,

124 131

I/

I).

Pseudo matched-pair radionuclides have similar chemistries and pharmacokinetics when bound to
the same bioconjugate molecule. In contrast, identical chemistries and pharmacokinetics can be
obtained by using the matched-pair radionuclides.
The isotopes of Sc include two diagnostic radioisotopes,
radioisotope,

47

43

Sc &

44

Sc, and one theranostic

Sc, that have nuclear properties well-suited for use with bioconjugate molecules

that target disease. These novel Sc radioisotopes can be produced using Ca or Ti nuclei; however,
the optimal route for their production is still being actively investigated. Thus, the aim of this work
was to investigate the production of 43Sc, 44Sc, and 47Sc using proton- and photon-induced nuclear
reactions at energies up to 24 MeV on Ti nuclei, the digestion of Ti target material, and the
xiii

purification of Sc radioisotopes from radioactive and non-radioactive impurities. Additional
studies were carried out to investigate the in vitro properties of PSMA-617 labeled with these
radioisotopes.
Solid target holders fabricated from Al, Nb, and Ta were designed and tested for use on a
negative-ion cyclotron and medical electron linear accelerator. These targets mounted metal foil
and metal oxide materials for irradiation and were tested at varying conditions (beam energy and
current) to determine their durability and the best parameters for maximizing radionuclide yield.
These targets were used to experimentally validate the predicted yields from the
nat
50

Ti(p,x)43,44g,44m,47Sc,

48

Ti(γ,p)47Sc,

46

Ti(p,α)43Sc,

47

Ti(p,α)44g,44mSc,

48

Ti(p,2p)47Sc, and

Ti(p,α)47Sc nuclear reactions. Methods to digest Ti foil and TiO2 were developed that combined

pressure, heat, and the in situ generation of HF in a closed-vessel. The typical digestion times for
these methods were 45 min (Ti foil) and 75 min (TiO2) and the average digestion efficiencies were
(98 ± 3)% and (95 ± 1)%, respectively. The purification of aqueous Sc was investigated using three
cation exchange resins, branched N,N,N’,N’-tetra-2-ethylhexyldiglycolamide (BDGA) and two
styrene divinylbenzene copolymer lattices functionalized with either sulphonic acid (AG MP-50)
or iminodiacetic acid (CHELEX 100). Average Sc recoveries of (77 ± 7)% and (94 ± 3)% were
realized using either a two-step purification (AG MP-50 followed by CHELEX 100) or a singlestep purification using BDGA, respectively. After purification, the concentrations of common
trace metal contaminants (e.g., Fe, Cu, and Zn) that can interfere with Sc chemistry were
approximately 1 mg/L or less. Enriched Ti target materials (i.e.,

46

Ti,

47

Ti,

48

Ti, and

50

Ti) were

irradiated and recovered via alkali precipitation at pH 8 using ammonia solution as a titrant.
Recovered precipitant was combusted to regenerate the enriched TiO2 for iterative use. The
average percent recoveries of Ti from digested

nat

xiv

Ti foil and

nat

TiO2 collected after precipitation

and combustion were (108 ± 8)% and (104 ± 5)%, respectively. High-purity Sc radioisotopes were
used to label two bioconjugates: DOTATOC and PSMA-617, and the in vitro properties of these
radiolabeled compounds were investigated using AR42J or LNCaP cells. The radiochemical yield
of DOTATOC labeled with 47Sc (1.28 mg/mL) was greater than 99.9%. A blocking study with the
somatostatin receptor subtype 2 (SSTR2) agonist Octreotide showed receptor-mediated uptake of
[47Sc]Sc-DOTATOC in AR42J (SSTR2+) cells. Similarly, the radiochemical yields of PSMA-617
labeled with 43Sc and 47Sc were greater than 99.9% at molar activities between 32-74 MBq/nmol.
The stability of [43Sc/47Sc]Sc-PSMA-617 was greater than 95% at 168 h in PBS, human serum,
and mouse serum. The percentages of [43Sc/47Sc]Sc-PSMA-617 associated with LNCaP (PSMA+)
and PC3 (PSMA-) cells after 4 h of incubation at 37 °C were (22 ± 1)% and (0.30 ± 0.01)%,
respectively.
These results demonstrated a robust method for the cyclotron production of Sc radioisotopes
via proton-induced reactions that could be used with natural or enriched TiO2 target material. In
turn, DOTATOC and PSMA-617 were labeled with high-purity Sc radioisotopes produced via
these methods and their in vitro properties were investigated. The strategies developed in this work
and data from initial studies will be used to support future work to compare the in vitro and in vivo
efficacy of [43Sc/47Sc]Sc-PSMA-617 to [68Ga/177Lu]Ga/Lu-PSMA-617.

xv

Chapter 1: Introduction
1.1

Research Focus

The purpose of this research is to investigate the production of different Sc radioisotopes via
nuclear reactions on titanium targets, the development of different separation techniques to purify
these radionuclides, the preparation of different radiolabeled bioconjugate molecules, and the in
vitro properties of these radiolabeled compounds. Ultimately, this research aims to produce
medically relevant radionuclides, which can be used to diagnose and treat disease. Moreover, as
no consensus exists on the best route to produce and supply Sc radioisotopes, this research
developed methods that could be easily adopted for the production of research quantities of highpurity 43Sc, 44Sc, and 47Sc.
The role of radionuclides in medicine, a select history of their development, and the chart of
nuclides are presented in Section 1.2 to lay a foundation for the importance of this work. The
different modes of radioactive decay (see Section 1.3) are presented along with a description of
the techniques used for molecular imaging in nuclear medicine (see Section 1.4). The application
of targeted radionuclide therapy to treat disease is discussed in Section 1.5. Two examples of
theranostic agents that combine diagnostic imaging and radionuclide therapy are given in Section
1.6 to highlight recent successes of this theranostic approach. These successes have motivated
research directed at developing new methods of production and supply of novel medical
radionuclides.
In Chapter 2, the nuclear properties of different radioisotopes of Sc (see Section 2.1) and V
(see Section 2.2) are presented. The means and techniques to produce radionuclides are discussed
in Section 2.4. The production of the radioisotopes of interest investigated in this work is presented
1

in Section 2.5 (Sc radioisotopes) and Section 2.6 (44Ti). The digestion of solid target materials and
techniques for chemical purification of radionuclides are presented in Section 2.7.
Findings from the photonuclear production, purification, and in vitro evaluation of the
theranostic radionuclide
radioisotopes from

nat

47

Sc (Chapter 3) and the cyclotron production and separation of Sc

Ti metal and natTiO2 (Chapter 4) are presented and discussed. Results from

in vitro studies carried out using Sc radionuclides produced in this work are presented in Chapter
5. Lastly, opportunities for future work, and a brief concluding summary that details how the
findings in this work contribute to knowledge pertinent to the production and supply of these
important Sc radionuclides are outlined in Chapter 6.

1.2

Radionuclides in Medicine

High-energy rays from radioactive substances were used as early as 1899 to treat rodent ulcer and
epithelioma; however, at the time the mechanism of action was unknown.1 The invention of a
stationary gamma camera (Anger camera) in 1957 and subsequent work in the 1960s and 1970s to
develop platforms for tomographic imaging laid a foundation for modern nuclear medicine.2, 3
Today, modern nuclear medicine employs different strategies to deliver radioactive compounds in
a targeted manner to localized and non-localized disease for treatment or diagnostic imaging.4 In
the field of theranostics, these two applications are combined such that treatment of disease is
guided by diagnostic imaging. The production of new radionuclides and study of their nuclear
properties plays an important role in the development of new radiopharmaceuticals, which are
becoming increasingly used in personalized medicine.5 This work investigates the production and
purification of different diagnostic and theranostic radioisotopes of Sc for incorporation into
theranostic agents.

2

1.2.1

History

The history of radionuclides in medicine began with the Nobel Laureates Wilhelm Konrad
Roentgen (Nobel Prize in Physics, 1901)6, Antoine Henri Becquerel, Marie and Pierre Curie
(Nobel Prize in Physics, 1903)7, and Frédéric Joliot and Iréne Joliot-Curie (Nobel Prize in
Chemistry, 1935). In particular, the work by Frédéric Joliot and Iréne Joliot-Curie was the first
demonstration of radionuclides produced via particle-induced reactions.8 Inspired by this work,
Lauritsen et al. (1934) bombarded LiF, Be, H3BO3, C, Mg and Al with deuterons and reported the
characteristics of the produced radionuclides.9, 10 Similarly, John Cockcroft and Ernest Walton
bombarded C, N, and O nuclei using protons (p), deuterons (d), and alpha (α) particles, to produce
radionuclides, including medically relevant

11

C (t1/2 = 20.36 min) and

13

N (t1/2 = 9.97 min).11, 12

The production of artificial radionuclides was further advanced by the work of Ernest Lawrence,
which included the construction of a series of cyclotrons at the University of California at Berkeley
capable of delivering different particles of increasing energy and intensity.13, 14 It was these efforts
that led to the discovery of the element technetium, and

131

I (t1/2 = 8.02 d) by Carlo Perrier and

Emilio Segré (1937) and Glenn Seaborg and John Livingood (1938), respectively.

15-17

Today,

99m

Tc (t1/2 = 6.01 h) is the most widely used diagnostic radionuclide in nuclear medicine and 131I,

a theranostic radionuclide, is still used to diagnose and treat differentiated cancer of the thyroid.15

1.2.2

The Chart of the Nuclides

The proliferation and application of different particle sources led to the discovery of thousands of
distinct nuclides over the last 120 years.18 The chart of nuclides (Figure 1-1) is a visual map of all
known nuclei and contains nuclear data on 4,040 experimentally-observed nuclide ground states
and isomers19.

3

Figure 1-1. The chart of the nuclides20
The nuclides are organized with the neutron number (N) on the abscissa and the proton number
(Z) on the ordinate. In this representation, the coloring of each box (nuclide) denotes the observed
type of radioactive decay: stable (black), alpha decay (yellow), positron decay/electron capture
(red), beta decay (blue), and spontaneous fission (green).19 Nuclides that appear along the same
row are isotopes (constant Z) and nuclides that have the same mass number (N + Z) are isobars.
The isobars form 45° lines that have a negative slope. Stable nuclides at low Z have approximately
equal numbers of protons and neutrons. This is evidenced by a line at N = Z of stable nuclides
(black). However, nuclides with larger Z values require more neutrons (N > Z) to be stable. This
trend is observed in Figure 1-1 as the line of stable nuclides becomes non-linear as Z increases.
This line through the stable nuclides can be described as the line of beta stability. Moreover,
the line of stability can be further visualized as a valley of stability based on the binding energy
4

(BE) of each nuclide. The BE is the energy required to break apart a nuclide into its proton and
neutron components. If the mass is set as a third dimension than stable nuclides (with the lowest
mass at a certain isobar) will lie towards the valley and unstable nuclides (with combinations of N
and Z that lie off the N = Z line) will lie further up the sides of the valley of stability.
Characteristics of these nuclides which lie off the valley of stability, like their radioactive decay
and nuclear structure, can determine their potential use in medicine to diagnostically image and
treat disease. Some of these radionuclides, like

131

I, have been developed for use in medicine to

diagnose and treat disease based on their unique nuclear characteristics. Others, like 60Co (t1/2 =
5.27 y), are used for gamma sterilization (irradiation of material to kill microorganisms) and
industrial radiography (non-destructive testing using γ-rays to verify internal structure).

1.3

Radioactive Decay

The nucleus of an atom consists of a densely packed arrangement of nucleons (i.e. protons and
neutrons). Radionuclides are atoms with a nucleus that contains an unstable arrangement of
nucleons in a state of excess energy. The process of radioactive decay occurs when a nucleus emits
radiation (i.e., releases energy) spontaneously to arrive at a less energetic and more stable state.
Radioactive decay can be grouped into four general modes that include alpha (α), beta (β), electron
capture (EC) and gamma (γ) decay. In α, β, and EC decay, the mass-energy equivalence between
the reactant (parent nuclide) and products (daughter nuclide and particles) is conserved by a Qvalue. During spontaneous radioactive decay, the Q-value will always be positive.

1.3.1

Units of Radioactive Decay

Radioactivity refers to the amount of ionizing radiation emitted by a material, which represents
how many atoms in the material decay in a given period of time. The initial unit for measuring the
amount of radioactivity was defined by Ernest Rutherford (1910) as the curie (Ci).21 A Ci was
5

defined as the amount of radioactivity in one gram of 226Ra (t1/2 = 1600 y), which is now fixed at
3.7 × 1010 decays per second. The becquerel (Bq), defined as one nuclear decay per second, was
given official status as the SI unit of activity in 1975.22 Thus, 1 Ci is equal to 3.7 × 1010 Bq
(approximately the number of decays per second that occur in one gram of 226Ra).

1.3.2

Alpha Decay

The first mode, α decay, occurs when a heavy nucleus emits a 4He2+ nucleus (i.e., an α particle).
Alpha particles are monoenergetic and their loss by parent nuclei result in transmutation to a
daughter with four fewer nucleons (two protons and two neutrons), represented by Equation 1-1.
Equation 1-2 shows the α decay of the therapeutic radionuclide 211At (t1/2 = 7.2 h).23
A
ZX

→

211
83At

(A−4) 2−
(Z−2)Y(N−2)

→

207 2−
81Bi

+ 42He2+
2 + Qα

(1-1)

+ 42He2+ + Qα

(1-2)

The emitted heavy α particle travels in a relatively straight path and produces intense ionization
due to its 2+ charge. It is stopped in 2-10 cm of air depending upon its energy, and has an
approximate range of 30-50 μm in body tissues.24 Due to their short range in body tissues, α
particles can deposit cell-killing ionizing radiation in a small region, and are used for treatment of
small nonlocalized neoplasms and micrometastases.25

1.3.3

Beta Decay

The second mode, β decay, can occur via two different mechanisms, electron decay (β-) and
positron decay (β+). These types of decay result in no change in the total number of nucleons (A).
Decay by β- and β+ is accompanied by emission of an antineutrino (ῡe) or a neutrino (υe),
respectively. The energy and momentum associated with β- and β+ decay is conserved and shared
between the recoiling daughter (due to particle emission), the emitted electron (or positron), and
the emitted antineutrino (or neutrino). Electron and β+ decay end in a three-body final state where
6

the decay energies are shared between the daughter nucleus and the emitted particles. Beta particles
(i.e., electrons and positrons) are released with a continuous energy distribution that ranges from
zero to the maximum decay energy (Figure 1-2).

Figure 1-2. The beta spectrum of 210Bi26
In Figure 1-2, the width of the region defined by the dotted lines define the energy of a single
emitted antineutrino (Eυ = 0.76 MeV) and electron (Eel = 0.4 MeV). For each decay, the particle
energies can vary as long as their combined energy does not exceed the maximum decay energy
of 1.16 MeV.
Neutron-rich nuclei (right of the valley of beta stability, Figure 1-1) typically undergo β- decay
along an isobaric line. A nucleus that undergoes β- decay converts a neutron to a proton by emitting
an electron and antineutrino (Equation 1-3). The mass number of the parent remains unchanged,
but the atomic number of the daughter increases by one. Equation 1-4 shows the β- decay of the
therapeutic radionuclide 177Lu (t1/2 = 6.7 d).
A
ZX

→

A
(Z+1)Y

+

0
−1β

+ υ� + Qβ−

(1-3)
7

177
71Lu

→

177
72Hf

+

0
−1β

(1-4)

+ υ� + Q β−

Proton-rich nuclei (left of the line of beta stability, Figure 1-1) that have decay energies that
exceed 1.02 MeV can undergo β+ decay along an isobaric line. A nucleus that undergoes β+ decay
converts a proton to a neutron by emitting a positron and neutrino (Equation 1-5). The mass
number of the parent remains unchanged, but the atomic number of the daughter decreases by one
(the opposite of β- decay). Equation 1-6 shows the β+ decay of the diagnostic radionuclide 68Ga
(t1/2 = 68 min).
A
ZX

→

68
31Ga

A +
(Z−1)Y

→

68
+
30Zn

+

+

0
+1β

(1-5)

+ υ + Q β+

0
+1β

(1-6)

+ υ + Q β+

An important aspect of β+ decay is the emission of a positron (β+), an electron with a positive
charge. As the kinetic energy of the emitted positron is reduced via thermalization in its medium,
it will eventually undergo positron-electron annihilation (Equation 1-7) and produce two
annihilation photons. These photons are emitted in opposite directions in a collinear fashion
(approximately 180° apart).
β− + β+ → γ1 + γ2

(1-7)

Both the positron and electron have a rest energies of 0.511 MeV; thus, the photons have a total
combined energy of 1.022 MeV. The rest energy of both β particles (β- and β+) illustrate why only
proton-rich nuclei with decay energies exceeding 1.02 MeV can undergo β+ decay.
Beta particles have less mass than α particles and as a result experience different electronic
and nuclear interactions. They can be deflected multiple times in their medium due to their mass
and charge, and are stopped in tens to hundreds of centimeters of air depending upon the β particle
energy. In human tissues, β particles have an approximate range of 3 to 12 mm.25, 27 Lutetium-177
and other radionuclides that undergo β- decay (emitting low-energy electrons) are used for targeted
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radionuclide therapy. Unlike α particles, these electrons deposit their energy throughout a much
greater region and can deposit cell-killing ionizing radiation to medium and large heterogeneous
tumors. However, the long-range of these particles can result in damage to healthy tissue that
surrounds a targeted disease.25 Radionuclides that undergo β+ decay and emit positrons (like 68Ga)
have been clinically used for decades in nuclear medicine to diagnose diseases like cancer.

1.3.4

Electron Capture

The third mode involves proton-rich nuclei (left of the line of beta stability, Figure 1-1) that have
a decay energy of less than 1.02 MeV. Further, EC decay competes with β+ decay for these nuclei
when decay energies exceed 1.02 MeV. These proton-rich nuclei undergo decay by EC along an
isobaric line. Decay by EC involves the capture of an orbital electron by a nucleus that results in
the conversion of a proton into a neutron (Equation 1-8). Equation 1-9 shows the EC decay of
the cosmogenic radionuclide 7Be (t1/2 = 53.3 d).
A +
ZX

+ −10e →

7
+
4Be

A
(Z−1)Y

(1-8)

+ υ + QEC

+ −10e → 73Li + υ + QEC

(1-9)

The mass number of the parent remains unchanged, but the atomic number of the daughter
decreases by one (like β+ decay). This process ends in a two-body final state and results in the
emission of a monoenergetic neutrino. Further, the orbital shell vacancy is filled by a higher shell
electron. The difference in shell energy can be emitted as a characteristic x-ray or mediated by the
Auger effect. The Auger effect involves the transfer of the excess energy to an orbital electron,
which is ejected.28 In general, Auger electrons have energies of only a few eV. Auger electrons at
these energies have a range of a few nm to 100 μm in human tissues.29 The short range of Auger
electrons limits their ability to deposit cell-killing ionizing radiation to DNA and cells; thus,
therapeutic agents that incorporate Auger-emitting radionuclides require localization of the
9

radioactivity proximal to the cell nucleus.30

1.3.5

Isomeric Transition and Gamma Rays

After a nucleus undergoes α, β, or EC decay, the daughter nucleus may be in an excited state. The
final mode involves a nucleus in this intermediate state that undergoes an isomeric transition (IT)
to emit excess energy as a photon. Photons emitted during ITs (approximately 8 keV to 8 MeV)
are known as gamma rays (γ-rays). Typically, nuclei undergo prompt IT; however, some nuclei
remain in an intermediate state for longer periods that are known as metastable states. The nuclear
isomer

99m

Tc (see Section 1.2.1) has branched radioactive decay, undergoing β- decay to stable

99

Ru (0.004%) or IT (99.99%) to its ground state 99Tc (t1/2 = 2.1 × 105 y) that results in a 140.5

keV (Iγ = 89%) γ-ray. Figure 1-3 shows a simplified decay scheme (i.e. energy level diagram) for
the IT of 99mTc to 99Tc.

Figure 1-3. The isomeric transition of 99mTc
This critical isomer of Tc is the most widely used radioisotope in medicine and is employed in
approximately 80% of all nuclear medicine procedures.31
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When the excess energy of the excited nucleus exceeds the binding energy of an orbital
electron, internal conversion (IC) competes with IT. In IC, the excess energy is transferred to an
orbital electron that is ejected with an energy equal to the excess energy minus the electron binding
energy. The electron shell vacancy is filled by higher-shell electrons, resulting in the emission of
characteristic x-rays and Auger electrons. In both cases, IT and IC, the number of nucleons does
not change. Isomeric transitions allow some radionuclides to be used in nuclear medicine for both
therapy (via particles emitted during radioactive decay of the parent) and diagnosis (via γ-rays).

1.4

Molecular Imaging Techniques

Diagnostic radiopharmaceuticals are molecular agents that incorporate a radionuclide to probe
physiological processes. These agents often have selectivity for a distinct biomarker. After
administration, the gamma rays emitted during decay of the radionuclide escape the body and can
be imaged externally. These techniques are sensitive and non-invasive. They require only small
masses of a radiopharmaceutical (pmol—nmol) to obtain data that is either difficult or impossible
to obtain with other imaging modalities such as radiography, optical imaging, fluoroscopy,
computed tomography, and magnetic resonance imaging. They can be used to screen for disease
at its earliest stages, and in some cases can pinpoint the exact location of a tumor well before it
can be detected by other diagnostic tests. Molecular imaging with radiopharmaceuticals can also
provide individualized care by profiling a patient’s response to treatment, providing critical data
to inform treatment plans, assessing disease progression, and identifying recurrence of disease.32
Two different nuclear molecular imaging modalities are widely used in nuclear medicine.

1.4.1

Positron Emission Tomography

Positron emission tomography (PET) is a tomographic imaging technique. The basis for PET relies
on the two 511 keV annihilation photons resultant from β+ decay (see Section 1.3.3). The
11

annihilation photons escape the subject and can be detected using an array of γ-ray detectors.33
These detectors use scintillation crystals (e.g. bismuth germanium oxide, lutetium yttrium
orthosilicate, or lutetium oxyorthosilicate) coupled with photomultiplier tubes.34 In a PET scanner,
many detectors are positioned around a patient and configured to detect pairs of annihilation
photons in coincidence. The line of intersection (also called the line of response, LOR) determined
by the position of each coincident photon (in the detectors) can then be used to map their origin
(Figure 1-4).

Figure 1-4. A simplified PET scanner schematic
Using an array of detectors, a set of two-dimensional (2D) slices (composed of many coincident
photon pairs) can be collected that map electron-positron annihilation sites. These 2D slices
represent cross-sectional images of a patient. These raw data (contained in each slice) are stored
in a sinogram that captures all LORs as a function of angle relative to a reference point. The set of
sinograms can be reorganized into a three-dimensional (3D) projection image (tomographic view)
that displays all slices at a particular projection angle.
The spatial resolution of modern clinical PET imaging and small animal imaging is 4-6 mm
12

and approximately 1 mm, respectively.35 This resolution can be limited by two physics-related
factors, namely annihilation photon non-collinearity and the positron range.36 The first factor, noncollinearity of annihilation photons, can be explained by non-zero momentum of electron-positron
annihilation. The non-collinearity increases uncertainty in the origin of the annihilation event. The
second factor, the positron range, is dependent on the positron energy and is the distance a positron
travels after β+ decay. Due to the three-body nature of β+ decay, a positron has a mean energy,
(Eβ+mean) at approximately one-third of the Emax. Thus, positrons at or near Emax can limit (along
with non-collinearity) resolution since they travel further from the site of β+ decay before
thermalization leads to annihilation (Figure 1-5).

Figure 1-5. The dependence of PET resolution on positron energy (i.e., range)
Figure 1-5 illustrates the longer range of higher-energy positrons (left) and shows how the smaller
region defined by the lower-energy positrons (right) could afford an improved resolution in a PET
scanner. This impact on resolution is most often observed when using small-animal PET scanners
based on their spatial resolution. Even though these two phenomena (non-collinearity and positron
range) can limit PET imaging resolution, their effects can be taken into account during
reconstruction of raw PET data to improve resolution in a projection image.37
13

There are several FDA-approved (Food and Drug Administration) PET radiopharmaceuticals
used clinically. The most commonly used radionuclide in PET imaging is

18

F (t1/2 = 110 min),

which is widely used to label deoxy-glucose ([18F]FDG, Figure 1-6), a glucose analogue, for the
imaging of glucose metabolism. The upregulation of glucose metabolism is a widely used
biomarker.

Figure 1-6. The chemical structure of deoxy-glucose and [18F]FDG
Imaging of this biomarker occurs after transport of [18F]FDG into the cell followed by
phosphorylation. The presence of

18

F at the C-2 position prevents participation in the standard

metabolic pathway. For example, 18F accumulates in neoplastic cells and disease that has increased
glycolytic activity. Beyond its use to assess glucose metabolism in heart, lungs, and brain, it may
also be used in oncology for screening, staging, pre-surgical planning, radiotherapy planning, and
monitoring treatment of cancers (and reoccurrence of disease). It has clinically been used with
breast cancer, colorectal cancer, head and neck cancer, lung cancer, esophageal cancer, and
lymphoma.38

1.4.2

Single Photon Emission Computed Tomography

Single photon emission computed tomography (SPECT) is a tomographic imaging technique with
some similarities to PET imaging. The basis for SPECT is detection of γ-rays using nuclear
detectors that contain scintillation crystals (e.g. thallium doped sodium iodide or cesium iodide
and cerium doped lanthanum chloride) coupled with photomultiplier tubes.39 In a SPECT scanner,
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one or more detectors, is rotated around the patient (Figure 1-7) to acquire a 2-D slice at multiple
angles.

Figure 1-7. A simplified SPECT scanner schematic
Similar to PET, the raw data included in a set of 2D slices can be reorganized into a 3D projection
image that displays all slices at a particular projection angle. The spatial resolution of the latest
clinical SPECT imaging systems vary from 3 mm to 8 mm.40
The main limitation of SPECT imaging arises due to the use of γ-rays that emit at all angles
(Figure 1-7). To extract data on the γ-ray origin, a collimator must be used to restrict the γ-ray
acceptance angle. In practice, these collimators are composed of a high Z material (e.g., tungsten),
capable of attenuating γ-rays outside of the acceptance angle (Figure 1-7). Position information is
extracted from γ-rays that pass through a collimator and interact with the detector (orthogonal to
the collimator face) while γ-rays that would otherwise degrade resolution and contrast are absorbed
by the high Z material.41 Generally, radionuclides suitable for use in SPECT emit low-energy γ-
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rays (<160 keV). Higher-energy γ-rays require larger collimators and the increased material
needed between the collimating holes (i.e., septa) to absorb γ-rays lead to a reduction in sensitivity.
Thus, radionuclides that emit high-energy γ-rays require larger quantities of the radioactive
compound to acquire usable image data compared to the greater sensitivity of a PET scanner.
Historically, the most important radionuclide in SPECT imaging is the nuclear isomer 99mTc
(see Section 1.2.1). For example, [99mTc]Tc-sestamibi is indicated for imaging myocardial
perfusion, identification of parathyroid adenomas, and is also used for radioguided surgery of the
parathyroid. Imaging agents, like [99mTc]Tc-sestamibi that incorporate

99m

Tc, are clinically used

in SPECT imaging for successful patient management with at least twenty-three different

99m

Tc

radiopharmaceuticals in wide use.42

1.5

Targeted Radionuclide Therapy

Targeted radionuclide therapy (TRNT) uses molecular compounds labeled with therapeutic
radionuclides (e.g., α and β- emitters). These radiolabeled compounds target disease by having
high affinities for specific biomarkers of disease that are overexpressed relative to healthy tissue.
Targeted radionuclide therapy can be coupled with other types of cancer treatment (e.g., surgery,
external beam radiation therapy, brachytherapy, chemotherapy, hormonal therapy, and biological
therapy) to form a personalized multimodal treatment plan. Therapeutic radionuclides, unlike PET
and SPECT radionuclides, emit ionizing radiation with short path lengths like a β- particle, α
particle, or Auger electrons. As these ionizing particles slow, they transfer energy to their local
environment in the form of ionizations and excitations.
The primary mechanism of action for TRNT is direct or indirect damage to DNA induced by
the ionizing particles that can lead to cell cycle delay and cell death.43 Moreover, multiple reports
support the existence of bystander responses (cell-to-cell signaling) mediated by radiation-induced
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DNA damage, which may improve efficacy of treatment; however, the mechanisms underpinning
bystander signaling in TRNT are not fully understood.44-46 An additional feature of TRNT is the
crossfire effect that occurs when a β- or α particle causes DNA damage as it crosses multiple
cells.47 The crossfire effect leads to greater therapeutic efficacy as one radioactive decay can lead
to DNA damage in multiple cells.
Many TRNT compounds have been approved for human use or are in development for clinical
use. For example, the FDA-approved treatment of thyroid carcinoma with the β- emitting
radionuclide

131

I is used after thyroidectomy to ablate any remaining cancerous remnants. In a

retrospective study of 261 patients given

131

I ablation therapy between 2012 and 2015 had a

success rate of 65.9% after their first treatment.48
Several compounds that incorporate radionuclides that emit α particles are in clinical
development and the effort to develop these radiopharmaceuticals has been motivated by the
success of

223

RaCl2, the first FDA-approved α emitting radionuclide. Radium-223 dichloride is

indicated for the treatment of patients with metastatic castration resistant prostate cancer
(mCRPC). It preferentially targets areas of increased bone turnover in in bone metastases and its
emitted α particles have an average range that is less than 100 µm in tissue. The development of
new α particle emitting radiopharmaceuticals include phase I clinical trials with monoclonal
antibodies labeled with 213Bi (t1/2 = 45.6 min) and 211At (t1/2 = 7.2 h), and the initial evaluation of
223

Ra (t1/2 = 11.4 d) to treat breast cancer.49,50

1.6

Theranostics

The theranostic approach uses a combination of diagnostic and therapeutic techniques to identify
and treat disease in the same patient. In nuclear medicine, molecular compounds are labeled with
a theranostic radionuclide (suitable for both diagnostic imaging and radionuclide therapy) or a
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combination of two different diagnostic and therapeutic radionuclides. These theranostic
compounds can be used to identify disease, stage progression, and predict patient response to
treatment by profiling the concentration or presence of a targeted biomarker.
The first widely used theranostic radiopharmaceutical was 131I, a theranostic radionuclide that
undergoes β- decay to 131Xe, followed by emission of 284.3 keV (Iγ = 6.12%) and 364.5 keV (Iγ
= 81.5%) γ-rays. Iodine-131 was first used to treat thyroid cancer in 1946.51 Its emitted β- particles
have a Eβ-mean of 181.9 keV and their max range in tissue can reach 2.4 mm.52 The β- particles
deliver ionizing radiation to targeted cells. Additionally, the γ-rays emitted during nuclear decay
of 131Xe to its ground state can be imaged with a gamma camera (via SPECT). Therefore, 131I is a
theranostic radionuclide.

1.6.1

Targeting Neuroendocrine Tumors with Somatostatin Analogues

Neuroendocrine tumors (NET) are a rare group of neoplasms with an incidence of approximately
7 cases per 100,000 people in the United States (2012).53 These tumors can overexpress
somatostatin receptors (SSTR), primarily subtype two (SSTR2). Somatostatin receptors are a G
protein-coupled receptor (GPCR) that detect molecules outside the cell and activate internal signal
transduction. When activated, SSTR transit the cell membrane and offer a pathway to transport
radioactive agents into the cell nucleus. Approximately 34% of all FDA-approved drugs target
GPCRs and exploit this mechanism.54 Three examples of recently FDA-approved
radiopharmaceuticals, [68Ga]Ga-DOTATOC and [68Ga/177Lu]Ga/Lu-DOTATATE, allow PET
imaging and treatment of NETs. These molecular agents target SSTR, with high affinity and
specificity for SSTR2.55
DOTATOC (Figure 1-8) was approved for use with
radiopharmaceutical in 2019.
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68

Ga (see Section 1.3.3) as a PET

Figure 1-8. The chemical structure of DOTATOC.
In Figure 1-8, the central 12 membered tetraaza ring (DOTA) has a high affinity for chelating diand trivalent cations. For La and most lanthanide-like elements including Ga(III), DOTA functions
as an octadentate ligand and binds the metal through its four amine N atoms and four carboxylate
O atoms. In most cases, DOTA coordinates an additional water ligand yielding an overall
coordination number of nine.56 In contrast, DOTA binds Sc(III) yielding an overall coordination
number of eight. Similar coordination by DOTA to Lu(III) and Y(III) has been reported.57
DOTATATE (Figure 1-9) was approved for use with
2016 and 2018, respectively.
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68

Ga and

177

Lu (see Section 1.3.3) in

Figure 1-9. The chemical structure of DOTATATE.
It forms two compounds which can be used in a theranostic fashion.
Diagnostic imaging with [68Ga]Ga-DOTATATE identified NET recurrence in 26 of 29 patients
(sensitivity, 90%) and excluded recurrent NET in 28 of 34 patients (specificity, 82%).58 Targeted
radionuclide therapy with [177Lu]Lu-DOTATATE in 116 patients with advanced, progressive,
SSTR-positive midgut NETS showed markedly longer progression-free survival and significantly
higher response rates versus a control group of 113 patients given non-radioactive DOTATATE.59
These results contributed to the FDA approval of [68Ga]Ga-DOTATATE and [177Lu]LuDOTATATE to detect NETs, monitor NETs progression, and determine patient response to
TRNT.
The coordination of DOTA in DOTATATE (Figure 1-9) is similar to that reported in
DOTATOC for

68

Ga. For

177

Lu, the change in coordination number (9 → 8) affects the

pharmacokinetics of the radiopharmaceutical and increases the lipophilicity of the radiolabeled
20

compound. In fact, reports have shown a four to fivefold increase in the IC50 value for DOTATOC
coordinated to Y (which is coordinated similarly to Lu-DOTATOC).57,

60

The similarities in

coordination number between Sc(III), Y(III), and Lu(III) present a case where DOTATATE
labeled with the Sc radionuclides investigated in this work would yield similar (e.g., 43,44Sc/177Lu)
or identical (e.g., 43,44Sc/47Sc) pharmacokinetic profiles when screening for and treating NETs.

1.6.2

Targeting Prostate Cancer with PSMA Agonists

Prostate cancer is the second leading cause of cancer-related death in men in the United States.
From 1999 to 2005, disseminated and advanced forms of prostate cancer had an approximate 5year survival rate of 31% for all races.61 Prostate cancer overexpresses prostate-specific membrane
antigen (PSMA). This biomarker is expressed at greater levels in castration-resistant and dedifferentiated (i.e., disseminated) disease. The bioconjugate PSMA-617 (Figure 1-10) combines
the DOTA chelator with a urea-derived targeting agent that has high affinity for PSMA was
reported in 2015.62
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Figure 1-10. The chemical structure of PSMA-617.
After PSMA-binding, PSMA-617 is internalized into the cell nucleus via clathrin-coated pits.63
Similar to targeting SSTR, PSMA is a favorable biomarker as it will transport PSMA-617 labeled
with a radionuclide into the cell. Many recent clinical studies have showed excellent safety and
efficacy. Based on these studies, a randomized phase 3 study of 177Lu-PSMA-617 for the treatment
of patients with progressive PSMA-positive mCRPC is currently underway. A theranostic
approach to mCRPC can be pursued by using the bioconjugate PSMA-11 (Figure 1-11) labeled
with 68Ga or 18F. Gallium-68 and 18F-labeled PSMA-targeting bioconjugates like PSMA-11 and
PSMA-1007 are increasingly being used to detect and monitor progression of prostate cancer. For
example, [68Ga]Ga-PSMA-11 has shown a sensitivity and specificity of 77% and 97%,
respectively in a pooled analysis of greater than 5000 patients for the detection of prostate cancer.64
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Figure 1-11. The chemical structure of PSMA-11.
Similar to DOTATATE, interest exists in advancing PSMA-617 due to its ability to coordinate
Ga(III), Sc(III), and Lu(III). It would allow a theranostic approach using the same bioconjugate
molecule, and its use would provide a more accurate pharmacokinetic profile that could inform
treatment. Thus, investigating the in vitro properties of PSMA-617 labeled with

43

Sc,

44

Sc, and

47

Sc represents another case where the Sc radionuclides investigated in this work could play an

important role.
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Chapter 2: Cyclotron Production of
Radioscandium
2.1

Nuclear Properties of Radioscandium

The element Sc has one naturally-occurring stable isotope,

45

Sc, and several medically relevant

radioisotopes.1 Figure 2-1 shows the five radioisotopes of Sc (including isomeric states) that have
ground state half-lives greater than 60 minutes: 43Sc, 44Sc, 46Sc, 47Sc, and 48Sc.

Figure 2-1. The isotopes of Sc with mass numbers from 43 to 481
Three of these radioisotopes (43Sc, 44Sc, and 47Sc) were investigated in this work for their use as
diagnostic, therapeutic, and theranostic radioisotopes. The remaining two isotopes (46Sc and 48Sc),
have properties that are less advantageous for medical use. The properties of all five radioisotopes
are noted below because most
production of

46

Sc and

43

Sc,

44

Sc, and

47

Sc production methods will result in the co-

48

Sc, which are considered radionuclidic impurities that lower the

radioisotopic purity of the desired 43Sc, 44Sc, or 47Sc.

2.1.1 Scandium-43

Scandium-43 (t1/2 = 3.90 h) decays by β+ decay (Iβ+ = 88.1%) and EC decay (IEC+ = 11.9%) to 43Ca
(Figure 2-2) with emission of a 373 keV γ-ray (Iγ = 22.5%).1
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Figure 2-2. A simplified 43Sc decay scheme1
Scandium-43 has nuclear properties that make it an excellent PET radionuclide. First, its half-life
is similar to the biological half-lives of many compounds such as peptides (1-10 kDa), peptidic
proteins (10-50 kDa) and mAbs (150 kDa) commonly used in diagnostic imaging.2 Next, its mean
positron energy is 476 keV; thus, a better image resolution would be predicted compared to 68Ga,
which has a mean positron energy of 830 keV.3 Lastly, it has a low intensity 373 keV γ-ray emitted
by the excited daughter.

2.1.2 Scandium-44

Scandium-44 (t1/2 = 3.93 h) decays by β+ decay (Iβ+ = 94.3%) and EC decay (IEC+ = 5.7%) to an
excited state of 44Ca (Figure 2-3) with emission of an 1157 keV γ-ray (Iγ = 99.9%).1
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Figure 2-3. A simplified 44Sc decay scheme1
Scandium-44 has a similar decay mode and half-life as

43

Sc, and emits a positron with a mean

energy of 632 keV during decay. Its excited daughter, 44Ca, emits an 1157 keV γ-ray. The highenergy γ-ray will lead to an increased γ-ray dose to patients and clinical staff. Moreover, the higher
energy positron will have an increased range relative to 43Sc (potentially leading to loss of PET
resolution). Scandium-44 produced by particle-induced nuclear reactions results in a mixture of its
ground state and nuclear isomer (44mSc). Scandium-44m (t1/2 = 58.61 h) decays by EC (IEC = 1.2%)
to an excited state of 44Ca with emission of a 1.002 (Iγ = 1.2%), 1.126 (Iγ = 1.2%), and 1.157 MeV
γ-ray (Iγ = 1.2%). It also undergoes decay by IT (IIT = 98.8%) to the ground state of

44

Sc with

emission of a 271 keV γ-ray (Iγ = 98.8%) .1 Figure 2-4 shows the branched decay of 44mSc.
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Figure 2-4. A simplified 44mSc decay scheme showing the branched decay of 44mSc1
A mixture of the

44

Sc ground state and excited state can increase the patient dose when this

radionuclide is used for diagnostic imaging. To simplify patient dosimetry, 44Sc in its ground state
(with no isomer) would be the best scenario for clinical use of this PET radionuclide.
The long-lived radionuclide 44Ti could serve as a reliable source of 44Sc in only its ground state
(Figure 2-5).

Figure 2-5. Titanium-44 and Sc radioisotopes are shown1
Multiple groups have investigated the production of 44Ti and the design of a system that would
allow harvesting of

44

Sc from the decay of

44

Ti.4, 5 Thus, the nuclear properties of

44

Ti are an

important element of this work. Titanium-44 decays by electron capture decay (IEC = 100%) to an
excited state of

44

Sc with emission of a 67.9 (Iγ = 93.0%) and 78.3 keV γ-ray (Iγ = 96.4%) as
34

depicted in Figure 2-6.1

Figure 2-6. A simplified 44Ti decay scheme1

2.1.3 Scandium-47

Scandium-47 (t1/2 = 3.34 d) decays by β- decay (Iβ- = 100%) to 47Ti (Figure 2-7) with emission of
a 159.4 keV γ-ray (Iγ = 68.3%).1

Figure 2-7. A simplified 47Sc decay scheme1
Scandium-47 has properties similar to the theranostic radionuclide

177

Lu (see Section 1.6). Its

moderate half-life, β- particle energies, and imageable 159.4 keV γ-ray make 47Sc well suited for
use as a theranostic radionuclide. Targeted delivery of

47

Sc-labeled compounds to cancer cells

would provide localized radiation treatment and simultaneous imaging to monitor disease
progression.6, 7
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2.1.4 Scandium-46 & Scandium-48

Scandium-46 (t1/2 = 83.79 d) decays by β- decay (Iβ- = 100%) to an excited state of 46Ti (Figure
2-8). Similarly,

48

Sc (t1/2 = 43.67 h) decays by β- decay (Iβ- = 100%) to an excited state of 48Ti

(Figure 2-9). The decay products (46Ti and 48Ti) emit multiple high-energy γ-rays during nuclear
decay.

Figure 2-8. A simplified 46Sc decay scheme1

Figure 2-9. A simplified 48Sc decay scheme1
Scandium-46 and 48Sc are not ideal candidates for use as medical radionuclides for several reasons.
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The relatively long half-life of 46Sc is not compatible with the shorter biological half-life of most
diagnostic and therapeutic agents, and both radionuclides decay to daughters that emit several
high-energy γ-rays that cause unnecessary radiation exposure to patients and clinical staff (shown
in Figure 2-8 and Figure 2-9).

2.2

Nuclear Properties of Radiovanadium

The element V has one naturally-occurring stable isotope and several predicted or known
radioisotopes.1 Figure 2-10 shows the three radioisotopes of V that have half-lives greater than 1
minute: 47V, 48V, and 49V.

Figure 2-10. The isotopes of V with mass numbers from 47 to 511
Two of these radioisotopes, 47V (t1/2 = 32.6 min) and 48V (t1/2 = 15.97 d), were co-produced in this
work as contaminants. The properties of both radioisotopes are noted below because the chemical
separation of Sc from these V contaminants was a significant focus of this work.
Vanadium-47 and 48V decay by β+ decay (Iβ+ = 96.5% and 49.9%) and EC decay (IEC+ = 3.46%
and 50.1%) to 47Ti (Figure 2-11) and 48Ti (Figure 2-12), respectively.
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Figure 2-11. A simplified 47V decay scheme1

Figure 2-12. A simplified 48V decay scheme1
The EC decay of

47

V to

47

Ti results in the emission of a 159.8 keV and 1.793 MeV γ-ray (Iγ =

0.11% and 0.19%).1 The remaining γ-rays that are emitted during the de-excitation of 47Ti have
intensities <0.01%. Similarly, the decay of 48V results in an excited state of 48Ti that emits a 928.3
keV (Iγ = 0.78%), 983.5 keV (Iγ = 99.98%), 1.3121 MeV (Iγ = 98.2%), and 2.240 MeV (Iγ =
2.33%) γ-ray. The remainder of emitted γ-rays have intensities <0.2%.
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2.3

Nuclear Reactions

Each of the radionuclides discussed in Section 2.1 and Section 2.2 are produced by bombarding
target material (nuclei) using different particle sources to induce nuclear reactions. Nuclear
reactions can be described as a change in the identity or characteristic of a nucleus when it is
bombarded with a particle of sufficient energy. These reactions can be categorized into many types
such as elastic scattering, inelastic scattering, fission, fusion, spallation, and transmutation. This
work investigated the production of Sc radioisotopes and 44Ti produced by inducing transmutation
reactions with protons and photons.
Nuclear reactions are represented in a manner similar to a balanced chemical reaction. For
example, Equation 2-1 details the reaction that produces the PET radionuclide 43Sc using protons
incident on 46Ti nucleus.
46
22Ti

+ 11p →

43
21Sc

+ 42𝛼𝛼

(2-1)

This reaction can be represented in shorthand by writing the target nucleus, projectile particle,
ejected particle, and product nucleus in sequence for a two-body reaction (Equation 2-2). The
comma represents the reaction arrow, and the incident and ejected particles are housed within
parentheses.
46
43
22Ti(p, α) 21Sc

(2-2)

These transmutation reactions are best described as an event where a projectile merges with a
target (nucleus) by striking it. If the nucleus retains the proton then its kinetic energy is distributed
among all available nucleons leading to formation of a compound nucleus. The compound nucleus
can undergo different processes by which it de-excites (i.e., evaporates particles) to assume a more
stable configuration of nucleons. This process of de-excitation to the final products depends only
on energy, spin (i.e., the combined contribution of the angular momenta of the nucleons), and
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parity of the compound nucleus. The spin of a nuclear state is an intrinsic property and the parity
can be determined by studying the behavior of its wave function under the reflection of its space
coordinates through the origin. For instance, a 24 MeV proton incident on a

48

Ti nucleus may

produce one of several probable reaction products (Figure 2-13).

Figure 2-13. Potential nuclear reactions on a 48Ti nucleus
Each nuclear reaction has a distinct thermodynamic threshold energy that can be expressed as
a Q-value. The Q-value is the enthalpy (-ΔHrxn) of a chemical reaction and, in the T=0 limit, a Qvalue > 0 indicates a spontaneous decay. The Q-value is determined by subtracting the mass excess
(∆) of the products from the reactants. The mass excess of a nuclide in atomic mass units (u) is the
difference between its actual mass and mass number (A). For example, the mass excess of 43Sc is
shown in Equation 2-3.
∆43Sc = M( 43
21Sc) − A = (42.96115 − 43) = −0.03885 u

(2-3)

Thus, the difference in the total mass excess of the products from the reactants can be used to
calculate the Q-value for the general reaction A(a,b)B (Equation 2-4).
Q = [(Δa + ΔA ) − (Δb + ΔB )]

(2-4)

In the reaction 46Ti(p,α)43Sc, the mass excess difference between the products and reactants is 40

0.0033 u. This mass excess can be expressed in units of MeV (after multiplying by u = 931.478
MeV/c2), making the Q-value for 46Ti(p,α)43Sc equal to -3.07 MeV. The sign on the Q-value (-)
indicates that the mass of the products is more than that of the reactants. Thus, an incident proton
must have an energy above 3.07 MeV to overcome the thermodynamic threshold.
In some cases, the Q-value may not fully describe the particle energy required for a reaction to
occur due to Coulombic forces. The positively charged proton in Figure 2-13 will experience
repulsion due to the positive charge of the

48

Ti nucleus. Thus, the proton must overcome the

Coulomb barrier. Equation 2-5 can be used to approximate the energy required to overcome the
Coulomb barrier were Z1 and Z2 are the atomic numbers of the incident particle and target nucleus,
respectively, and R is the radius of the combined incident particle and target nucleus. If the atomic
radii are expressed in fermis (fm) then VC has units of MeV. The radius (R) can be obtained in fm
using Equation 2-6.
VC =

1.44 × Z1 × Z2
R

1
3

(2-5)

1
3

(2-6)

R = 1.4 �A1 + A2 �

For the 46Ti(p,α)43Sc reaction, the energy required for a proton to overcome the Coulomb barrier
is 3.1 MeV. Thus, the magnitude of the Coulomb barrier imposes a kinetic threshold (in contrast
to the thermodynamic limit imposed by a negative Q-value) that must be overcome in order for
the reaction to occur. The actual threshold energy for a reaction to occur is the value (negative Qvalue or Coulomb barrier) with the greatest magnitude. For the 46Ti(p,α)43Sc reaction, the kinetic
threshold (3.1 MeV) is the proton energy required for the reaction to occur.
For particles above the threshold energy, the probability of inducing a reaction is determined
by the reaction cross section (σ). The cross section is expressed as area per target nucleus
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(cm2/nucleus), or more commonly in units of barns (1 barn = 10-24 cm2/nucleus), which have been
adopted for convenience. Figure 2-14 illustrates the cross section for a reaction where the particle
strikes the target nucleus.

Figure 2-14. The geometric probability for a particle striking a target nucleus8
In this case, particles in the beam may “miss” the target nuclei. However, a fraction will experience
an electrostatic interaction with the nuclei that results in scattering with no loss of energy. A subset
of this fraction may interact with the target nuclei via a direct collision, and will merge to form a
compound nucleus. The excitation energy of the compound nucleus, which is dependent on the
energy of the incident particle, will determine the different final products that may occur via deexcitation. Thus, the cross section for each reaction is dependent on the incident particle energy
and therefore its magnitude can be plotted as a function of particle energy to yield an excitation
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function. It should be noted that this simplified geometric view (Figure 2-14) does not represent
all variables that determine the magnitude of the nuclear reaction cross section. Instead, the cross
section of a nuclear reaction is a prediction of its probability to occur. Thus, the magnitude of the
actual cross section can be larger or smaller than the geometrical cross sectional area of a target
nucleus.
The magnitude of a nuclear reaction cross section (i.e., excitation function) may be measured
experimentally, and can be used to determine the optimal particle energies for maximizing
radionuclide yield. The excitation function for the 48Ti(p,x)48V reaction is shown in Figure 2-15.

Figure 2-15. The 48Ti(p,x)48V excitation function9-11
Figure 2-15 indicates that the peak cross section is approximately 380 mb at 12 MeV for the
48

Ti(p,x)48V reaction. Thus, bombarding a thin 48Ti target with 12 MeV protons will capture the

portion of the excitation function with the greatest cross section magnitude. The total yield could
be further increased by bombarding a thick target with 20 MeV protons. An appropriately thick
target would result in a proton exit energy of approximately 6 MeV, thus a larger portion of the
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excitation function peak would be utilized. In that case, the envelope of proton energies occurring
within the target would span a larger region of the excitation function peak and increase the
probability of the reaction occurring.
The proton and photon energies used in this work range from 0-24 MeV. Reactions induced at
these energies such as (γ,n), (γ,p), (γ,n+p), (p,n), (p,xn), (p,α), (p,n+α), and (p,xn+α) are
commonly observed. In these reactions, the “x” accounts for the emission of multiple nucleons
(often neutrons at these energies).

2.4

Radionuclide Production

Radionuclides are produced using nuclear reactors12, 13, cyclotrons14, 15, and linear accelerators1619

, or are obtained from a nuclear generator via the radioactive decay of a long-lived parent

radionuclide.20, 21 This work investigated radionuclide production using an H- (i.e., negative ion)
cyclotron and an electron linear accelerator (eLINAC).

2.4.1 Cyclotron

The acceleration of a proton in a negative ion cyclotron starts with an external ion source, which
generates H- ions and injects them into the center of a strong magnetic field. The magnetic field
moves the ions in a circular path over large electrodes (i.e., dees) in a vacuum chamber. The radius
of this path depends on the charge and velocity of the ion as well as the strength of the magnetic
field. The radius can be modeled by Equation 2-7 where m is the ion mass in kg, v is the ion
velocity in m/s, q is the particle charge in C, and B is the magnitude of the magnetic field in kg•s1

•C-1 .
R=

mv

(2-7)

qB

These ions are accelerated by applying a high-frequency voltage across the dees. The voltage, in
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an alternating fashion, attracts and repels the ions, which causes them to accelerate across a gap
between each dee. As the protons gain more energy, their radius increases until they reach the
outer edge of the dees. At the outer edge of the vacuum chamber, the excess electrons can be
stripped by impinging them onto a thin carbon foil (Figure 2-16).

Figure 2-16. Diagram of a negative ion cyclotron
The newly formed H+ ions are deflected down a vacuum beam line until they reach a target, where
the energetic positive ions (i.e., protons) are used to induce nuclear reactions in a target material.

2.4.2 Electron Linear Accelerator

The acceleration of an electron in a linear accelerator (eLINAC) starts with an electron gun, which
uses a hot cathode that emits electrons. The emitted electrons are accelerated towards an anode
and collimated to produce an electron beam. In an eLINAC, the electron beam is injected into a
linear accelerator structure. Inside this structure, a wave-guide delivers high-frequency
microwaves that are reflected to form standing waves that accelerate the electrons via an effective
electric field (i.e., sum of incident and reflected wave). The accelerated electrons (traveling as a
beam organized into bunches of electrons) are directed down a flight tube and their horizontal
trajectory is bent 90° using a bending magnet. This is a typical configuration for a medical eLINAC
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where a downward focused electron beam is well suited for external beam therapy. In this work, a
downward focused electron beam was used to generate bremsstrahlung radiation.
Bremsstrahlung radiation is electromagnetic radiation that is produced by the deceleration of
a charged particle (i.e., electron) when it is deflected by an atomic nucleus. The electrostatic
attraction between the moving electron and the atomic nucleus causes the particle to lose energy,
which is converted into a photon. Bremsstrahlung photons have a continuous spectrum and the
peak of the spectrum occurs at approximately one-third of Emax. To obtain bremsstrahlung photons
in this work the electron beam was made incident on a high Z converter made of W (Figure 2-16).

Figure 2-17. Bremsstrahlung photons generated by a converter material
Figure 2-16 shows the conversion of an electron beam to a beam of forward-directed
bremsstrahlung photons that were used to induce nuclear reactions in a target material.

2.4.3 Production Rates and Yields

The production rate of reaction products produced during an irradiation is dependent on several
parameters, including the magnitude of the reaction cross section in cm2, the energy of the incident
particle in MeV, the thickness of the target material in nuclei/cm2, and the flux of the incoming
particles in particles/s. For instance, the 48Ti(p,x)48V cross section will be roughly constant for a
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thin 48Ti target bombarded with 11-12 MeV protons (Figure 2-15). For a reaction with a constant
cross section (dσ/dE = 0), the production rate (nuclei formed/s) is given by Equation 2-8 where
Nt is the target thickness, φparticle is the beam intensity in particles per second, and σ is the cross
section.
(2-8)

R = Nt ϕparticle σ

Since the cross section varies as the energy of the incident particle drops due to energy
attenuation in the target material, a more exact production rate can be obtained by integrating
Equation 2-7 from the initial energy to the final energy of the incident particle. This integral
(Equation 2-9) extracts the magnitude of the cross section in cm2 via the σ(E) term. The particle
energy at each infinitely thin slice is accounted for by the dE/dx term.
E σ(E)

R = Nt ϕparticle ∫E 0
f

dE
dx

(2-9)

dE

The integrated yield for a finite time bombardment must account for the decay of the produced
activity during bombardment. Accounting for decay yields Equation 2-10, where NA is
Avogadro’s number, At is the molecular weight of the target material in g/mol, λ is the decay
constant of the reaction product in s-1, t is the time of irradiation in s, σ(E) is the cross section as a
function of energy in cm2, and S(E) is the total stopping power in units of MeV•cm2•g-1.
Yield =

NA
AT

E σ(E)

ϕparticle (1 − e−λt ) ∫E 0
f

S(E)

dE

(2-10)

A physical yield rate in units of Bq/µA•h can be obtained by evaluating Equation 2-10 for 1 h at
1 µA over any given energy range. When the initial and final particle energies are known, these
rates can be useful for estimating yield at the end of an irradiation, otherwise known as end of
bombardment (EOB).
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2.4.4 General Targetry

Several methods to produce traditional PET radionuclides using a low-energy cyclotron have been
optimized.22 In most cases, these methods involve the use of gas or liquid targets containing nonmetal target material (e.g., H2O, N2, and Ne) that allow for rapid heat exchange. These targets
enable prompt transfer of the radionuclide after production via pressurized tubing to automated
radiosynthesis modules.
In contrast, novel radionuclides are often produced using solid targets that contain metal or
metal oxide target materials. Unlike gas or liquid targets, the most limiting factor in solid targets
is heat dissipation.23 Energy deposition (heat) occurs as particles pass through a material. The
majority of energy loss takes place as the particles decelerate due to stopping power. The stopping
power is the incremental loss of energy E per unit distance traveled, x (Equation 2-11) in a
medium.
S(E) =

−dE

(2-11)

dx

The stopping power of a material is dependent on the material properties, the particle energy, and
the particle type. In this work, the software The Stopping and Range of Ions in Matter (SRIM) was
used to model the energy loss of ions in matter and their range.24 For solid targets and their target
material, the stopping power will increase as the traveling particle decelerates and loses energy
before reaching a maximum and dropping to zero. This maximum, known as the Bragg peak, is
the region with the greatest heat deposition. Thus, solid targets are often designed using materials
with high thermal conductivity (Table 2-1) to promote heat conduction from this region.
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Table 2-1. Material Properties25
Property

Aluminum Niobium

Tantalum

Thermal Conductivity (W⋅m-1⋅K-1)

237

53.7

57.5

Heat Capacity (J⋅mol-1⋅K-1)

21.5

10.6

3.34

Melting Point (°C)

660

2470

2996

To increase cooling of the solid target and target material, the heat can be drawn from the
conductive target by forced convective heat transfer. This is often accomplished using flowing
water driven by a pump. Other factors that affect radionuclide production with solid targets include
cost and availability of the target material, complexity of the chemical separation, and recycling
of enriched target material (if necessary). In most cases, production with solid targets will increase
material handling and require development of technologies for automating the production (to limit
worker exposure to strong radiation fields), digestion, and purification of an irradiated target
(which are different from those reported with gas and liquid targets).14

2.4.5 Radionuclide Production on the TR-24 Cyclotron

The TR-24 cyclotron at UAB can deliver proton beams with energies of 17-24 MeV with a 1 cm
diameter at currents up to 0.3 mA. These protons can be used to produce various radioisotopes.
For example, protons accelerated by the TR-24 under 20 MeV are used to produce 18F (see Section
1.4.1), 11C (see Section 1.2.1), 13N (see Section 1.2.1) 15O (t1/2 = 122.2 s), 89Zr (t1/2 = 78.4 h), and
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Cu (t1/2 = 12.7 h).1 Unlike lower-energy cyclotrons, the TR-24 also allows production of

radionuclides via intermediate energy nuclear reactions that have low cross section values at
energies below 20 MeV. Generally, the majority of cyclotrons producing medical radionuclides
employ protons with an energy below 20 MeV to produce PET radionuclides.22 The TR-24 was
manufactured by Advanced Cyclotron Systems Incorporated (ACSI) and has four external beam
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lines and the capability to irradiate two targets simultaneously (Figure 2-18).

Figure 2-18. The TR-24 cyclotron and vault schematic
It currently has three target stations that were designed to mount solid targets and irradiate them at
energies up to 24 MeV (Figure 2-18). The three target stations are configured to mount target
material at a grazing angle of 7°and 20°, or orthogonal to the horizontal beam. Target assemblies
mounted onto target stations are cooled by flowing water that contacts the back of the target. For
targets mounted onto the 20° and 90° target stations, the target face is cooled using helium gas.
The configuration of each target station constrains the design of the entire target assembly (also
referred to as the target), which houses the target material (i.e., the material that is irradiated to
produce the radionuclide of interest) in a fixed position on the TR-24. These constraints are
detailed below.
The 90° target station accepts circular targets that have a maximum target thickness of 2 mm
and a maximum diameter of 24 mm. The TR-24 water cooling system operates on a closed loop
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and services all components of the cyclotron including the target stations. To avoid affecting
cyclotron performance, protons must fully stop in the target during target irradiation to prevent
activation of the cooling water. At 24 MeV, the maximum range of a proton in aluminum is
approximately 3 mm.24 Thus, the combination of target material and the choice of metal housing
material for each target were carefully considered to prevent the exit of low-energy protons.
Targets designed to mount powders or poorly densified material included features that fully
contained the target material to avoid radiological contamination.
The 7° and 20° target stations, due to their slant relative to the proton beam, will stop protons
in the target. The stations accept maximum target thicknesses of 5.7 mm and 3 mm, respectively.
Due to the incident angle of the beam, the beam profiles for both stations are elliptical, which leads
to a more diffuse deposition of beam power. The stock ACSI high power targets (7° station) were
designed to allow greater water flow rates that improve cooling efficiencies and the 20° station has
water flow rates similar to the 90° station. Like the 90° target station, target material mounted onto
either slant target station must be secured, and powders or poorly densified material must be
contained to avoid radiological contamination.
Solid target assemblies were developed and tested in this work using materials shown in Table
2-1. These targets were designed based on the desired target material and physical constraints
levied by the solid target end-stations on the TR-24 (Figure 2-18). Each target was also designed
to promote heat transfer via conductive and forced convective cooling.
Aluminum Target Holder
An Al (ρAl = 2.7 g/cm3) solid target was designed by Dr. Tommaso S. Carzaniga and Dr. Saverio
Braccini at the University of Bern at the Laboratory for High Energy Physics. The 2 mm thick
circular two-piece assembly had a 24 mm diameter (Figure 2-19).
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Figure 2-19. Cross section drawing of Al target assembly
The solid target had a base and cap that were secured by radially positioned SmCo (samariumcobalt) magnets. These magnets lay outside the beam strike area. The circular 500 μm bore
centered in the base had a diameter of 7 mm. It contained up to 60 mg of pressed TiO2. A 1 mm
diameter Viton O-ring created a seal between the base and cap that enclosed the target material.
Based on the TR-24 constraints, these Al targets were tested at proton energies and beam currents
of up to 17 MeV and 20 μA, respectively.
Niobium Target Holder
A Nb (ρNb = 8.57 g/cm3) solid target was designed at UAB. The 2 mm thick circular assembly had
a 24 mm diameter (Figure 2-20).

Figure 2-20. Cross section drawing of Nb target assembly
The solid target base had a centered 600 μm circular bore with a 10 mm diameter. It contained a
250 μm thick Ti foil with a 10 mm diameter. Direct contact (heat conduction) between the foil and
Nb was achieved using a single-turn stainless steel spiral internal retaining ring with a 10.1 mm
outer diameter. After each irradiation, the retaining rings were removed, radionuclides produced
in them were allowed to decay, and they were discarded. The Nb targets were tested at proton
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energies and beam currents of up to 24 MeV and 40 μA, respectively.
Tantalum Target holder
A Ta (ρTa = 16.69 g/cm3) solid target was designed at UAB. The 2mm thick circular two-piece
assembly had a 24 mm diameter (Figure 2-21).

Figure 2-21. Cross section drawing of Ta target assembly
The solid target base had a centered 400 μm circular bore with a 10 mm diameter. It contained up
to 120 mg of pressed TiO2. A 0.5 mm diameter Viton O-ring created a seal between the base and
a 100 μm thin cap that enclosed the target material (similar to the Al target design). Direct contact
between the pressed TiO2, Ta base, and thin cap (Ti or Ta) was achieved using a single-turn
stainless steel spiral internal retaining ring with a 10.1 mm outer diameter. After each irradiation,
the retaining rings were removed, allowed to decay, and discarded. These Ta targets were tested
at proton energies and beam currents up to 24 MeV and 35 μA, respectively.

2.5

Production of Sc Radioisotopes from Titanium

2.5.1 Nuclear Reactions on Natural Titanium

Titanium (Z = 22) is a low-density (4.5 g/cm3) lustrous-silver transition metal with five stable
isotopes.25 It is known for its corrosion resistance and strength-to-density ratio and is primarily
used as an alloy with other metals (e.g. Fe or Al) to produce strong and lightweight alloys. In 2016,
170,000 tons of Ti was produced. It most often adopts a +4 oxidation state and octahedral
coordination geometry. It has a low (relative to Al) thermal conductivity of 21.9 W⋅m-1⋅K-1 (Table
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2-1).25 It is not a refractory metal but has many of the common refractory metal characteristics
(e.g. m.p. = 1660 °C).25 Titanium nuclei (Figure 2-22) bombarded with protons and photons at
energies that range from 0-24 MeV will induce nuclear reactions that produce 43Sc, 44mSc, 44gSc,
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Sc, 47Sc, and 48Sc and other radionuclides.

Figure 2-22. A select region of the Chart of the Nuclides (Z = 21 to 23)1
A summary of the different reactions that can occur when bombarding natural titanium with
photons and protons (at energies up to 24 MeV) are given in Table 2-2.
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Table 2-2. Proton- and photon-induced nuclear reactions on Ti nuclei9, 26
Radionuclide

Nuclear Reaction

Q-value (MeV)

Threshold (MeV)

Ti(p,α)

-3.07

3.14

Ti(p,n+α)

-11.95

12.21

Ti(p,α)

-2.25

2.30

Ti(p,n+α)

-13.88

14.17

Ti(p,2n+α)

-22.02

22.47

47

Ti(p,2p)

-10.46

10.69

Ti(γ,n+p)

-2.21

2.21

Ti(p,α)

-14.37

14.67

Ti(p,n+α)

-1.94

1.98

-11.44

11.68

Ti(γ,p)

-1.14

1.14

Ti(γ,n+p)

-1.96

1.96

-2.23

2.28

Ti(γ,p)

-1.13

1.13

Ti(p,2p)

-11.35

11.59

Ti(p,n)

-3.71

3.79

Ti(p,2n)

-15.34

15.66

Ti(p,γ)

6.83

0.0

Ti(p,n)

-4.79

4.89

Ti(p,2n)

-12.93

13.20

43Sc

46
47

44mSc/44gSc

47
48
49

46Sc

48

49
50
47Sc

48

Ti(p,2p)

48
49

50
48Sc

49
49

47V

47
48

48V

Ti(p,α)

47
48
49

The proton-induced reactions on naturally isotopic Ti (natTi) have been described and these
reactions on natTi were initially investigated using Ti foils to develop targetry and target processing
strategies.9 Developing this expertise allowed the use of more expensive isotopically enriched Ti
target material to produce 43Sc, 44Sc, and 47Sc.
Nuclear data describing the natTi(p,x) reactions was retrieved from the Experimental Nuclear
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Reaction Data (EXFOR) database and used to predict (Equation 2-9) the approximate end-ofbombardment (EOB) yields of reaction products. In parallel, these predicted yields were verified
using the TR-24 (90° target station) to bombard natTi foils with protons at energies up to 24 MeV.
The

nat

Ti foils were mounted onto disc shaped Nb target holders (see Section 2.4.5), irradiated,

dissolved in mineral acid, and their EOB yields were determined by measuring small aliquots of
each digestant with a gamma detector. The measured and predicted yields are shown in Figure
2-23.

Figure 2-23. Plot showing predicted EOB yield and experimental EOB yield for natTi(p,x)
reactions
The yields (determined by γ-ray measurement) agreed with the predicted yields based on EXFOR
data. These results from early experiments showed that significant quantities of Sc radioisotopes
could be produced at UAB. In turn, these Sc radiotracers could be used for the development of
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target processing strategies and radiosynthesis of nuclear molecular imaging agents. The key
limitation of this production route (with natTi) is the low radioisotopic and radionuclidic purity of
43

Sc, 44Sc, and 47Sc. Thus, production using enriched 46Ti, 47Ti, and 50Ti was investigated in order

to obtain radiopure mixtures of 43Sc, 44Sc, and 47Sc.

2.5.2 Nuclear Reactions on Enriched Titanium

Enriched Ti material (46Ti, 47Ti, 48Ti, and 50Ti) can be used to produce 43Sc, 44Sc, and 47Sc while
minimizing the co-production of 46Sc and 48Sc and other radionuclidic impurities. Due to the cost
of enriched Ti ($3-30/mg), irradiated target material must be recovered during target processing
so that it can be recycled. After recovery, this material can be precipitated and combusted as TiO2.
The recovered TiO2 can be directly converted to Ti metal via reduction but this process can be
difficult due to a large and positive Gibbs energy (e.g., >350 kJ⸱mol-1). The direct reduction of
TiO2 to Ti metal can occur via a metallothermic reaction. Metallothermic reactions are
displacement reactions that use reactive metals to reduce compounds so that metals, alloys,
nonmetal elementary substances, and composites are produced.27 For example, metallic calcium,
which is air reactive and requires handling in inert atmosphere, can be used to reduce TiO2 to Ti
at temperatures above 1000°C.3 Due to the stability of TiO2 (positively large Gibbs energy) the
reduction to Ti using hydrogen is not feasible.
In this work, direct reduction was avoided due to the many handling steps and likely loss of
enriched target material that would occur during iterative use (i.e., recycling target material).
Instead, target holders were developed to contain and mount TiO2 such that it could be irradiated
with protons. The Al target holder (see Section 2.4.5) and Ta target holder (see Section 2.4.5) were
used for irradiation of TiO2 at energies up to 17 MeV and 24 MeV, respectively.
In all cases, Ti enrichment factors that are <100% will lead to some co-production of unwanted
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47

V and 48V (from reactions on 47Ti and 48Ti) due to the magnitude of their cross sections (Figure

2-24).

Figure 2-24. Reactions that produce 48V and 47V on Ti nuclei28-32
Figure 2-24 shows that as proton energies drop below 20 MeV increasing quantities of 47V and
48

V will be produced. The EOB yields for these contaminants will depend on the amount of 46Ti,

47

Ti, and 48Ti present in the target material. Fortunately, co-produced 47V and 48V can be separated

from radioscandium during target processing to improve radionuclidic purity of the desired
product.
In contrast, co-produced contaminant radioisotopes of Sc cannot be chemically separated from
the desired Sc product; thus, their excitation functions should be used to define proton energies
that limit their production. Likewise, the excitation functions for the desired
47

Ti(p,α)44m,44gSc,

48

Ti(p,2p)47Sc and

50

46

Ti(p,α)43Sc,

Ti(p,α)47Sc reactions can be used to maximize the

production of the 43Sc, 44Sc, or 47Sc radioisotope of interest. Unfortunately, few measurements of
the 46Ti(p,α)43Sc, 47Ti(p,α)44m,44gSc, 48Ti(p,2p)47Sc and 50Ti(p,α)47Sc reactions have been carried
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out and so cross section quantities predicted by the nuclear reaction code TALYS have been
included in the plots below.29
Production of Scandium-43
Scandium-43 can be produced via the 46Ti(p,α)43Sc reaction (Figure 2-25) using enriched 46Ti.

Figure 2-25. The 46Ti(p,α)43Sc excitation function28, 33
Figure 2-25 indicates that proton energies from 24 MeV to 10 MeV span the excitation function
peak. Titanium-46 can be obtained at enrichment levels up to 97%. The likely isotopic impurities
are 47Ti and

48

Ti, the latter due to its high natural abundance. Figure 2-26 shows the excitation

function for the reactions on these impurities that produce radioisotopic contaminants.
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Figure 2-26. Excitation functions of contaminant reactions on 47Ti and 48Ti28
If the proton energy range is reduced to 18 MeV or less, the predicted radioisotopic contaminants
will be 44mSc and 44gSc (Figure 2-26).
Production of Scandium-44
Scandium-44 in its ground state and its nuclear isomer, can be produced via the 47Ti(p,α)44m,44gSc
reaction (Figure 2-27) using enriched 47Ti.
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Figure 2-27. The 47Ti(p,α)44m,44gSc excitation function28, 29
Figure 2-27 indicates that proton energies from 24 MeV to 10 MeV span the excitation function
peak. Titanium-47 can be obtained at enrichment levels up to 95%. The most likely isotopic
contaminants are 48Ti and 49Ti due to similar mass numbers and natural abundance. Figure 2-28
shows the excitation function for the reactions on these Ti impurities that produce Sc radioisotopic
contaminants.
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Figure 2-28. Excitation functions of contaminant reactions on 47Ti, 48Ti and 49Ti28, 29
If the proton energy range is narrowed (approximately 20 MeV to 10 MeV), the primary
radioisotopic contaminants will be 46Sc and 47gSc (Figure 2-28).
Production of Scandium-47
Scandium-47 can be produced via the

48

Ti(p,2p)47Sc and

using enriched 48Ti or enriched 50Ti.

62

50

Ti(p,α)47Sc reactions (Figure 2-29)

Figure 2-29. The 48Ti(p,2p)47Sc and 50Ti(p,α)47Sc excitation functions28, 29, 32
Figure 2-29 indicates that proton energies from 24 MeV to 17 MeV and 24 MeV to 8 MeV span
portions of the excitation function peak for the

48

Ti(p,2p)47Sc and

50

Ti(p,α)47Sc reactions,

respectively. These enriched isotopes can be obtained at enrichment levels up to 99% and 80%,
respectively. Titanium-48 can be obtained with the highest enrichment factor (due to its natural
abundance); however,

48

Ti is the likely isotopic impurity in enriched

50

Ti. Enriched

50

Ti that

contains mostly 48Ti as an isotopic contaminant allows 47Sc production via both reaction pathways.
Figure 2-30 shows the excitation function for the reactions on these impurities (i.e., 48Ti, 49Ti, and
50

Ti) that produce radioisotopic contaminants.
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Figure 2-30. Excitation functions of contaminant reactions on 48Ti and 50Ti28, 29
Figure 2-30 indicates that a thick target could be used with 24 MeV protons and the predicted
radioisotopic contaminants will be 46Sc,

44m

Sc,

44g

Sc, and

48

Sc (Figure 2-30). However, in both

cases (enriched 48Ti and 50Ti), due to the long half-life of 46Sc, a maximum proton energy of 24
MeV can be used without significant co-production of 46Sc.
The above excitation functions illustrate that production of Sc radionuclides with enriched Ti
target material will result in complex mixtures that include radioisotopic contaminants that will
affect radionuclidic purity. Further, in most cases, experimental measurements are needed to
determine the optimal proton energies to maximize 43Sc, 44Sc, and 47Sc yield while minimizing coproduction of radioisotopic contaminants.

2.6

Production of Titanium-44 from Scandium

Scandium (Z = 21) is a low-density (2.99 g/cm3), naturally occurring silvery-white metal with 1
stable isotope 45Sc.25 It develops a yellowish hue when oxidized by air. It is extracted as Sc2O3
(10-15 ton/y) from Sc-containing minerals and has few commercial applications. It has a low
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thermal conductivity (relative to Al) of 15.8 W⋅m-1⋅K-1.25 It is a soft metal that can be easily
machined and has a melting point of 1541°C.25 Sc nuclei bombarded with protons at energies from
0 – 30 MeV will produce 44mSc, 44gSc, 45Ti (t1/2 = 184.8 min), and 44Ti.
Table 2-3. Proton-induced nuclear reactions on Sc nuclei9, 26
Radionuclide
44mSc/44gSc
45Ti
44Ti

Nuclear Reaction

Q-value (MeV)

Threshold (MeV)

-11.33

11.58

Sc(p,n)

-2.84

2.91

Sc(p,2n)

-12.38

12.65

45

Sc(p,n+p)

45
45

Titanium-44, which is of interest for its use in a

44

Ti/44Sc generator, can be produced via the

45

Sc(p,2n)44Ti reaction using monoisotopic 45Sc (Figure 2-31).

Figure 2-31. The 45Sc(p,2n)44Ti excitation functions28, 29, 34, 35
Figure 2-31 indicates that a proton energy from 24 MeV to 13 MeV will span a large portion of
the excitation function peak (at energies up to 24 MeV) for the 45Sc(p,2n)44Ti reaction. Scandium45 can be obtained at greater than 99.99% chemical purity. Figure 2-32 shows the excitation
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function for the reactions on 45Sc that will co-produce radionuclides.

Figure 2-32. Excitation functions of contaminant reactions on 45Sc28, 29, 34, 36
Due to the long half-life of 44Ti (see Section 2.1), co-production of 45Ti, 44mSc, and 44gSc do not do
not need to be taken into account when selecting the irradiation parameters, such as proton energy.
In this case, the irradiated 45Sc can be stored for 30 days to allow decay of 44mSc. The short-lived
45

Ti will mostly decay 30 h after EOB.

2.7

Post-Irradiation Target Processing

The radionuclides produced via irradiation of a target must be chemically separated from the target
material and purified from both stable and radioactive contaminants. In this work, approximately
10 kBq to 3 GBq (10-15 to 10-8 g) of 43Sc, 44Sc, or 47Sc was produced in Ti (0.05 to 0.12 g) along
with elemental impurities like Fe and Zn (10-7 to 10-5 g) that lead to contaminant radionuclides
(via unwanted nuclear reactions). In general, techniques that are utilized for purification and
isolation of target radionuclides include solvent extraction, electro-deposition, precipitation,
distillation, and ion-exchange chromatography. This work uses ion-exchange chromatography,
which is an analytical technique used to separate complexes based on differences in their
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electrostatic interactions with functional groups fixed to a chromatographic support. The nature of
this technique requires that irradiated target materials be digested to obtain the target radionuclide
in a stable solvated form.

2.7.1 Target Digestion

The digestion (i.e., dissolution) of irradiated Ti metal and TiO2 is an essential part of the production
and purification of 43Sc, 44Sc, and 47Sc. Titanium is known to have excellent corrosion resistance
due to a stable and strongly adherent oxide film (TiO2) that spontaneously forms when it is exposed
to air. The formation of this film can be accelerated by heating or by exposure to oxidizing agents
(e.g., HNO3). Thus, a successful digestion method must be able to attack the TiO2 film.
Historically, hydrofluoric acid (HF) has been the most effective acid for breaking the strong
Si-O bond (Average bond enthalpy = 798 kJ/mol) that prevents or complicates extraction of metals
from geological samples.37 Likewise, It can be used to rapidly attack (i.e., break) the strong Ti-O
bond (Average bond enthalpy = 662 kJ/mol).37 In aqueous HF, the digestion of TiO2 occurs via
Equation 2-12 to form the colorless hydrogen hexafluorotitanate(IV).
TiO2 + 6HF → H2 TiF6 + 2H2 O

(2-12)

2Ti (s) + 6HF (aq) → 2TiF3 (aq) + 3H2 (g)

(2-13)

The digestion of Ti metal in aqueous HF occurs via two steps (Equation 2-13 and Equation 214).37, 38

4TiF3 (aq) + 4HF (aq) + O2 (g) → 4TiF4 (aq) + 2H2 O (l)

(2-14)

Thus, Ti digested by HF, results in solutions containing Ti(III) and Ti(IV) that have an intense
dark-violet color.
Alternatively, mixtures of HF-HCl can be used in place of concentrated HF. These systems at
low acid molarities (0.1 to 1.0 M) have been shown to digest Ti metal and results in dark-violet
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colored solution.39 The use of HF-HCl systems were investigated in this work to digest Ti metal
and TiO2.

2.7.2 Ion-exchange Chromatography

Ion-exchange chromatography, like other liquid chromatography techniques, involves a mobile
phase and a stationary phase. In this application, the mobile phase contains the dissolved target
material, the desired radionuclide, and any impurities. The stationary phase is a chromatographic
support (inert organic matrix) fixed with ionizable functional groups that can carry displaceable
ions. Equation 2-16 models the interaction of a cationic radionuclide (M+) and a mobile phase
cation (C+) carried by an anionic functional group (F-) bound to a solid support (S).
S − F − C+ + M+ ↔ S − F − M+ + C+

(2-16)

If the magnitude of the electrostatic interactions between M+ and F- are greater than C+ and F- then
the cationic radionuclide (present as a complex ion in solution) will be retained by the functional
group. This action displaces the mobile phase cation. Subsequently, the mobile phase composition
can be adjusted to displace the retained M+.
The three chromatographic resins (Figure 2-33) used in this work were branched N,N,N’,N’tetra-2-ethylhexyldiglycolamide (BDGA) and two styrene divinylbenzene copolymer lattices
functionalized with either sulphonic acid (AG MP-50) or iminodiacetic acid (CHELEX 100).
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Figure 2-33. Three cation exchange resins used in this work
The magnitude of the electrostatic interaction at different mobile phase compositions with these
resins can be measured to determine selectivity for one cation over another. These data can be used
to develop selective gradients that separate one cationic species from another. This same process
could be used with anionic species when the ionizable functional groups are capable of carrying
displaceable anions.

2.8

Summary

The medically relevant radioisotopes of Sc (43Sc, 44Sc, and 47Sc) can be produced using natTi and
enriched Ti (46Ti, 47Ti, 48Ti, and 50Ti) as a target material. Further, an alternative production route
for 44Sc (which yields only the ground state of this isotope) involves the cyclotron production of
44

Ti via the 45Sc(p,2n)44Ti reaction. Titanium-44 via its decay to 44Sc could be used in a 44Ti/44Sc

radioisotope generator. These radioisotopes can be produced using energetic protons and photons
to induce nuclear reactions; however, in some cases the probabilities of these reactions (i.e., cross
sections) are not well studied. In each case, the radioisotope of interest will be contained in a Ti
metal, TiO2, or Sc matrix. After irradiation, these materials must be digested and aqueous
analytical techniques employed to purify

43

Sc,

44

Sc,

47

Sc, and

44

Ti from the irradiated target

material and co-produced radioactive contaminants. The next chapter details an investigation into
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the photonuclear production of 47Sc using natTi metal using a 22 MeV medical eLINAC that was
repurposed for basic physics research.

2.9
1.

References

Kinsey, R. R.; Dunford, C. L.; Tuli, J. K.; Burrows, T. W. The NUDAT/PCNUDAT
Program for Nuclear Data, paper submitted to the 9th International Symposium of
Capture Gamma-Ray Spectroscopy and Related Topics, Budapest, Hungary, October
1996; Data extracted from the NUDAT database, v2.8, February 17th, 2020.

2.

AlDeghaither, D.; Smaglo, B. G.; Weiner, L. M., Beyond peptides and mAbs--current
status and future perspectives for biotherapeutics with novel constructs. Journal of
clinical pharmacology 2015, 55 Suppl 3 (0 3), S4-S20.

3.

Domnanich, K. A.; Eichler, R.; Müller, C.; Jordi, S.; Yakusheva, V.; Braccini, S.;
Behe, M.; Schibli, R.; Türler, A.; van der Meulen, N. P., Production and separation of
(43)Sc for radiopharmaceutical purposes. EJNMMI radiopharmacy and chemistry 2017,
2 (1), 14-14.

4.

Filosofov, D.; Loktionova, N.; Roesch, F., A 44 Ti/ 44 Sc radionuclide generator for
potential application of 44 Sc-based PET-radiopharmaceuticals. Radiochimica Acta RADIOCHIM ACTA 2010, 98, 149-156.

5.

Radchenko, V.; Engle, J. W.; Medvedev, D. G.; Maassen, J. M.; Naranjo, C. M.; Unc,
G. A.; Meyer, C. A. L.; Mastren, T.; Brugh, M.; Mausner, L.; Cutler, C. S.;
Birnbaum, E. R.; John, K. D.; Nortier, F. M.; Fassbender, M. E., Proton-induced
production and radiochemical isolation of (44)Ti from scandium metal targets for
(44)Ti/(44)Sc generator development. Nucl Med Biol 2017, 50, 25-32.

6.

Domnanich, K. A.; Müller, C.; Benešová, M.; Dressler, R.; Haller, S.; Köster, U.;
Ponsard, B.; Schibli, R.; Türler, A.; van der Meulen, N. P., 47Sc as useful β–-emitter for
the radiotheragnostic paradigm: a comparative study of feasible production routes.
EJNMMI Radiopharmacy and Chemistry 2017, 2 (1), 5.
70

7.

Muller, C.; Bunka, M.; Haller, S.; Koster, U.; Groehn, V.; Bernhardt, P.; van der
Meulen, N.; Turler, A.; Schibli, R., Promising prospects for 44Sc-/47Sc-based
theragnostics: application of 47Sc for radionuclide tumor therapy in mice. J Nucl Med
2014, 55 (10), 1658-64.

8.

Kelsey, C. A., The Physics of Radiology, 4th Edition edited by H. E. Johns and J. R.
Cunningham. Medical Physics 1984, 11 (5), 731-732.

9.

Khandaker, M. U.; Kim, K.; Lee, M. W.; Kim, K. S.; Kim, G. N.; Cho, Y. S.; Lee, Y.
O., Investigations of the natTi(p,x)43,44m,44g,46,47,48Sc,48V nuclear processes up to
40MeV. Applied Radiation and Isotopes 2009, 67 (7), 1348-1354.

10.

Takács, S.; Tárkányi, F.; Sonck, M.; Hermanne, A., New cross-sections and
intercomparison of proton monitor reactions on Ti, Ni and Cu. Nuclear Instruments and
Methods in Physics Research Section B: Beam Interactions with Materials and Atoms
2002, 188 (1), 106-111.

11.

Zarie, K.; Al-Hammad, N.; Azzam, A., Experimental study of excitation functions of
some proton induced reactions on natTi for beam monitoring purposes. In Radiochimica
Acta, 2006; Vol. 94, p 795.

12.

Knapp, F.; Mirzadeh, S.; Beets, A., Reactor production and processing of therapeutic
radioisotopes for applications in nuclear medicine. J Radioanal Nucl Chem 1996, 205,
93-100.

13.

Knapp, F. F.; Mirzadeh, S.; Beets, A. L.; O'Doherty, M.; Blower, P. J.; Verdera, E. S.;
Gaudiano, J. S.; Kropp, J.; Guhlke, J.; Palmedo, H.; Biersack, H. J., Reactor-produced
radioisotopes from ORNL for bone pain palliation. Appl Radiat Isotopes 1998, 49 (4),
309-315.

14.

Synowiecki, M. A.; Perk, L. R.; Nijsen, J. F. W., Production of novel diagnostic
radionuclides in small medical cyclotrons. EJNMMI Radiopharm Chem 2018, 3 (1), 3-3.

71

15.

Qaim, S. M., The present and future of medical radionuclide production. In Radiochimica
Acta, 2012; Vol. 100, p 635.

16.

Habs, D.; Köster, U., Production of medical radioisotopes with high specific activity
in photonuclear reactions with γ-beams of high intensity and large brilliance. Appl Phys B
2011, 103 (2), 501-519.

17.

Mang’era, K.; Ogbomo, K.; Zriba, R.; Fitzpatrick, J.; Brown, J.; Pellerin, E.; Barnard,
J.; Saunders, C.; de Jong, M., Processing and evaluation of linear accelerator-produced
99

18.

Mo/99mTc in Canada. J Radioanal Nucl Chem 2015, 305 (1), 79-85.

Grimm, T. L.; Boulware, C. H.; Hollister, J. L.; Jecks, R. W.; Mamtimin, M.;
Starovoitova, V. Commercial Superconducting Electron Linac for Radioisotope
Production; 13-0019--FTR-0001; Other: 13-0019 United States 10.2172/1209691 Other:
13-0019 CHO English; ; Niowave, Inc., Lansing, MI (United States): 2015; p Medium:
ED; Size: 27 p.

19.

Queern, S. L.; Cardman, R.; Loveless, C. S.; Shepherd, M. R.; Lapi, S. E., Production
of 15O for medical applications via the 16O(γ,n)15O reaction. Journal of Nuclear
Medicine 2018.

20.

Council, N. R., Medical Isotope Production Without Highly Enriched Uranium. The
National Academies Press: Washington, DC, 2009; p 220.

21.

INTERNATIONAL ATOMIC ENERGY AGENCY Production of Long Lived Parent
Radionuclides for Generators: 68Ge, 82Sr, 90Sr and 188W; IAEA: Vienna, 2010.

22.

INTERNATIONAL ATOMIC ENERGY AGENCY Cyclotron Produced Radionuclides:
Principles and Practice; IAEA: Vienna, 2009.

23.

Pavan, R. A.; Gelbart, W. Z.; Zeisler, S. K., Thermal modeling of high-current solid
targets. J Radioanal Nucl Chem 2003, 257 (1), 203-206.

72

24.

Ziegler, J. F.; Ziegler, M. D.; Biersack, J. P., SRIM – The stopping and range of ions in
matter (2010). Nuclear Instruments and Methods in Physics Research Section B 2010,
268 (11), 1818-1823.

25.

CRC handbook of chemistry and physics. 1977.

26.

B. Pritychenko, A.; Sonzogni, A., Q-value calculator. Brookhaven National Laboratory:
NNDC, 2012.

27.

Xing, Z.; Lu, J.; Ji, X., A Brief Review of Metallothermic Reduction Reactions for
Materials Preparation. Small Methods 2018, 2 (12), 1800062.

28.

Levkovski, V. N., Middle mass nuclides activation cross-sections by medium energy
protons and a particles. Inter-Vesi: Moscow, 1991.

29.

Koning, A. J.; Rochman, D., Modern Nuclear Data Evaluation with the TALYS Code
System. Nuclear Data Sheets 2012, 113 (12), 2841-2934.

30.

Tanaka, S.; Furukawa, M., Excitation runctions for (p,n) reactions with titanium,
vanadium, chromium, iron and nickel up to Ep=14 MeV. J Physical Soc Japan 1959, 14
(10), 1269-1275.

31.

West Jr., H. I.; Lanier, R. G.; Mustafa, M. G. Excitation Functions for the Nuclear
Reactions on Titanium Leading to the Production of 48V, 44Sc, and 47Sc by Proton,
Deuteron and Triton Irradiations at 0–35 MeV; U.C., Lawrence Rad. Lab., Berkeley and
Livermore, 1993, 1993; pp 1 (UCRL-ID-115738).

32.

Gadioli, E.; Gadioli Erba, E.; Hogan, J. J.; Burns, K. I., Emission of alpha particles in
the interaction of 10–85 MeV protons with48,50Ti. Zeitschrift für Physik A Atoms and
Nuclei 1981, 301 (4), 289-300.

33.

Carzaniga, T. S.; Auger, M.; Braccini, S.; Bunka, M.; Ereditato, A.; Nesteruk, K. P.;
Scampoli, P.; Türler, A.; van der Meulen, N., Measurement of 43Sc and 44Sc production

73

cross-section with an 18MeV medical PET cyclotron. Applied Radiation and Isotopes
2017, 129, 96-102.
34.

McGee, T.; Rao, C. L.; Saha, G. B.; Yaffe, L., Nuclear interactions of 45Sc and 68Zn
with protons of medium energy. Nucl. Phys. A 1970, 150 (1), 11-29.

35.

Daraban, L.; Adam Rebeles, R.; Hermanne, A.; Tarkanyi, F.; Takacs, S., Study of the
excitation functions for 43K, 43,44,44mSc and 44Ti by proton irradiation on 45Sc up to
37MeV. Nuclear Instruments and Methods in Physics Research Section B: Beam
Interactions with Materials and Atoms 2009, 267 (5), 755-759.

36.

Meadows, J. W.; Diamond, R. M.; Sharp, R. A., Excitation Functions and Yield Ratios
for the Isomeric Pairs Br80,80m, Co58,58m, and Sc44,44m Formed in (p,pn) Reactions. Phys.
Rev. 1956, 102 (1), 190-195.

37.

Cottrell, T. L., The strengths of chemical bonds. 2d ed. ed.; Butterworths: London, 1958.

38.

Straumanis, M. E.; Chen, P. C., The mechanism and rate of dissolution of titanium in
hydrofluoric acid. J. Electrochem. Soc 1951, 98 (6), 234.

39.

Straumanis, M. E.; James, W. J.; Ratliff, J. L., A reaction rate study in hydrofluoric acid
of the dissolution of titanium and the alpha solid solution of oxygen in titanium. Journal
of the Less Common Metals 1961, 3 (4), 327-332.

74

Chapter 3: Photonuclear Production,
Chemistry, and In Vitro Evaluation of the
Theranostic Radionuclide 47Sc
3.1

Introduction

Theranostic applications in molecular imaging and therapy involve the use of a radionuclide or
radionuclide pairs with nuclear, physical and biological characteristics that allow tailored imaging
and therapy in the same patient.1 This personalized approach to nuclear medicine offers the
possibility of matching the properties of different theranostic radionuclides with a targeting vector
for distinct tumor types. Important parameters considered when selecting suitable radionuclides
include availability, chemistry, biological properties, half-life and decay properties. Therefore,
better matching of radionuclide properties to different diseases can be enabled by the development
of new production routes for hard to obtain theranostic radionuclides. Thus, increasing the number
of available medical radionuclides will motivate more innovative diagnostic and therapeutic agents
for use in personalized nuclear medicine.1-3
Recently, the development of multiple receptor-targeted radionuclide therapies has highlighted
the need for the rapid and complete assessment of their pharmacokinetics.4-6 To address this need,
imaging with a chemically identical diagnostic (labeled with a radionuclide of the same element)
affords the truest picture of in vivo distribution for the therapeutic agent.7 Therefore, the
development of matched-pair radionuclides for use in receptor-targeted therapies and imaging is
an emerging area of research. Unfortunately, the limited availability of a number of the most
promising matched-pair radionuclides has hindered pre-clinical research and translation of new
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therapeutic agents to the clinic.7
The theranostic radionuclide 47Sc (Figure 2-7) is compatible with the biological half-life of
antibodies or peptide-based radiopharmaceuticals.8, 9 Further, 43Sc (Figure 2-2) and 44Sc (Figure
2-3) have been proposed as diagnostic radionuclides for PET imaging.10 The mode of decay,
emitted particles, and emitted γ-rays for each Sc radioisotope were introduced in Chapter 2, Section
2.1.
Reactor production of 47Sc has been investigated using neutron capture on enriched titanium
via the

47

Ti(n,p)47Sc reaction (En > 1 MeV) or neutron capture on enriched

46

Ca(n,γ)47Ca (En =

0.025 eV), resulting in 47Ca (t1/2 = 4.54 d), which may be used for a 47Ca-47Sc generator system.11,
12

One challenge facing development of a

47

Ca-47Sc generator is the natural abundance of

46

Ca

(0.004%). Due to this abundance, it is only available at enrichment levels up to 30%.13 Accelerator
production and measurement of cross sections for the production of 47Sc have been investigated
using medium to high energy protons (17 < Ep < 150 MeV) via the natTi(p,2p)47Sc, 48Ti(p,2p)47Sc,
51

V(p,3pn)47Sc, and natCa(p,2n)47Sc reactions.1, 13, 14 Cyclotron production via the above methods

resulted in co-production of 46Sc (Figure 2-8) and 48Sc (Figure 2-9), decreasing the radionuclidic
purity of
nat

47

Sc. Production with spallation neutrons was also investigated via the

V(n,x)47Sc and

nat

47

Ti(n,p)47Sc,

Ti(n,x)47Sc reactions.15 Based on these data, production routes that afford

radionuclidic purity suitable for clinical application require costly enriched targets or access to
nuclear reactors with a high-energy neutron flux (En > 1 MeV). Therefore, the poor availability of
47

Sc, due to the above factors, has hampered preclinical investigation and clinical application of

the theranostic 47Sc/43Sc and 47Sc/ 44Sc matched-pair radioisotopes.
In an effort to address the above challenges, recent work has investigated the use of highintensity electron linear accelerators (eLINACs) with 20-55 MeV electron beams to produce 47Sc
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via photonuclear reactions on titanium nuclei.16, 17 The electrons accelerated by these machines
emit bremsstrahlung radiation (Figure 2-17) as they pass through matter, resulting in a spectrum
of photon energies ranging from zero to the electron energy. A high-intensity flux of
bremsstrahlung photons can be obtained by using a radiator or “converter” made from a high Z
material, like W. A small fraction of the generated bremsstrahlung photons are energetic enough
to induce photonuclear reactions such as (γ,n) and (γ,p) for radionuclide production.18, 19 The flux
of bremsstrahlung photons can be enhanced with the use of a radiator or “converter” made from a
high Z material, like W. The use of converter does not significantly alter the energy distribution of
radiated photons, but it enhances the number of radiated photons and hence increases the number
of radiated photons that are energetic enough to induce photonuclear reactions. For example,
Rotsch et al. (2018) used natTiO2 targets to demonstrate a 47Sc production rate at 35 MeV and 40
MeV of 4.25 MBq/g·kW·hr and 6.92 MBq/g·kW·hr, respectively, using bremsstrahlung photons.20
Belyshev et al. (2015) showed that the integrated cross section of the natTi(γ,p)47Sc reaction, using
thin titanium foils of natural isotopic composition, was 110 ± 19 mb using a 55 MeV electron
beam.17 T. R. Sherwood and W. E. Turchinetz (1962) measured the cumulative cross section of
the natTi(γ,p)47Sc reaction (Figure 3-1), yielding a peak cross section of approximately 28 mb at
23 MeV and integrated cross section of 217 ± 32 MeV·mb between 13-29 MeV.21
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Figure 3-1. Excitation functions for the photon-induced 48,49Ti(γ,p)47Sc nuclear reaction21, 22
A high-intensity eLINAC facility capable of photonuclear radionuclide production has many
advantages in contrast to reactor or other accelerator facilities. These advantages include reduced
volume of radioactive waste, low cost and operation expense, and fewer nuclear reaction channels,
which may lead to a higher radionuclidic and radioisotopic purity of the final product. The
photonuclear production of

47

Sc,

99

Mo for

99

Mo-99mTc generators,

67

Cu for the

67

Cu/64Cu

theranostic matched-pair, 225Ac for targeted alpha therapy and 195mPt as a theranostic radionuclide
has been reported using bremsstrahlung radiation.16, 19, 23-25 These reports show that a number of
long-lived theranostic radionuclides or radionuclide pairs, including 47Sc, that suffer from lack of
availability, may be produced by photonuclear reactions at eLINAC facilities.
In this work, the photonuclear production of carrier-free

47

Sc via the

nat

Ti(γ,p)47Sc reaction

using bremsstrahlung radiation generated by an electron beam (22 MeV Varian CLINAC) was
investigated. To isolate the produced 47Sc from natTi target material, a separation method using AG
MP-50 cation exchange resin was developed. Following separation, the 47Sc was further purified
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using CHELEX 100 chelating resin. The purified

47

Sc was used to radiolabel 1,4,7,10-

acid-DPhe-c(Cys-Tyr-DTrp-Lys-Thr-Cys)-Thr-ol

tetraazacyclododecane-1,4,7,10-tetraacetic

(DOTATOC) and the in vitro binding of [47Sc]Sc-DOTATOC was then established in somatostatin
receptor subtype 2 (SSTR2)-expressing AR42J cells (Figure 3-2).

Figure 3-2. The methods developed in this work
These results show that future photonuclear production of 47Sc at a high-intensity eLINAC facility
could represent a production route capable of producing the quantities needed for pre-clinical
research and translation to the clinic of this important theranostic radionuclide.

3.2

Materials & Methods

The materials and methods used to investigate the photonuclear production of 47Sc are described
below.
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General Materials
All chemicals were analytical or trace metals grade. Deionized 18.2 MΩ⋅cm water (Milli-Q
System; Millipore, Billerica, MA, USA) was used unless otherwise specified. Ammonium acetate
(NH4CH3CO2, 99.999%), sodium hydroxide (NaOH, pellets, 99.995%), hydrogen peroxide (H2O2,
TraceSELECT® Ultra ≥30), hydrochloric acid (HCl, 37 % wt. in water, 99.999%), nitric acid
(HNO3, 70% wt. in water, 99.999%), and sulfuric acid (H2SO4, 95-98% wt. in water, 99.999%)
were purchased from Sigma-Aldrich (St. Louis, Missouri, USA). Chelex® 100 chelating resin
(100-200 mesh, Na+ form) and AG MP-50 cation exchange resin (100-200 mesh, H+ form) were
purchased from BIO-RAD (Hercules, California, USA). 1,4,7,10-tetraazacyclododecane-1,4,7,10tetraacetic acid-DPhe-c(Cys-Tyr-DTrp-Lys-Thr-Cys)-Thr-ol (DOTATOC) and L-Cysteinamide,
D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2→7)-disulfide (Octreotide) were purchased from
Bachem Americas, Inc. (Torrance, CA, USA). Type 4N high-purity, 0.127 mm thick, natural
titanium foil was purchased from ESPI Metals (Ashland, OR, USA). Scandium(III) nitrate hydrate
(Sc(NO3)3, FW: 240.97 g/mol, 99.9%) was purchased from Alfa Aesar (Heysharn, Lancashire,
UK). Stock solutions of 0.25 and 1.0 M ammonium acetate, pH adjusted to 4.7, were purified with
columns containing Chelex® 100 resin prior to use. All glassware was acid washed in a 50% HNO3
bath overnight at room temperature.
Instrumentation
A modified Varian CLINAC (2100, Palo Alto, CA, USA) located at Indiana University
(Bloomington, IN, USA) was used for all irradiations. The CLINAC was described in previous
work by Queern et al. (2018).26 To obtain a high-intensity flux of bremsstrahlung photons, a thin
high Z material, W, was placed immediately upstream of the Ti target. The average electron beam
current was calibrated using an open-air AC current transformer fabricated by Bergoz
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Instrumentation (Saint Genis Pouilly, France). For calibration measurements, the transformer was
mounted in the same location as the target holder. An electron beam energy of 22 MeV, the top
setting with this CLINAC, was selected to maximize the photon flux in the region most likely to
contain the highest photonuclear cross section for natTi(γ,p)47Sc.
Photonuclear Production
Scandium-47 was produced via the

48

Ti(γ,p)47Sc nuclear reaction by irradiation of a

nat

Ti target

foil-stack (39 foils, 2.0 x 2.0 x 0.135 mm) using bremsstrahlung radiation generated by impinging
22 MeV electrons onto a 0.762 mm thick W radiator.
Target Dissolution
The region where the bremsstrahlung beam struck each foil was determined by imaging select foils
for several hours with Gafchromic EBT3 radiographic film (Bridgewater, NJ, USA). The exposed
films were used to create punch templates for foil 1, 5, 10, 15, 20, 25, 30, and 35. The templates
were used to extract the activated Ti metal in each Ti target foil as discs using a McMaster Carr
portable lever-operated hole-punch with a 3 to 4 mm punch (Douglasville, GA, USA). The
extracted discs were split into three sets. Each foil set was placed in a 50 mL round bottom flask
along with 20 mL of aqueous 2.0 M H2SO4. The flask was fitted with a reflux condenser, and the
apparatus was heated at 350°C for 4 h using a sand filled mantle heater. During heating, the
colorless solution became deep-violet and remained clear. After heating, 1.16 mL of 30% H2O2
was added, resulting in a prompt color change from deep-violet to intense orange (Figure 3-3).
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Figure 3-3. The method used to digest 3-4 mm Ti discs
The solution was quantitatively transferred to a 100 mL beaker and the H2SO4 molarity was
adjusted to 0.5 M by adding 59 mL of water. The final solution contained approximately 0.5%
H2O2 in 80 mL of 0.5 M H2SO4.
Resin Conditioning
AG MP-50 and Chelex-100 resin were treated (to remove contaminants) before use by transferring
50 g of each to a separate clean 500 mL glass media bottle. First, the resins were mixed with 20
mL of 5.0 M HNO3. After sedimentation, the supernatant was decanted to remove fine resin
particles and contaminants. This process was repeated twice. Next, the resins were mixed with 20
mL of water. Similarly, the supernatant was decanted after sedimentation. This was repeated until
the water, after mixing, had a pH of 7. The above process was then repeated using 2.0 M HCl.
Finally, the treated resin was stored under water until use.
Separation Method
A separation method previously described by Kolsky et al. was adapted for this work.27 A glass
column (0.5 x 20 cm) was slurry packed with treated AG MP-50 cation exchange resin to a wet
bed height of 2.5 cm. A glass wool plug was placed atop the resin bed and eluents were passed
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through the column at a flow rate of 1.5 mL/min. The resin was equilibrated by passing 15 mL of
0.5 M H2SO4 containing 2% H2O2 through the column. The digested Ti target material and 47Sc in
approximately 80 mL of 0.5 M H2SO4 was loaded onto the column. The adsorbed Ti was eluted
with 40 mL of 2% H2O2 in 2.0 M H2SO4. The resin was equilibrated with 10 mL of water and the
adsorbed 47Sc was eluted with 20 mL of 1 M ammonium acetate (pH 4-5). This eluate, containing
47

Sc, was loaded onto a column (0.5 x 20 cm) containing Chelex® 100 chelating resin packed and

prepared under conditions as described above. The adsorbed 47Sc was rinsed with 20 mL of water
and eluted in 5.0 mL of 12.1 M HCl (Figure 3-4).

Figure 3-4. The two-step purification of 47Sc
After elution, the eluate was evaporated to a wet salt by gentle heating under nitrogen gas flow.
This residue was dissolved in 1 mL of water and evaporated to dryness. This process was
completed twice, resulting in a final product pH of 7. The final product was dissolved in 400 µL
of 0.25 M ammonium acetate (pH 4), which was used as the

47

Sc solution for subsequent

radiolabeling reactions. A typical separation and purification required 4 h.
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Elemental Analysis
Fractions preserved from separations in this work were analyzed via inductively coupled plasma
mass spectrometry (ICP-MS) to determine the concentration of elements present. Multi-element
standards in 2% HNO3 at 1, 50, 100, 250, 500, 750, and 1000 mg/L were used for instrument
calibration. For each collected fraction, an aliquot was diluted in 2% HNO3 and analyzed on an
Agilent Technologies 7800 ICP-MS (Santa Clara, CA, USA) to determine the presence of
transition metals. Agilent software, ICP-MS MassHunter v4.3, was used for data acquisition and
analysis.
γ-Ray Spectroscopy
Samples containing radionuclides in this work were characterized and quantified by γ-ray
spectroscopy using a Canberra GC2018 high-purity germanium (HPGe) detector with a relative
efficiency of 24.5% (Meriden, CT, USA) connected to a Canberra DSA-100 multichannel analyzer
(Meriden, CT, USA). Canberra Genie 2000 software was used for all data acquisition and analysis
(Meriden, CT, USA). An energy and efficiency calibration was performed using a mixed nuclide
source in a sealed 1.5 mL microcentrifuge vial prepared by Eckert & Ziegler Analytics (Atlanta,
GA, USA). Efficiency-calibration spectra with a minimum photopeak area of 2 x 105 counts were
collected and fit to a fourth-order polynomial to determine the detector efficiency.28 For all
measurements, aliquots of sample material were transferred to a 1.5 mL vial, diluted to 1 mL, and
suspended in a fixed acrylic holder at a distance of 5 cm from the HPGe detector. This geometry
was maintained for all samples. The activity of characterized radioisotopes was determined based
on the net peak area in each photopeak.29 For each photopeak, the activity (A0) at the beginning of
the decay-counting measurement was determined according to Equation 4-1 where λ is the decay
constant of the radioisotope in s-1, NA is the net peak area, Iγ is the branching ratio of the γ-ray, ε
is the energy-dependent photopeak efficiency of the detector, DT is average dead time during the
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measurement, and tR is the real time of measurement in s.
𝐀𝐀 𝟎𝟎 = 𝐈𝐈

𝛌𝛌𝐍𝐍𝐀𝐀

𝛄𝛄 𝛆𝛆(𝟏𝟏−𝐃𝐃𝐃𝐃)(𝟏𝟏−𝐞𝐞

(4-1)

−𝛌𝛌𝐭𝐭 𝐑𝐑 )

For all measurements, the average dead time was less than 5%.
Radiosynthesis of [47Sc]Sc-DOTATOC
As described by Pruszynski et al., radiolabeling of DOTATOC (1,421.60 g/mol) with

47

Sc was

carried out in pH 4-5 0.25 M ammonium acetate buffer.30 In brief, 60 μL of a 6.4 μg/μl aqueous
DOTATOC stock solution was added to 40 μL of 0.25 M ammonium acetate buffer in a 1.5 mL
centrifuge vial. To this vial, 1.7 MBq of 47Sc dissolved in 200 μL of 0.25 M ammonium acetate
was added. The reaction pH and final concentration of DOTATOC (270 nmol in 300 µL) was pH
4-5 and 0.9 mM, respectively. The reaction mixture was incubated for 30 minutes at 95°C using
an Eppendorf Thermomixer set to 800 rpm.
[47Sc]Sc-DOTATOC Characterization
Radiochemical analyses were performed using radio thin layer chromatography (radio-TLC) and
radio high-performance liquid chromatography (radio-HPLC). Radio-TLC analyses were
performed using Agilent Technologies instant TLC-SA (iTLC) chromatography paper (Santa
Clara, CA, USA) and were developed using a 1:1 mixture of 1.0 M ammonium acetate and
methanol. TLC plates were read using an Eckert & Ziegler AR-2000 radio-TLC system
(Hopkington, MA, USA) and Eckert & Ziegler Winscan 3.0 software (Hopkington, MA, USA)
was used to define regions of interest (ROI) and integrate peaks. Radio-HPLC analyses were
performed on an Agilent Technologies HPLC (Infinity 1260, Santa Clara, CA, USA) equipped
with a multi-wavelength diode-array detector followed by an in-line LabLogic NaI detector (FlowRAM Galbi NaI, Brandon, FL, USA) using a Thermo Scientific C18 analytical column (BetaBasic,
150 mm x 4.6 mm x 5 µm, 150 Å, Waltham, MA, USA). LabLogic Laura radiochromatography
85

software was used for radio-HPLC data collection and analysis. Before any measurement by radioHPLC, solvents (HPLC grade) were degassed and water used for HPLC mobile phase was passed
through a 0.22 µm filter. The HPLC method involved use of two solvents (A & B). Solvent A was
acetonitrile (ACN) with 0.1% trifluoroacetic acid (TFA) and Solvent B was water with 0.1% TFA.
The gradient elution began at 5%(A):95%(B) and changed linearly to 80%(A):20%(B) over 20
min at 1.0 mL/min.
Cell Culture
All cell culture materials were purchased from Fisher Scientific unless otherwise noted. The
SSTR2 positive rat pancreatic cancer cell line AR42J (ATCC, Manassas, VA, USA) was cultured
in GibcoTM IMDM media supplemented with 10% fetal bovine serum (FBS) and 0.1% gentamicin.
Cells were incubated at 37 °C in a 5% CO2 atmosphere and were harvested using 0.05% trypsinEDTA. Cells were washed once with supplemented IMDM prior to use. Cells were counted with
a Nexcelom (Lawrence, MA, USA) auto T4 bright field cell counter.
Competitive Binding Assay
AR42J cells were seeded into two 24-well plates (8-wells/plate) in 1 mL of media (1 x 105
cells/well) and incubated overnight. After incubation, media was discarded, and 1 mL of 75 kBq
[47Sc]Sc-DOTATOC (12 μM) in IMDM media was transferred into each non-blocking well (4wells/plate). For the blocking study, 1 mL of 75 kBq [47Sc]Sc-DOTATOC containing 40 μM
Octreotide was added into each blocking well (4 wells/plate). Additional 1 mL aliquots of the
blocking and non-blocking solutions were transferred into empty wells on each plate as a reference.
One mL of each solution, blocking and non-blocking, was transferred to separate 1.5 mL centrifuge
tubes and used as reference standards to determine total 47Sc added to each well. Subsequently,
the two 24-well plates were incubated at 37 °C for 2 h (first plate) or 4 h (second plate). At each
time point, cells were washed three times with PBS, lysed with 1.0 M NaOH, and transferred into
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1.5 mL centrifuge tubes. All centrifuge tubes were counted in a HIDEX 300 SL automatic γcounter using a 3” NaI crystal (Turku, Finland). Data is expressed as percentage of added dose
bound (% Bound) with the standard error of the mean (SEM). A one-way ANOVA test was applied
to each set of data (blocking and non-blocking) at 2 h and 4 h to determine P values and difference
between each observed mean.

3.3

Results

3.3.1

Scandium-47 Production

An average 47Sc yield (n = 3 ± 1σ) of 80 MBq/mA·h was obtained using a 22 MeV electron beam
with an average beam current of 2.5 μA (Table 3-1).
Table 3-1. The parameters for each natTi irradiation31
Run

EOB

Time
(min)

Average
Current (μA)

Radiator
THK (mm)

Titanium
Foils (no.)

1

03/29/2017 17:03:00

630

2.5

0.762

39

2

05/07/2017 11:35:00

680

2.5

0.762

40

3

10/06/2017 20:51:00

840

2.5

0.762

39

Using radiographic film, the region attributed to

47

Sc was mapped in select Ti foils. The beam

strike, imaged on the film, of the entry (no. 1) and exit (no. 39) foil had an average diameter of 3
and 4 mm, respectively. Select foils were characterized and the presence of 46Sc (Figure 2-8), 47Sc,
and 48Sc (Figure 2-9) were confirmed by γ-ray analysis. The EOB radioisotopic purities of 47Sc,
46

Sc, and

48

Sc were determined by γ-ray analysis. The average Sc decay-corrected to EOB

radioisotopic purities (n = 9 ± 1σ) were (90.0 ± 0.1)% 47Sc, (1.2 ± 0.1)% 46Sc, and (8.3 ± 0.1)%
48

Sc. Figure 3-5 shows the post-EOB radioactive decay of 46Sc, 47Sc, and 48Sc and the change in

47

Sc radioisotopic purity (relative to 46Sc and 48Sc) as a function of time for Run 3.
87

Figure 3-5. The decay of Sc radioisotopes and 47Sc radioisotopic purity31
The maximum 47Sc radioisotopic purity (Figure 3-5) was reached approximately 5.85 d post-EOB.
Templates fashioned from exposed radiographic films were used to mechanically extract the
region containing the greatest concentration of 47Sc. The average (n = 3 ± 1σ) extraction efficiency
(Figure 3-6) was (91 ± 8)%.
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Figure 3-6. Scandium-47 extraction efficiencies from irradiated natTi foil31

3.3.2

Digestion and Purification

The extracted discs from each irradiation were split into three groups (A, B, and C) and dissolved
in 2.0 M H2SO4 under reflux conditions. After digestion, the clear and deep-violet solution was
cooled to room temperature. A 1 mL aliquot was removed from each group and analyzed with an
HPGe detector to measure the activity associated with each radionuclide. Table 3-2 shows the
average radioactivities decay-corrected to EOB for

46

Sc,

47

Sc, and

48

Sc (sum of A, B, and C

radioactivities).
Table 3-2. The average (n = 3 ± 1σ) 46,47,48Sc radioactivities measured in the
extracted natTi discs31
Run

46

Sc (kBq)

1

26 (1)

2178 (7)

229 (1)

2

25 (1)

2111 (124)

210 (17)

3

32 (1)

2420 (138)

222 (14)

47

Sc (kBq)

Sc (kBq)

48

The digestion solution was adjusted to contain two percent of 30% H2O2 dissolved in 0.5 M H2SO4.
Upon addition of hydrogen peroxide, the solution rapidly changed color to an intense orange but
remained clear. In previous work, Müller and Schwarzenbach characterized the orange
peroxytitanium(IV) species in solutions below pH 1, in general form, as Ti(O2)(OH)n-2(4-n)+;
however, the number of hydroxyl groups has not been shown conclusively.32 The mixture of Sc
radioisotopes and peroxytitanium species mixture was directly loaded onto a column containing
AG MP-50 resin.
For the final optimized separation and purification (Run 3), an aliquot was taken at each point
in the separation and analyzed by HPGe and ICP-MS. Due to weak peroxytitanium affinity for AG
MP-50 resin at low H2SO4 concentration, the

nat

Ti target material was recovered in the flow-
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through and 1 M H2SO4 eluate. The average recovery (n = 3 ± 1σ) of bulk natTi target material was
quantitative as measured by ICP-MS. After the first eluent, the AG MP-50 resin was rinsed with
10 mL of water to remove hydrogen peroxide from the column. The strongly adsorbed Sc
radioisotopes were recovered in 20 mL of 1 M ammonium acetate (pH 4.7). The average decaycorrected EOB radioscandium recovery (n = 3 ± 1σ) was (92.2 ± 4.7)%. The concentration of
metal contaminants including Cr, Cu, Fe, Ni, and Zn, were measured in the 1 M ammonium acetate
eluate. The average concentrations (n = 3 ± 1σ) of each trace metal contaminant were 191 ± 15
μg/L (Cr), 188 ± 36 μg/L (Cu), 414 ± 89 μg/L (Fe), 100 ± 30 μg/L (Ni), and 620 ± 296 μg/L (Zn)
in 20 mL of eluate.
The eluate containing Sc radioisotopes was further purified by loading onto a column
containing CHELEX 100 resin whereupon the Sc radioisotopes were strongly adsorbed. After
rinsing with water, these radioisotopes were stripped from the column in 5 mL of 12.1 M HCl with
an average (n = 3 ± 1σ) recovery of (91 ± 3)% decay-corrected to EOB. The total decay-corrected
EOB average (n = 3 ± 1σ) recovery was (83 ± 3)%. Similar to the analysis after the first column,
metal contaminants with a concentration greater than 1 μg/L were measured in the 5 mL of 12.1
M HCl eluate. The average concentrations (n = 3, 1σ) of Cr, Cu, Fe, Ni, and Zn were 127 ± 6 μg/L
(Cr), 169 ± 34 μg/L (Cu), 357 ± 154 μg/L (Fe), 107 ± 33 μg/L (Ni) and 189 ± 25 μg/L (Zn) in 5
mL of eluate. These data are shown in Table 4-3.
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Table 3-3. The average (n = 3 ± 1σ) metal mass measured in the digestant and the
Sample

Cr

Cu

Fe

Ni

Zn

Digestant Mass (μg)

552 (30)

493 (72)

946 (35)

206 (24)

908 (620)

Post AG MP-50 (μg)

3.9 (0.3)

3.8 (0.7)

8.4 (1.8)

2.0 (0.6)

13 (6)

Post CHELEX 100 (μg)

0.6 (0.2)

0.8 (0.2)

1.8 (0.8)

0.5 (0.2)

1.9 (0.1)

The overall reductions in Cr, Cu, Fe, Ni, and Zn after separation and purification were 99.9%,
99.8%, 99.8%, 99.8%, and 99.9%, respectively.
For the final irradiation (Run 3), the 12.1 M HCl eluates containing Sc radioisotopes from
groups A, B, and C were combined and evaporated to a wet residue under nitrogen gas with gentle
heating (95°C). The residue was dissolved in 1 mL of water and evaporated. This process was
repeated twice more. After the final evaporation was conducted, the residue was dissolved in 255
µL of 0.25 M ammonium acetate (pH 4) after which a 10 µL aliquot was taken and analyzed.
Figure 3-7 shows the characterized HPGe spectra of the final product.
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Figure 3-7. γ-ray spectra of the purified 47Sc solution31
This solution contained a 47Sc concentration of 8.5 ± 0.4 kBq/μL. The average concentration of
trace metal contaminants in 255 μL of solution were 0.8 ± 0.1 mg/L (Cr), 0.8 ± 0.1 mg/L (Cu), 1.6
± 0.1 mg/L (Fe), 1.8 ± 0.1 mg/L (Ni), and 6.0 ± 0.3 mg/L (Zn).

3.3.3

Radiosynthesis of [47Sc]Sc-DOTATOC

DOTATOC was radiolabeled by adding 200 μL of 0.25 M ammonium acetate (pH 4.7) containing
1.7 MBq of 47Sc to 100 μL of 0.1 M ammonium acetate (pH 4) containing 0.384 mg of DOTATOC
(270 nmol). The final concentration of DOTATOC was 0.9 mM with a molar activity of 6.3
kBq/nmol. The mixture was vortexed and incubated at 95°C for 30 minutes. The radiochemical
yield was determined by radio-TLC and radio-HPLC (Figure 3-8).

Figure 3-8. Radio-HPLC and radio-TLC chromatograms. Radio-HPLC analysis of DOTATOC
(A, gray, tR = 8.8 min) and 47Sc (A, black, tR = 1.9 min). Radio-HPLC analysis of DOTATOC
(B, gray, tR = 8.8 min) and [47Sc]Sc-DOTATOC (B, black, tR = 8.5 min). Radio-TLC analysis of
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47

Sc (C, Rf = 0) and [47Sc]Sc-DOTATOC (D, Rf = 0.8) in 0.25 M ammonium acetate developed
in a 1:1 mixture of 1.0 M ammonium acetate and methanol.31

The radio-TLC analysis of 47Sc, in a 1:1 mixture of 1.0 M ammonium acetate and methanol, had
a single peak with an Rf value of 0. The same analysis of [47Sc]Sc-DOTATOC had a single peak
with an Rf value of 0.8. The retention time of 47Sc and DOTATOC determined by HPLC analysis
was 1.9 min and 8.8 min, respectively. The same analysis of the [47Sc]Sc-DOTATOC solution
diluted with 0.25 M ammonium acetate showed a peak in the radio and UV/Vis (λ = 280 nm)
spectra at 8.5 min and 8.8 min, respectively. These analyses showed the radiochemical yield was
greater than 99.9%. Thus, the compound was used without further purification.

3.3.4

Competitive Cell Binding Assay

Binding of [47Sc]Sc-DOTATOC to AR42J cells was determined in vitro at 2 and 4 h. To determine
if uptake of [47Sc]Sc-DOTATOC was receptor-mediated, the ligand Octreotide was used as a
blocking agent due to its known affinity for SSTR2.33, 34 At 2 and 4 h (n =4 ) the percentage of
bound [47Sc]Sc-DOTATOC was significantly decreased (p<0.0001 and p = 0.0071) in cells that
were co-incubated with Octreotide (Figure 4-6).
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Figure 3-9. The percentage of cell receptor bound or internalized [47Sc]Sc-DOTATOC is shown
on the ordinate axis at 2 and 4 h (n = 4±1σ, SEM). Co-incubation (blocked) with SSTR blocking
agent Octreotide significantly decreased cell uptake.31
The maximum mean uptake and standard error of [47Sc]Sc-DOTATOC was achieved by 2 h (0.31
± 0.02)%, as uptake at 4 h (0.32 ± 0.02)% was not significantly increased.

3.4

Discussion

Multiple irradiations of a natTi target foil-stack were carried out using a modified Varian CLINAC.
The radioactivities and the beam dispersion throughout the target foil-stack were measured. The
diameter of the region activated by the bremsstrahlung radiation increased from 3 to 4 mm
throughout 39

nat

Ti foils. For each foil, the region containing

47

Sc was mechanically extracted,

reducing the Ti mass involved in the separation. While this method and the use of natural titanium
metal was suitable for this work, future studies that seek to optimize

47

Sc yield will require

enriched TiO2 (48Ti) target material, well-defined target geometry, target cooling, and optimized
target mass due to the strong dependence between 47Sc yield and the target nuclei population (mass
of the Ti target). The use of TiO2 as a target material has multiple advantages. Firstly, an enriched
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TiO2 target with a profile commensurate to the bremsstrahlung beam diameter will not require
mechanical extraction. Secondly, the aqueous Ti4+ obtained after purification of

47

Sc can be

recovered as TiO2 at pH 8 by alkali-precipitation; thus, enriched target material could be recycled
without employing high temperature techniques to reduce TiO2 to Ti metal. The disadvantage of
this approach and of production methods that use photon-induced reactions are the large target
masses (grams) required for production of large quantities of the radioisotope of interest. During
purification, the analytical techniques developed in this work must be able to sequester grams of
target material from 10-12 to 10-15 g of 47Sc. As future work continues on developing photonuclear
production of 47Sc, these parameters should be optimized for high-intensity electron beams, as they
will directly affect the recovery and purity of the chemically purified 47Sc product.
A number of Sc radionuclides may be co-produced when using a natTi target, including 44Sc,
46

Sc, 48Sc, and 49Sc. Similar to the photonuclear work previously reported by Mamtimin et al., 46Sc

and 48Sc were experimentally observed in the Ti foils; however, 44Sc and 49Sc were not observed
due to their short half-lives and maximum bremsstrahlung photon energy used in this work.18 The
co-production of

46

Sc presents the most significant challenge to using

nat

Ti as a target material

since the 47Sc radionuclidic purity decreases over time due to the longer half-life of 46Sc. The two
contaminant radionuclides, can, in principle, be produced via the
50

48

Ti(γ,np)46Sc,

47

Ti(γ,p)46Sc,

Ti(γ,np)48Sc, and 49Ti(γ,p)48Sc reactions and have threshold energies of 22.1 MeV, 10.5 MeV,

22.3 MeV and 11.3 MeV, respectively.
In the work by Mamtimin, using a 22 MeV electron beam, the EOB ratio of 46Sc, 47Sc, and
48

Sc were 0.03, 0.82, and 0.14, respectively.18 In work by Rotsch et al., using a 35 MeV electron

beam and capturing a larger portion of the

nat

Ti(γ,p)47Sc cross section (Figure 4-1), the ratio of

46

Sc, 47Sc, and 48Sc EOB radioactivities produced were 0.01, 0.90, and 0.09.20 The ratio of 46Sc,
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47

Sc, and 48Sc EOB radioactivities in this work using a 22 MeV electron beam were 0.01, 0.90,

and 0.09. For each study, natTi target material was used and the irradiation times were less than one
half-life of the three radionuclides. These studies show that the slope (dσ/dE) of the excitation
functions for each radionuclide was similar, resulting in comparable radioisotopic purity at EOB
even at different electron beam energies. Furthermore, when using a 22 MeV electron beam in our
work, which generated photons less than the threshold energies of the (γ,np) channels, no
improvement in 47Sc radionuclidic purity was observed when compared to the work by Mamtimin
and Rotsch, suggesting the (γ,p) reactions on

47

Ti and

49

Ti are the dominant sources of Sc

impurities. These data agree with the only published measurements of these cross sections (Figure
3-10) at energies used in this work.

Figure 3-10. Excitation functions for the (γ,p) reactions on 47Ti, 48Ti, and 49Ti21, 22
The 47Sc EOB radionuclidic purity was impacted by co-production of 46Sc and 48Sc for each
study when using natTi target material. Thus, the best case scenario for limiting co-production of
contaminants,

46

Sc and

48

Sc, involves the use of enriched
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48

Ti target material, available

commercially at enrichment levels up to 99.6%.35 Favorably, the abundant

48

Ti (73.8%) may be

purchased commercially at a relatively low cost (2-3$/mg).35
The extracted Ti foils were acid digested and a separation method using AG MP-50 cation
exchange resin and CHELEX 100 resin was used to isolate the 47Sc. This separation system was
selected based on previously published work using both resins.27, 36 Initial elemental analysis of
fractions preserved during separation with AG MP-50 showed varying levels of trace metal
contamination due to Cr, Cu, Fe, Ni, and Zn. To reduce the concentration of these cations, which
may compete with radioscandium for DOTA binding or cause transmetallation of the
radioscandium-DOTA complex, a second separation step was performed to further purify the
isolated

47

Sc.37 For this two-step method, the overall recovery of

47

Sc for the separation and

purification of was (77 ± 7)%. The observed losses during radiochemical separation were due to
material transfer and loss to both the AG MP-50 and CHELEX 100 resins. The typical masses of
impurities measured after both steps were less than 1 μg for Cr, Cu, and Ni while Fe and Zn was
less than 2 μg. These data on overall recovery compares well with recent work by Rotsch et al.
(2018) and Domnanich et al. (2017) where a 76.3% and 89.7% overall recovery was reported using
branched DGA cation-exchange resin.20, 38 Further, the mass of Zn and Fe measured in the purified
47

Sc fraction was reduced by 60% and 45%, respectively, compared to the mass reported by Rotsch

et al. (2018).20
As a proof of concept, the purified

47

Sc was used to radiolabel DOTATOC, a somatostatin

analog that when radiolabeled can be used for diagnosis and therapy of neuroendocrine tumors
that overexpress SSTR2. This small peptide was selected due to its well characterized affinity for
trivalent radiometals.39 A high radiochemical yield of 99.9% was achieved for the radiosynthesis
of [47Sc]Sc-DOTATOC, which was subsequently used in an in vitro cell uptake assay in SSTR297

expressing AR42J cells. The maximum uptake was achieved by 2 h, and co-incubation of the
radiolabeled compound with Octreotide lead to a 70% reduction in uptake at 2 h, indicating
receptor-mediated uptake. In previous work [43,44Sc]Sc-DOTATOC has been synthesized and
evaluated for SSTR2-binding, however the work performed in this study illustrates the feasibility
of performing initial radiosynthetic and pre-clinical screening studies using the moderate

47

Sc

yields obtained from a CLINAC.12, 30, 40, 41

3.5

Conclusion

This work demonstrated the photonuclear production of 47Sc using a modified Varian CLINAC,
tungsten radiator, and targets composed of natTi foil. These results show that CLINACs no longer
in clinical use may be used to produce small quantities of medically relevant radionuclides for
small experiments. Moreover, the methods shown in this work could be applied to obtain 47Sc in
higher yields with potentially higher molar activities from similar targets irradiated using a
higher intensity eLINAC. Based on this work, future photonuclear production of 47Sc using
enriched 48Ti targets and high-intensity eLINACs may be a feasible route to developing this
promising theranostic radionuclide; however, the limited cross section data on the 48Ti(γ,p)47Sc
reaction must be improved in order to optimize radionuclidic purity and 47Sc yield.
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Chapter 4: Cyclotron Production and
Separation of Sc Radionuclides from Natural
Titanium Metal and Titanium Dioxide
Targets
4.1

Introduction

The element Sc has three radionuclides with properties suitable for diagnostic and therapeutic
applications in nuclear medicine. Scandium-43 (Figure 2-2) and

44

Sc (Figure 2-3) undergo

positron decay with an overall mean energy of 476.0 keV (88.1%) and 632.0 keV (94.3%),
respectively, making it well-suited for PET (see Section 1.4.1). Scandium-47 (Figure 2-7)
undergoes beta decay, with a β-mean energy of 162 keV to 47Ti, followed by emission of a 159 keV
γ-ray (68.4%). Thus,

47

Sc could be used for targeted radionuclide therapy (see Section 1.5) and

SPECT (see Section 1.4.2). The combined use of these Sc radionuclides in theranostic agents with
the same structure allows diagnostic imaging and radiotherapy in the same patient.
Interest in these radioisotopes has been motivated by the recent clinical success of DOTA(Tyr3)-octreotate (DOTATATE) and findings from multiple clinical trials investigating smallmolecule inhibitors of prostate specific membrane antigen (PSMA). The somatostatin analogue
DOTATATE labeled with

68

Ga (t1/2 = 67.71 min) or

177

Lu (t1/2 = 6.647 d) can be used in a

theranostic manner to diagnose and treat SSTR-expressing neuroendocrine tumors.1, 2 Similarly,
inhibitors of PSMA like PSMA-11, PSMA-617, DCFPyL and MIP-1072 labeled with 68Ga, 177Lu,
18

F (t1/2 = 109.7 min),

131

I (t1/2 = 8.03 d), 123I (t1/2 =13.2 h) or 99mTc (Figure 1-3) can be used for

diagnosis and treatment of PSMA positive prostate cancer.3 Theranostic agents that incorporate
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radionuclides of different elements can have differences in their in vivo kinetics.4 The selection of
43

a matched-pair (e.g.,

Sc/47Sc), guarantees identical pharmacodynamic and pharmacokinetic

profiles, and provides the truest picture of in vivo distribution prior to radionuclide therapy.
Further, the half-lives of

43

Sc/44Sc could allow imaging at longer time points after injection

compared to the shorter lived 68Ga.5 Therefore, the development of efficient methods to produce
43

Sc, 44Sc, and 47Sc is an important first step to translating these matched-pair radioisotopes of Sc

to the clinic.
Scandium-43 and

44

Sc can be produced via multiple routes. Accelerator production using α

particles, protons, and deuterons on Ca and Ti nuclei have been investigated for the
nat

Ca(α,x)43,44,47Sc,

42

Ca(d,n)43Sc,

43

Ca(p,n)43Sc,

44

Ca(p,2n)43Sc,

46

Ti(p,α)43Sc,

47

Ti(p,α)44Sc,

44

Ca(p,n)44Sc, natCa(p,n)44Sc and 44Ca(d,2n)44Sc nuclear reactions.6-12 The use of Ca and Ti have

been shown to provide GBqs and hundreds of MBqs of 43Sc and 44Sc depending upon beam current
and irradiation time; however, 44Sc produced by these reactions will result in the co-production of
its nuclear isomer,

44m

Sc (t1/2 = 58.6 h). The presence of this longer-lived metastable state may

complicate patient dosimetry. Alternatively,

44

Sc may be obtained without its nuclear isomer

(44mSc) from a 44Ti (t1/2 = 59.2 y)/44Sc generator due to the preferred transition from the 0+ excited
state of 44Ti to the ground state of 44Sc during β- decay (see Figure 2-4 and Figure 2-6).13-15
Scandium-47 can also be produced via multiple routes. Reactor production of 47Sc has been
investigated using fast neutrons on enriched Ti via the

47

Ti(n,p)47Sc reaction (En > 1-MeV) or

thermal neutrons (En = 0.025 eV) on enriched Ca via the 46Ca(n,γ)47Ca→47Sc reaction for a 47Ca47

Sc (t1/2 = 4.54 d) generator system.16 One challenge facing development of a 47Ca-47Sc generator

is the low natural abundance of
48

46

Ca (0.004%). Scandium-47 may also be produced by the

Ti(γ,p)47Sc reaction using bremsstrahlung radiation and accelerator production by the
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48

Ca(p,2n)47Sc reaction was investigated at 18 MeV and resulted in a saturation yield of 12

GBq/μA.17-20
Unlike production routes using Ca, the use of Ti could allow production of 43Sc, 44Sc, and 47Sc
on a single proton accelerator using a unified separation methodology that takes advantage of
identical targetry and target processing chemistries, and results in better radionuclidic purity of
43

Sc, 44Sc, and 47Sc. However, the magnitudes of the cross section for reactions on Ti are much

less than those on Ca at lower energies (16 to 18 MeV). Favorably, the cross section values increase
at the higher energies (up to 24 MeV) used in this study. Multiple challenges must be addressed to
produce Sc radioisotopes from stable nuclei of Ti using this unified approach. First, the powdery
TiO2 targets require a holder that encapsulates the irradiated material to prevent radiological
contamination. Next, the slow TiO2 digestion kinetics and short half-life of

43,44

Sc necessitate

development of a rapid digestion method. Lastly, 43Sc, 44Sc, and 47Sc with high radionuclidic purity
can only be obtained using enriched Ti, since

46

Ti,

47

Ti, and

50

Ti have natural abundancies of

8.25%, 7.44%, and 5.18%, respectively. Thus, efficient recycling chemistry must be developed to
recover and reuse the enriched target material.
To address these challenges, methods were developed to investigate 43Sc, 44Sc, and 47Sc yields
and purification chemistry using natural Ti and TiO2. The results from this work suggest that 43Sc,
44

Sc, and 47Sc could be produced at energies up to 24 MeV using enriched TiO2 and purified using

a unified methodology to supply quantities needed for the pre-clinical evaluation of these matchedpair radioisotopes.

4.2

Materials and Methods

Reagents
All chemicals were analytical or trace metals grade. Deionized 18.2 MΩ⋅cm water (Milli-Q
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System; Millipore, Billerica, MA). Ammonium bifluoride (NH4HF2, 99.999%), hydrochloric acid
(HCl, 37% wt. in water, 99.999%), 25% ammonia solution (NH4OH, EMSURE), TiO2 (anatase
form, 99.8%), periodic table analytical standards (Mix 1, 10-mg/L, TraceCERT), ammonium
acetate (CH3CO2NH4, 99.999%) and nitric acid (HNO3, 70% wt. in water, 99.999%) were
purchased from Sigma-Aldrich (St. Louis, Missouri). Analytical standards containing Ti (1000
mg/L) and Sc (1000 mg/L) were purchased from Agilent (Santa Clara, CA). Analytical grade
branched N,N,N’,N’-tetra-2-ethylhexyldiglycolamide (BDGA) resin was purchased from Eichrom
Technologies (Lisle, IL). 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was
purchased from Macrocyclics (Plano, TX). All glassware was acid washed in a 50% HNO3 bath
overnight.
Target Holders
Multiple target holders were developed to mount and irradiate Ti foil and TiO2 target materials.
The disc shaped 2 mm thick target holders fabricated from Al, Ta and Nb were described in Section
2.4.5 (Figure 2-19, Figure 2-20, and Figure 2-21).
Preparation of Target Material
Titanium foil targets were prepared using a Precision Brand Products 10 mm punch and die
(Downers Grove, IL). Prior to pressing, TiO2 was dried overnight at 230°C in a vacuum oven at
0.3 Pa. Approximately 35 or 70 mg of TiO2 was transferred into a clean 7 or 10 mm die (Specac,
Kent, United Kingdom) and pressed for 5 min at 4 tons pressure on a manual press (Carver,
Wabash, Indiana). Additional TiO2 was iteratively added and pressed. This process was repeated
twice to achieve final target masses of approximately 52 or 110 mg.
Cyclotron Parameters
Irradiations were conducted on a TR-24 cyclotron (Advanced Cyclotron Systems, Inc., Richmond,
BC, Canada). Scandium-43, 44Sc, and 47Sc were produced via the natTi(p,x) nuclear reaction at 17107

and 24 MeV. Ti and TiO2 targets were mounted at an incident angle of 90° and bombarded at beam
currents up to 40 and 30 μA, respectively. The targets were cooled by high-pressure, low-flow He
gas (275 to 345 kPa, 1 L/min) on the front and pumped water (2 to 3 L/min) on the back.
Bombarded targets were allowed to decay for 1 to 5 h, depending upon irradiation parameters to
allow for the decay of co-produced 47V (Figure 2-11).
Production Yields
The radionuclidic yields were determined using a high-purity germanium (HPGe) detector.
Predicted yields were calculated using nuclear data retrieved from the Experimental Nuclear
Reaction Data (EXFOR) database.21, 22 The code SRIM was used to model the entrance and exit
proton energies. End-of-bombardment (EOB) yields were determined using Mathcad 14.0 and
Equation 1, where NA is Avogadro’s constant (atoms/mol), I is incident particle flux (particles/s),
At is atomic weight (g/mol), λ is the decay constant (1/s), t is irradiation time (s), E0 is the initial
proton energy (MeV), Ee is the exit proton energy (MeV), σ(E) is the energy-dependent reaction
cross section (cm2), and S(E) is the total stopping power (MeV·cm2/g).23
YEOB =

NA I
AT

E

dE

(1 − e−λt ) ∫E 0 σ(E) S(E)
e

(4-1)

Determination of Equilibrium Dissociation Constant.
A mixture of 100 mg BDGA resin, 990 μL of HCl (0.1 to 10 M) and 10 μL of 48V (100 kBq/mL),
47

Sc (500 kBq/mL) or 45Ti (222 MBq/mL) were prepared in quadruplicate to determine the average

(n = 4 ± 1σ) equilibrium dissociation constant (Kd). Each sample was equilibrated on a rocker for
24 h after which the supernatant was removed and filtered with a 0.22 μm hydrophilic membrane
filter. A 100 uL aliquot of the filtered supernatant was diluted to 1 mL with water for each sample
and measured with an HPGe detector. At an HCl concentration of 6 to 10 M, no photopeak was
observed for 47Sc. The minimum detectable radioactivity (MDA) for 47Sc was calculated based on
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a 2 h measurement of the supernatant. The Kd coefficients were calculated using equation 2, where
Ai is the initial activity in Bq, Aeq is the activity in filtered supernatant in Bq, V is the volume of
the filtered supernatant in mL, and m is the mass of the resin in g.15
Kd = C

Cresin

aqueous

=

Ai −Aeq
Aeq

∙

m

(5-2)

V

Digestion of Ti foil and TiO2
Irradiated Ti was transferred into a conical 15 mL screw-cap perfluoroalkoxy alkane (PFA) vial
(Savillex, Eden Prairie, MN) containing approximately 200 mg of NH4HF2 dissolved in 3 mL of
12.1 M HCl. The vial was capped and heated at 230°C for 45 min. Irradiated TiO2 was transferred
into a conical 15 mL screw-cap vial and mixed with NH4 HF2 (1:3 ratio). The vial was capped and
heated to 230°C for 45 min. After heating, the dry residue was dissolved by adding 5 mL of 12.1
M HCl and heating the closed vessel for 45 min in a Si-oil bath at 160°C. Both digestion methods
were validated using non-radioactive Ti. For these validation experiments, samples were taken in
triplicate, filtered, and diluted in 2% HNO3 for trace metal analyses. The digestion methods are
illustrated in Figure 2.
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Figure 4-1. Methods for the digestion of Ti foil and TiO2
BDGA Separation
Approximately 110 mg of BDGA resin was vortexed with 5 mL of 7 M HNO3. The mixture was
transferred into a Biorad 0.8 x 9 cm polypropylene column (Hercules, CA) and the HNO3 was
eluted at a flow rate of 1.0 mL/min To protect the packed resin (7 mm height), a glass wool plug
was placed on top of the resin bed. The resin was washed with 5 mL each of 7.0 M HNO3, water,
0.1 M HCl and 7.0 M HCl. The digestant was loaded onto the column in approximately 7 8 M HCl
at a flow rate of 1 mL/min Eluent 1 (20 mL, 7.0 M HCl), eluent 2 (10 mL, 7.0 M HNO3) and eluent
3 (10 mL, 0.1 M HCl) were passed through the column and collected at a flow rate of 1.0 mL/min
The final eluate containing the Sc radionuclides was collected into a 10 mL v-shaped vial and
evaporated to dryness under vacuum at 100°C. After evaporation, the purified Sc was digested in
0.5 M CH3CO2NH4 buffer (pH 4.7). The separation method is shown in Figure 3.
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Figure 4-2. The 43Sc, 44Sc, and 47Sc separation.
The elution profile of stable Ti, V and Sc on BDGA resin was determined by taking 1 mL fractions
of each eluate. Samples were prepared in triplicate and measured with an HPGe detector and by
ICP-MS to determine the recovery. The decontamination factor, a measure of the Sc purification,
was determined using Equation 3, where DA,B is the factor giving the change in ratio of constituent
1 (A) to constituent 2 (B).24

DA,B =

QA

QA,0

×

QB,0

(5-3)

QB

Alkali Precipitation of Ti
Eluate containing Ti was diluted to 500 mL with water and heated for 45 min at 160 °C. While
stirring on a stir plate, the pH was adjusted to 8 by dropwise addition of 19 mL 25% ammonia
solution. The stir bar was removed after precipitation at pH 8. The precipitate was allowed to settle
for 1 h. The solution was vacuum filtered onto GE Healthcare Life Sciences Grade 43 Ashless
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(Pittsburgh, PA) filter paper and rinsed twice with 10 mL 1% ammonia solution in water. The
precipitate was dried by rinsing with 10 mL of acetone. The filter paper was transferred to a
zirconia crucible and combusted in a tube furnace at 1000 °C for 24 h.
High Purity Germanium Spectroscopy
Radioactive samples were characterized by gamma-ray spectroscopy using a Canberra GC2018
HPGe detector with a relative efficiency of 24.5% (Meriden, CT). Canberra Genie 2000 software
was used for data acquisition and analysis. Energy and efficiency calibrations were performed
using a mixed nuclide source in a sealed 1.5 mL microcentrifuge vial prepared by Eckert & Ziegler
Analytics (Atlanta, GA). Efficiency-calibration spectra with a minimum photopeak area of 2 x 105
counts were collected and fit to determine the detector efficiency. For all measurements, aliquots
of sample material were transferred into a 1.5 mL vial, diluted to 1 mL, and suspended in a fixed
acrylic holder at a distance of 5 or 25 mm from the HPGe detector. This geometry was maintained
for all sample measurements.
Inductively Coupled Plasma Mass Spectrometry
Samples containing stable elements were preserved and analyzed via ICP-MS. Multi-element
standards in 2% HNO3 at 0.1, 1, 10, 100 and 1000 μg/L were used for instrument calibration. Each
sample was diluted in 2% HNO3 and measured on an Agilent Technologies 7700 ICP-MS (Santa
Clara, CA). Agilent Technologies MassHunter (version 4.3) was used for data acquisition and
analysis.

4.3

Results

4.3.1

Target Irradiations

The Nb target holder was used to irradiate 250 μm thick metallic Ti foils (ρ = 4.506 g/cm3) at
approximately 24 MeV. The average (n = 3 ± 1σ) mass of a Ti foil was (91.5 ± 0.3) mg. The Nb
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target holders tolerated beam currents up to 40 μA. A two-piece Al target holder was used to
irradiate a 400 μm thick pressed TiO2 (ρ = 4.23 g/cm3) disc at approximately 17 MeV. The average
(n = 3 ± 1σ) mass of the disc target was (52.2 ± 0.4) mg. The magnetization of the SmCo magnets
was confirmed after each irradiation (n = 6). At a beam current of 20 μA, thermal damage was
observed on the Al cap and base; thus, future irradiations were limited to 15 μA. The Ta target
holder was used to irradiate a 400 μm thick pressed TiO2 disc at approximately 24 MeV. The
average (n = 3 ± 1σ) mass of the disc target was (110.1 ± 0.5) mg. The Ta target holder allowed
for irradiation at beam currents up to 30 μA. No damage to the target holder or material was
observed at 30 μA after a 30 min irradiation.

4.3.2

Target Digestion

The methods developed in this work were validated using non-radioactive TiO2 pressed disc
targets and Ti foils that were prepared in quadruplicate. The samples were weighed, dissolved, and
Ti ions in the digestant were precipitated using methods detailed in this work (Figure 4-4).

Figure 4-3. The initial, post-digestion, and post-precipitation Ti masses
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Figure 4-4 indicates that the average (n = 4 ± 1σ) percent of dissolved TiO2 and Ti was (100 ±
8)% and (96 ± 5)% of the initial masses. A typical digestion of an irradiated Ti foil and pressed
TiO2 disc required 45 and 90 min, respectively. Titanium foils were digested at 160°C using a
mixture of NH4HF2 and 12.1 M HCl. Trace metals analysis of the digestant via ICP-MS showed
that the average (n = 3 ± 1σ) percentage of Ti foil dissolved in solution was (98 ± 3)%. Likewise,
TiO2 discs were digested in two-steps and the average (n = 3 ± 1σ) percentage of TiO2 dissolved
in solution was (95 ± 1)%.

4.3.3

Radionuclide Yields

The radionuclides measured by HPGe were 48V (γ1 = 944.1 keV, γ2 = 983.5 keV, γ3 = 1312.1 keV),
43

Sc (372.9 keV),

44g

Sc (1157.0 keV),

44m

Sc (271.2 keV) and

47

Sc (159.4 keV). The sample

counting time was varied to achieve a minimum photopeak area of 500 counts and dead time was
kept below 5%. The average EOB production rate (n = 9 ± 1σ) and predicted rate for each
radionuclide are shown in Table 4-1.
Table 4-1. The average EOB production rate and predicted rate for each
radionuclide6, 22, 25, 26
Radionuclide Predicted rate(kBq·s-1·uA-1)

Average Rate (kBq·s-1·uA-1)

43

1.1

1.1(0.2)

4.3

4.2(0.4)

44m

0.20

0.11(0.01)

47

0.19

0.17(0.01)

0.23

0.25(0.01)

Sc

44g

Sc
Sc

Sc

48

V

The average production rate was determined by normalizing the experimental yields to 1 uA.
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4.3.4

BDGA Separation

The digestant containing Ti ions, Sc radioisotopes, and 48V was loaded onto BDGA resin at a 1.0
mL/min flow rate. The bulk Ti target material was eluted from the resin and resulted in an average
(n = 6 ± 1σ) Ti recovery factor of (96 ± 5)% in 12 mL of the load eluate and 20 mL of eluate 1. In
contrast, Sc radioisotopes were strongly adsorbed onto the resin in 7 to 8 M HCl. No Sc
radioisotopes were detected in the eluate from the load, eluent 1 and eluent 2. The Sc radioisotopes
were desorbed from the resin in 10 mL of eluent 3 (0.1 M HCl). The eluate containing the
recovered Sc radioisotopes (eluate 3) was free of any radionuclidic impurities including 48V. These
data are summarized in Table 4-2.
Table 4-2. The initial 47Sc and 48V activity and its recovery in each eluate.
Material
Ti Foil
TiO2

Activity

Initial (MBq) Load (MBq) E1 (MBq)

E2 (MBq)

E3 (MBq)

47

52.3(0.4)

5×10-5∗

1×10-5∗

1×10-5∗

49.0(0.5)

V

66.2(0.6)

63.5(0.3)

2.5(0.3)

0.4(0.1)

1×10-5∗

Sc

29.1(0.7)

3×10-5∗

1×10-5∗

1×10-5∗

27.6(0.6)

38.4(0.8)

35.1(0.2)

3.1(0.3)

0.3(0.1)

1×10-5∗

Sc

48
47
48

V

*Minimum Detectable Radioactivity
These data show an average (n = 3 ± 1σ) Sc recovery from Ti foil and TiO2 irradiated targets of
(94 ± 1)% and (94 ± 3)%. A typical elution profile of this separation method is shown in Figure
4-5.
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Figure 4-4. Typical elution profile for the DGA separation
Figure 4-5 indicates that the magnitude of the interaction between Ti and V ions and BDGA resin
is small, and the majority of these ions are recovered in the eluate from the load fraction. The
adsorbed 43Sc, 44Sc, and 47Sc are stripped from the BDGA in 0.1 M HCl over a broad elution band
(10 mL of 0.1 M HCl).
Samples taken from the final Sc product after reconstitution showed the presence of different
non-radioactive contaminants. After purification and evaporation, the identity and average (n = 3
± 1σ) concentration of contaminants in 400 μL of 0.50 M CH3CO2NH4 was Fe (1.0 ± 0.3)mg/L,
Cu (0.8 ± 0.3)mg/L, Zn (1.3 ± 0.3)mg/L, V (0.5 ± 0.3)mg/L, and Al (0.8 ± 0.3)mg/L. Scandium
was not detected or was below the detection limits of the ICP-MS used in this work. The complete
separation and concentration of Sc activities required approximately 180 min.

4.3.5

Ti Recycling

The combined eluate containing Ti was diluted and pH adjusted. Near pH 8 (verified by pH strip
test), a fine white cloudy precipitate formed. After filtration, the average (n = 4 ± 1σ) percent
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recovery of Ti was (103 ± 5)% and (108 ± 8)% from Ti foil and TiO2, respectively.

4.4

Discussion

Targets were created which allowed for the irradiation of TiO2 with a proton beam of 24 MeV at
a beam current up to 40 μA. The SmCo magnets (Al target) did not lose their magnetism due to
heat and could play a role in the design of compact cyclotron targets. The Ta target holder design
was robust and future work will be carried out to define the maximum tolerated beam current on
TiO2 in these target holders. These data show that

43

Sc,

44

Sc, and

47

Sc production can occur at

higher beam currents greater than those currently used for their cyclotron production via CaO or
CaCO3 (approximately 20 μA). Moreover, in most cases the (p,n) and (p,xn) reaction cross sections
on Ca nulcei have greater magnitudes; thus, it is important to focus on optimizing the design of
TiO2 target holders to offset the lower yields by increasing their tolerance to high beam currents.
The yield of

43

Sc,

44

Sc, and

47

Sc and co-produced

48

V in Ti foils agreed with EOB yields

predicted using published nuclear data sets for the natTi(p,x) reaction (Table 4-1). Using the same
methodology, the EOB yield of
predicted for the

46

Ti(p,α)43Sc,

43

Sc,

47

44

Sc, and

47

S from enriched TiO2 target material was

Ti(p,α)44g,44mSc,

50

Ti(p,α)47Sc and

48

Ti(p,2p)47Sc nuclear

reactions based on a 1 mm thick TiO2 target that drops the proton energy from 24 MeV to 15.5
MeV at 20 uA.
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Table 4-3. The predicted Sc yields at 1, 2, and 24 h.6, 25-27
Time

43Sc

(GBq)

44gSc

(GBq)

44mSc

(GBq)

1h

2.1

2.6

70

4h

6.5

8.2

270

24 h

12.6

16.1

1500

47Sc

(MBq)

60*
30†
230*
130†
1200*
700†

*Predicted yield from 50Ti(p,α)47Sc
†
Predicted yield from 48Ti(p,2p)47Sc

These yields from enriched TiO2 show that tens of MBq to Gbq quantities of Sc radioisotopes
could be produced based on this work. These quantities would be suitable for pre-clinical and in
some cases clinical investigations.
Previously reported methods to digest TiO2 have used concentrated HF with some methods
requiring hours or use of microwave/IR systems to reach completion.18, 28-32 These methods, in
practice, could result in the loss of at least one 43Sc and 44Sc half-life. The methods developed in
this work make use of pressure, heat, and the in situ generation of approximately 1.0 M HF via the
reaction of NH4HF2 with 12.1 M HCl.33 These two methods have been confirmed to work with a
mineral oil bath or convection oven and require no specialized equipment. The results show that
greater than 95% of Ti foil and TiO2 could be dissolved in 45 and 90 min, respectively. Further,
the closed PFA vessels used in this work were inexpensive and durable at temperatures up to
250°C. These data support future efforts to characterize and optimize the digestion parameters to
further decrease digestion times for Ti foil and TiO2.
Branched DGA and DGA resin have been used to separate Sc in multiple reports.7, 18, 34 The
equilibrium dissociation constants for Sc, Ti and V were determined to support development of
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the method used in this work (Figure 4-6).

Figure 4-5. Sc, V, and Ti equilibrium disassociation constants with BDGA
Based on the measured Kd for Sc, Ti and V, the separation method detailed in this work was
predicted to separate Sc from Ti and V at HCl concentrations greater than 4 M. This prediction
was confirmed by determining the Sc decontamination factor relative to each contaminant. Based
on quantities in Table 2, the decontamination factor for 47Sc relative to 48V was greater than 6x106
and 3x106 for Sc isolated from Ti foil and TiO2, respectively. Similarly, Ti present in the recovered
Sc fractions was below the ICP-MS detection limits (approximately 1 μg/L); thus, the data shows
the decontamination factor of

47

Sc relative to Ti was greater than 2.8x105 and 1.6x105 for Sc

isolated from Ti foil and TiO2, respectively. These data show that this method isolates Sc with
little contamination from Ti and V. The overall Sc recovery factor agreed with previously reported
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procedures using DGA resins.7, 18, 35 Trace metal analyses via ICP-MS of the Ti foil and TiO2
digestants and recovered Sc fractions showed the presence of Fe, Cu, Z, V and Al. The average
concentrations of these impurities were between 0.5-1.3 mg/L, which compared well to previously
reported methods to produce Sc.18, 35
Historically and in recent reports, Ti was precipitated from an aqueous solution using ammonia
solution at pH 8.7, 36, 37 In this work, a Ti precipitant was obtained using ammonia solution to adjust
the bulk media to pH 8. After sufficient time for aggregation and sedimentation, the precipitate
was filtered and combusted. The typical concentration of Ti in the filtrate was below 100 μg/L
(approximately 50 μg) which indicated the percent loss of Ti after precipitation was less than 0.1%.
The mass recovery of Ti exceeded 100% and may be attributed to two factors: (1) etching of glass
wool by HF generated in situ and (2) the incomplete combustion of the filter paper and presence
of water. These data show that the recovery of Ti in the oxide form using ammonia solution was
an effective approach to recycling Ti nuclei. However, additional work will be carried out to reduce
the introduction of external masses to avoid buildup of these contaminants during iterative use of
this method.

4.5

Conclusion

In this study, we investigated the feasibility of producing the theranostic radioisotopes of Sc on a
proton accelerator using a robust and unified process. Results from this work showed that routine
production of 43Sc, 44Sc, and 47Sc could be accomplished using enriched TiO2. Importantly, our
findings showed that TiO2 targets may tolerate beam currents greater than 30 μA using target
holders designed in this work, TiO2 can be digested via a two-step process in 90 min, and digested
Ti could be efficiently recovered via alkali precipitation with ammonia solution. Future work
should investigate the maximum tolerated beam current on TiO2 using these target holders and any
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impact on downstream chemistry that may be caused by the increased heat deposition in the target
material, which could lead to phase changes in the TiO2 that alter its physical characteristics.
Additionally, these efforts should seek to better understand and optimize the digestion methods
developed in this work to reduce digestion times. Finally, the method to precipitate Ti should be
modified to remove sources of carbon and silicon. Ultimately, the results in this work showed the
potential promise in using enriched Ti targets to produce these matched-pair theranostic
radioisotopes of Sc.
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Chapter 5: Radiochemistry and Investigation
of the In Vitro Properties of [43Sc/47Sc]ScPSMA-617
5.1

Introduction

Pharmaceutical development is a complex and expensive process that involves many key aspects
such as in vivo target identification , compound screening, secondary assays that investigate
mechanism and selectivity, and in vivo analyses that investigate pharmacology, efficacy, safety,
and toxicity.1 In most cases, the process begins by using high throughput screening assays to
identify a lead compound that could be useful as a targeting vector based on its affinity for a
biomarker. Post-screening, the pharmacokinetic profile of the lead compound is determined by
studying its absorption, biodistribution, metabolism, and elimination or excretion.1, 2 Each of these
physiological aspects can be studied using a radiotracer (i.e., a compound in which one or more
atoms are radioactive).3 A lead compound can be turned into a radiotracer by directly incorporating
a radionuclide or by conjugating the compound to a chelator capable of binding a radionuclide. In
some cases, this radiotracer can be used as a radiopharmaceutical for diagnostic imaging or
therapy.
Diagnostic radiopharmaceuticals can be detected at concentrations that range from fM to pM
using

highly

sensitive

nuclear

detectors

(see

Section

1.4).

Therefore,

diagnostic

radiopharmaceuticals (and radiotracers) can be used to study molecular function without
perturbing the physiological system being probed.4 Additionally, because radiopharmaceuticals
and radiotracers can be injected in ng – ug quantities (with an increase to the detectable
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concentrations primarily due to the presence unlabeled nonradioactive molecule) , they can be used
safely to determine dosimetry, efficacy and the biodistribution profile of a radiopharmaceutical.
The pre-clinical investigation of a new radiopharmaceutical often involves the study of its in
vitro and in vivo properties. These properties can be evaluated using different assays (in vitro) to
characterize radiopharmaceutical features such as IC50 (inhibitory concentration of 50%),
partition coefficient, binding potential, Kd (dissociation constant), Bmax (maximum number of
binding sites), and chemical stability. Likewise, its biological properties can be evaluated in vivo
using small animal models to investigate stability, target specificity, pharmacokinetic profile, and
dosimetry. Therapeutic radiopharmaceuticals typically undergo additional studies to evaluate their
therapeutic efficacy. A radiopharmaceutical with favorable in vitro and in vivo properties may be
a potential drug-candidate that warrants further investigation in initial human studies. For example,
the

clinically

used

radiopharmaceuticals

[68Ga/177Lu]Ga/Lu-DOTA-(Tyr3)-octreotate

(DOTATATE) underwent pre-clinical evaluation and the in vitro and in vivo properties of both
compounds were published prior to clinical trials and FDA approval. These radiopharmaceuticals
now play an important clinical role in detecting neuroendocrine tumors (NETs), monitoring NET
progression, and determining patient response prior to targeted radionuclide therapy (TRNT). The
use of [68Ga/177Lu]Ga/Lu-DOTATATE to diagnose and treat NETs was detailed earlier in this
work (see Section 1.6.1).
Recently, different radiopharmaceuticals labeled with the positron emitting radionuclides 43Sc
and 44Sc have been investigated to assess the in vitro and in vivo properties of these compounds.
For example, the in vitro and in vivo characteristics of DOTATATE, DOTATOC, and 1,4,7,10tetraazacyclododecane-1,4,7,10-tetraacetic acid–1-NaI3-octreotide (DOTANOC) radiolabeled
with

43

Sc or

44

Sc have been evaluated using Sc radionuclides produced via low-energy proton
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irradiation of Ca target material.5-8 These studies involved the direct comparison of 68Ga-labeled
compounds with their 43Sc- or 44Sc-labeled analogues. Unlike Y- or In-labeled analogues (e.g., YDOTA-lanreotide and In-DTPA-octreotide) that have lower affinities (i.e., higher IC50 values) for
SSTR2 receptors (see Section 1.6.1), the IC50 values for compounds labeled with 68Ga and 43Sc
or 44Sc were comparable with (0.20 ± 0.18) nM and (0.70 ± 0.20) nM, respectively. These results
indicate that the diagnostic capability of Sc-DOTATATE may be similar to the FDA-approved
[68Ga]Ga-DOTATATE.9 Additionally, compounds labeled with

44

Sc (cyclotron produced using

Ca) with indications for diagnosing human glioblastoma (i.e., an aggressive type of brain cancer)
and prostate cancer (see Section 1.6.2) have been investigated. For example, DOTA-functionalized
integrin αvβ3 cyclic peptide RGD (cRGD) that targets glioblastomas was labeled with

44

Sc and

had a yield of 90% and an effective specific activity of greater than 7.1 MBq/nmol.10 A different
DOTA-functionalized compound that targets prostate cancer, PSMA-617, was labeled with 44Sc
and may have indications for diagnosing castration resistant prostate cancer. The [44Sc]Sc-PSMA617 bioconjugate had a yield of greater than 97% and an effective specific activity of up to 10
MBq/nmol. The effective specific activity describes the amount of radioactivity per unit mass of
PSMA-617. Subsequent studies indicated that the in vitro properties of [44Sc]Sc-PSMA-617 were
similar to those of PSMA-617 labeled with

68

Ga and

177

Lu, and the biodistribution profile (i.e.,

distribution kinetics) of [44Sc]Sc-PSMA-617 was more similar to [177Lu]Lu-PSMA-617; than
[68Ga]Ga-PSMA-617. These results indicate that [43Sc/44Sc]Sc-PSMA-617 could provide a truer
picture of the in vivo pharmacokinetics (compared to [68Ga]Ga-PSMA-617). The use of PSMA617 labeled with 43Sc or 44Sc could better inform TRNT of prostate cancer and improve therapeutic
efficacy.
While the diagnostic radionuclides of Sc,

43

Sc and
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44

Sc, have been investigated for several

applications, few reports exist on 47Sc, their therapeutic analogue. Recently, DOTA-cm10 (cm10)
was labeled with 47Sc to target folate receptors (FR) that are expressed on a variety of tumor types,
including ovarian and lung cancers.11 The [47Sc]Sc-cm10 bioconjugate had a yield of greater than
96%, an effective specific activity of up to 13 MBq/nmol, and receptor-specific binding and uptake
in FR+ human cervical cancer cells (KB cells) was demonstrated. Its therapeutic efficacy was then
evaluated in vivo using two groups of KB tumor-bearing mice where the control and treatment
groups were given saline and [47Sc]Sc-cm10 (10 MBq, 10 Gy), respectively. The treatment group
had a 50% increase in survival time, compared to the control group. In order to increase the
availability of 47Sc, multiple groups are investigating novel methods to produce and supply this
theranostic radionuclide for preclinical studies. For example, in our work,

47

Sc produced by

bremsstrahlung radiation using natural Ti foil targets was used to label DOTATOC and show cellmediated uptake in SSTR2 expressing AR42J cells (see Section 3.3.3 and Section 3.3.4).
The findings reported in Chapter 3 and Chapter 4 showed that useful quantities of 43Sc, 44Sc,
and 47Sc could be produced using Ti as a target material on a 24 MeV cyclotron and used for preclinical evaluation of

47

Sc-labeled radiopharmaceuticals that have clinical potential. Using the

methods reported in Chapter 4, a purified mixture of 43Sc, 44Sc, and 47Sc was obtained and used to
prepare and characterize [43,44,47Sc]Sc-PSMA-617. The in vitro properties of PSMA-617 labeled
with Sc radionuclides (43Sc,

44

Sc, and

47

Sc),

68

Ga, and

177

Lu were evaluated in LNCaP cells, a

PSMA+ human prostate adenocarcinoma cell line.

5.2

Materials & Methods

Reagents
All chemicals were analytical or trace metals grade. Deionized 18.2 MΩ⋅cm water (Milli-Q
System; Millipore, Billerica, MA) was used unless otherwise specified. Ammonium bifluoride
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(NH4HF2, 99.999%), hydrochloric acid (HCl, 37% wt. in water, 99.999%), 25% ammonia solution
(NH4OH, EMSURE), TiO2 (anatase form, 99.8%), periodic table analytical standards (Mix 1,
10-mg/L, TraceCERT), ammonium acetate (CH3CO2NH4, 99.999%) and nitric acid (HNO3, 70%
wt. in water, 99.999%) were purchased from Sigma-Aldrich (St. Louis, Missouri). Analytical
grade branched N,N,N’,N’-tetra-2-ethylhexyldiglycolamide (BDGA) resin was purchased from
Eichrom Technologies (Lisle, IL). Cell culture media, Gibco RPMI 1640 and DMEM, and Gibco
fetal bovine serum were purchased from Fischer Scientific (Waltham, MA). Cell culture media,
Gibco RPMI 1640 and DMEM, Gibco fetal bovine serum, and Gibco trypsin-EDTA (0.25%
trypsin/0.53 mM EDTA) were purchased from Fischer Scientific (Waltham, MA). Glass
microfiber chromatography paper impregnated with silica-gel (iTLC-SG) was purchased from
Agilent Technologies (Santa Clara, California). All glassware was acid washed in a 50% HNO3
bath overnight.
Radionuclides
A mixture of Sc radionuclides

43

Sc,

44

Sc, and

47

Sc were obtained by the proton irradiation of

naturally isotopic Ti foil. The Ti targets was bombarded with 24 MeV protons for 3 hours at 30
µA. Post-irradiation, the targets were dissolved, and the Sc radionuclides were purified using
BDGA, a chromatographic resin (see Section 4.3.2 and Section 4.3.4). The Sc radionuclides were
recovered in 5 to 10 mL of 0.1 M HCl. The eluate was concentrated to a wet salt by vacuum
evaporation at 95°C for approximately 2 to 3 hours. A final stock solution was obtained by
dissolving the wet salt in 100 to 200 µL of 0.5 M ammonium acetate (pH 4.7) and was used directly
for labeling reactions. Gallium-68 was obtained from a 68Ge/68Ga generator obtained from Eckert
& Ziegler (Santa Clarita, CA). The

68

Ga was eluted from the generator in 0.1 M HCl with a

radionuclidic purity greater than 99%. During elution, the eluate was fractionated to obtain greater
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than 80% of the

68

Ga in 3 to 4 mL. The stock solution was used directly for labeling reactions.

Lutetium-177-chloride solution (0.05 M HCl) with a specific activity greater than 740 GBq/mg
and radionuclidic purity greater than 99% was obtained from the Missouri University Research
Reactor (Columbia, MO). A small aliquot (0.5 to 2 µL) of the 177Lu stock solution was diluted in
0.5 M ammonium acetate (pH 4.7) and was used directly for labeling reactions.
Radiolabeling of PSMA-617
The PSMA ligand PSMA-617 was obtained from Medkoo Biosciences (Morrisville, NC) and
stored at -20°C. Prior to use, PSMA-617 was reconstituted in 100 to 200 uL of water at a
concentration of 1 mg/mL to 5 mg/mL. The conditions to label PSMA-617 with a mixture of Sc
radionuclides,

177

Lu, and

68

Ga was tested at a small scale prior to batch labeling. [43,44,47Sc]Sc-

PSMA-617 was prepared in a 50 µL mixture of 0.5 M ammonium acetate (pH 4.7) containing 43Sc,
44

Sc, and 47Sc and aqueous PSMA-617 and incubated at 95°C for 30 min. [177Lu]Lu-PSMA-617

was prepared in a 50 µL mixture of 0.5 ammonium acetate (pH 4.7) and 0.05 M HCl containing
177

Lu and aqueous PSMA-617 and incubated at 95°C for 30 min. [68Ga]Ga-PSMA-617 was

prepared in a 1 mL mixture of 0.1 M HCl and aqueous PSMA-617 at a volume ratio of 1:1000
(unless otherwise stated) and incubated at 95°C for 30 min. For batch labeling of [43,44,47Sc]ScPSMA-617 and [177Lu]Lu-PSMA-617, a typical reaction labeled 1 nmol of PSMA-617 in 100 µL
of 0.5 M ammonium acetate (pH 4.7) containing 43Sc, 44Sc, and 47Sc or 177Lu. For batch labeling
of [68Ga]Ga-PSMA-617, a typical reaction labeled 10 nmol of PSMA-617 in 3 mL of 0.1 M HCl
containing 68Ga. These reactions were incubated at 95°C for 30 min.
Radiochemical Analyses
The radiochemical yields of [43,44,47Sc]Sc-PSMA-617, [177Lu]Lu-PSMA-617, and [68Ga]GaPSMA-617 were determined by radio-thin layer chromatography (radio-TLC) and radio-high131

pressure liquid chromatography (radio-HPLC). Radio-TLC was carried out using an Eckert &
Ziegler AR-2000 radio-TLC imaging scanner (Hopkinton, MA) and instant TLC paper developed
using a 1:1 ratio of 1.0 M ammonium acetate and methanol and 0.1 M citrate buffer (pH 4.0).
Radio-HPLC was carried out using an Agilent 1200 series HPLC (Lexington, MA) and an in-line
NaI(Tl) radiation detector. For all HPLC analyses, a Waters Xterra C18 reversed-phase column (5
μm, 150 × 4.6 mm, Milford, MA) was used with a binary mobile phase composed of (A) water
containing 0.1% trifluoracetic acid (TFA) and (B) acetonitrile containing 0.1% TFA with a
gradient of 95% A and 5% B to 20% A and 80% B over a period of 15 mins at a flow rate of 0.7
mL/min.
Cell Culture
Tumorigenic cell lines LNCaP (CRL-1704) and PC-3 (CRL-1435) were obtained from American
Type Culture Collection (Manassas, VA). LNCaP cells were maintained in RPMI 1640 containing
10% FBS (RPMI+) and grown at 37°C with 5% CO2. PC3 cells were maintained in DMEM
containing 10% FBS (DMEM+) and grown at 37°C with 5% CO2. LNCaP and PC3 cells were
cultured in poly-l-lysine coated cell culture flasks and passaged when approximately 70-90%
confluent.
EC50 Cell Titration
LNCaP cells were seeded in 24-well plates in 0.5 mL/well of RPMI+ at a concentration of 1 x 105
cells/well and incubated for 48 hours at 37°C in 5% CO2 atmosphere. The supernatant was
removed, and the cells were washed once with PBS before addition of 0.5 mL of RPMI+ containing
0.1 to 200 nM of [43,44,47Sc]Sc-PSMA-617. The sample size for each concentration was four. The
cells were incubated for 2 hours at 37° C, washed twice with 1 mL of ice-cold PBS, and lysed with
200 uL 0.2 N NaOH. The lysate was transferred into a 1.5 mL centrifuge tube and was measured
in a Perkin Elmer Wizard 2 gamma counter (Waltham, MA). The results were expressed as the
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percentage of added dose per milligram of protein (% AD/mg protein). A one site dose response
curve was used to fit the data and determine the EC50 using GraphPad Prism software (v. 7.0).
Specific Uptake
LNCaP and PC3 cells were seeded in 24-well plates in 0.5 mL/well of RPMI+ and DMEM+ and
incubated for 48 h at 37°C in 5% CO2 at a concentration of 1 x 105 cells/well and 0.5 x 105
cells/well, respectively. The supernatant was removed and the cells were washed once with warm
PBS before addition of 0.5 mL of RPMI+ (or DMEM+) containing up to 20 nM of each radioligand
or 0.5 mL of RPMI+ (or DMEM+) containing a mixture of up to 20 nM of each radioligand and
100 uM of 2-PMPA. The sample size for each blocking and non-blocking cell line was six. The
cells were incubated for 2 and 4 hours at 37° C in a 5% CO2 atmosphere, washed twice with 0.5
mL of ice-cold PBS, and lysed with 200 uL 0.2 M NaOH. The lysate was transferred into a 1.5
mL centrifuge tube. Each tube was measured in a gamma counter. To determine the percent of
initial activity per mg, the cell protein mass was determined with a Thermo Scientific Pierce BCA
protein assay kit (Waltham, MA) using Bovine Serum Albumin (BSA) as a standard. Samples
were measured in triplicate on a BioTek microplate reader (Winooski, VT). The results were
expressed as the percentage of the ratio of cell-associated activity to activity added to each well
per mg cell protein.
Cell Internalization
LNCaP cells were seeded in 24-well plates in 0.5 mL/well of RPMI+ at a concentration of 1 x 105
cells/well and incubated for 48 h at 37°C in 5% CO2 atmosphere. The supernatant was removed,
and the cells were washed once with warm PBS before addition of 0.5 mL of RPMI+ containing
up to 20 nM of each radioligand (10 MBq/nmol). The sample size for each blocking and nonblocking cell line was six. For 43,44,47Sc and 177Lu, the cells were incubated for 10 min, 30 min, 1
h, 2 h, 4 h, 8 h, 24 h, and 48 h at 37° C in a 5% CO2 atmosphere. For 68Ga, the cells were incubated
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for 10 min, 20 min, 30 min, 45 min, 1 h, and 2 h in a 5% CO2 atmosphere. At the same time points,
an additional set of reactions were carried out at 4° C (to prevent internalization) as a control.
Following incubation, the cells were washed once with 1 mL of ice-cold PBS. To determine the
receptor associated fraction of radioligand, the cells were washed with 0.2 mL of stripping buffer
(0.15 M NaCl in 0.1 M acetic acid at pH 3) which was transferred to 1.5 mL centrifuge tube and
centrifuged at 5000 rpm for 5 min to pelletize any LNCaP cells in the sample. The supernatant was
transferred to a new 1.5 mL centrifuge tube. To determine the internalized radioligand, the cells
were lysed with 200 uL 0.2 N NaOH. The lysate was transferred into the previous 1.5 mL
centrifuged tube containing any pelletized cells from the stripping buffer. Each tube (receptor
associated and internalized) was measured in a gamma counter. The results were expressed as
percentage of total internalized radioligand and percentage of total receptor associated radioligand.
High Purity Germanium Spectroscopy
Radioactive samples were characterized by gamma-ray spectroscopy using a Canberra GC2018
HPGe detector with a relative efficiency of 24.5% (Meriden, CT). Canberra Genie 2000 software
was used for data acquisition and analysis. Energy and efficiency calibrations were performed
using a mixed nuclide source in a sealed 1.5 mL microcentrifuge vial prepared by Eckert & Ziegler
Analytics (Atlanta, GA). Efficiency-calibration spectra with a minimum photopeak area of 2 x 105
counts were collected and fit to determine the detector efficiency. For all measurements, aliquots
of sample material were transferred into a 1.5 mL vial, diluted to 1 mL, and suspended in a fixed
acrylic holder at a distance of 5 or 25 mm from the HPGe detector. This geometry was maintained
for all sample measurements.
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5.3

Results

5.3.1

Production of Sc Radionuclides

The Nb target holder was used to irradiate 250 μm thick metallic Ti foils (ρ = 4.506 g/cm3) at
approximately 24 MeV for 3 hours. The average (n = 3 ± 1σ) mass of a Ti foil was (91.5 ± 0.3)
mg. Post-irradiation, the targets were allowed to sit and decay for 4 to 5 hours due to the coproduction of tens of GBqs of 47V (see Figure 2-11). The irradiated targets were digested at 250°C
in a closed PFA vessel containing 3 mL of 1.0 M ammonium bifluoride digested in 12.1 M HCl.
The complete digestion took 30 min and the digestant was dark-violet. The 43Sc, 44Sc, and 47Sc in
the digestant was separated from contaminants using BDGA resin. The recovery efficiency of the
Sc radionuclides was greater than 90%. After separation, the recovered 43Sc, 44Sc, and 47Sc was
concentrated by vacuum evaporation at 95°C. Typically, the digestion, purification, and
concentration of Sc radionuclides took 3-4 hr.

5.3.2

PSMA-617 Radiochemistry

[43,44,47Sc]Sc-PSMA-617

The purified 43Sc, 44Sc, and 47Sc digested in 0.5 M ammonium acetate (pH 4.7) was used to label
different quantities of aqueous PSMA-617 (0.5 to 20 nmol) in 50 µL of the ammonium acetate
buffer (Figure 5-1).
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Figure 5-1. The average (n = 3, 1σ) radiochemical yield of [43,44,47Sc]Sc-PSMA-617 as a
function of PSMA-617 mass
Figure 5-1 shows the average (n = 3, 1σ) radiochemical yield of [43,44,47Sc]Sc-PSMA-617
determined by radio-TLC under these conditions was greater than 99% at PSMA-617
concentrations as low as 20 uM (1 nmol). Different incubation times at 95°C were investigated by
labeling 20 uM PSMA-617 in 50 µL of 0.5 M ammonium acetate (pH 4.7) containing 43Sc, 44Sc,
and 47Sc for 10 min, 15 min, 20 min, 30 min, and 45 min (Figure 5-2).
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Figure 5-2. The average (n = 3, 1σ) radiochemical yield of [43,44,47Sc]Sc-PSMA-617 as a
function of incubation time
Figure 5-2 indicates the average (n = 3, 1σ) radiochemical yield of [43,44,47Sc]Sc-PSMA-617
determined by radio-TLC varied at incubation times less than 30 min (10 min, 15 min, and 20 min)
but was consistently greater than 99% when the reaction was incubated for at least 30 min. The
batch radiochemical synthesis of [43,44,47Sc]Sc-PSMA-617 for in vitro experiments typically
involved labeling 1 nmol of aqueous PSMA-617 (1 g/L) in 100 µL of 0.5 ammonium acetate (pH
4.7) containing purified 43Sc, 44Sc, and 47Sc.
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Figure 5-3. A representative chromatogram showing the radiochemical purity of [43,44,47Sc]ScPSMA-617 measured by radio-HPLC
Figure 5-3 indicates that the radiochemical purity of [43,44,47Sc]Sc-PSMA-617 measured by radioHPLC was greater than 99%.
[177Lu]Lu-PSMA-617
The high specific activity 177Lu digested in 0.05 M HCl (0.5 to 2 µL) was used to label different
quantities of aqueous PSMA-617 (0.5 to 20 nmol) at 95°C for 30 min in 50 µL of the ammonium
acetate buffer (Figure 5-4).
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Figure 5-4. The average (n = 3, 1σ) radiochemical yield of [177Lu]Lu-PSMA-617 as a function
of PSMA-617 mass
The specific activity for these reactions, depending upon ligand mass, varied from approximately
0.5 to 20 MBq/nmol and an average (n = 3, 1σ) radiochemical yield greater than 99% was observed
at a specific activity of 10 MBq/nmol using 1 nmol of PSMA-617. The batch radiochemical
synthesis of [177Lu]Lu-PSMA-617 for in vitro experiments typically involved labeling 2 nmol of
aqueous PSMA-617 (1 g/L) in 100 µL of 0.5 ammonium acetate (pH 4.7) containing 37 MBq of
177

Lu (18.5 MBq/nmol).
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Figure 5-5. A representative chromatogram showing the radiochemical purity of [43,44,47Sc]ScPSMA-617 measured by radio-HPLC
Figure 5-5 indicates that the radiochemical purity of [177Lu]Lu-PSMA-617 measured by radioHPLC was greater than 99%.
[68Ga]Ga-PSMA-617
The 68Ga obtained from a 68Ge/68Ga generator in 0.1 M HCl at a concentration of approximately
100 MBq/mL was used to label aqueous PSMA-617 (20 nmol) in 3 mL. The bulk volume required
an acid clean 5 mL glass v-vial and stir bar, and the generator eluate containing 68Ga was heated
to 95°C in a water bath prior to addition of the aqueous PSMA-617.
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Figure 5-6. The average (n = 4, 1σ) radiochemical purity of [68Ga]Ga-PSMA-617 measured by
radio-HPLC
Figure 5-6 indicates that the radiochemical purity of [68Ga]Ga-PSMA-617 was greater than 97%
(n = 3, 1σ) and the specific activity was approximately 10 MBq/nmol.

5.3.3

In Vitro Properties of [43,44,47Sc]Sc-PSMA-617

EC50 Cell Titration
Titration studies of [43,44,47Sc]Sc-PSMA-617 and LNCaP cells showed the average (n = 4, 1σ)
EC50 value of [43,44,47Sc]Sc-PSMA-617 on LNCaP cells was 2.0 ± 0.1 nM (Figure 5-7).
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Figure 5-7. Competitive binding of [43,44,47Sc]Sc-PSMA-617 on LNCaP cells
Specific Uptake
Cell uptake studies of [43,44,47Sc]Sc-PSMA-617, [177Lu]Lu-PSMA-617, and [68Ga]Ga-PSMA-617
were carried out on LNCaP (PSMA+) and PC3 (PSMA-) cells. Table 5-1 shows the average (n =
4, 1σ) cell uptake values of [43,44,47Sc]Sc-PSMA-617 and [177Lu]Lu-PSMA-617 at 2 hr and 4 hr,
and [68Ga]Ga-PSMA-617 at 1 hr and 2 hr.
Table 5-1. The average (n = 4, 1σ) cell uptake values of different PSMA-617 radioligands to
LNCaP cells.
Time

[43,44,47Sc]Sc-PSMA-617 [177Lu]Lu-PSMA-617

[PSMA-617]

2 nM

20 nM

2 hr (LNCaP)

(16.6 ± 1.6)%

(20.8 ± 1.1)%

(0.42 ± 0.03 )%

(1.02 ± 0.3)%

4 hr (LNCaP)

(21.9 ± 1.7)%

(27.0 ± 1.2 )%

4 hr (PC3)

(0.31 ± 0.03)%

(1.04 ± 0.11)%

2 hr (PC3)

*1

hr, †2 hr
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[68Ga]Ga-PSMA-617
20 nM
*

(10.8 ± 1.1)%

*

(0.7 ± 0.4)%

†

(15.5 ± 1.2)%

†

(2.2 ± 0.3)%

Specific uptake was confirmed by co-incubating each radioligand with 100 µM of the known
PSMA inhibitor 2-PMPA. Table 5-2 shows the average (n = 4, 1σ) cell uptake values of
[43,44,47Sc]Sc-PSMA-617 and [177Lu]Lu-PSMA-617 at 2 hr and 4 hr, and [68Ga]Ga-PSMA-617 at
1 hr and 2 hr (co-incubated with 2-PMPA).
Table 5-2. The average (n = 4, 1σ) cell uptake values of different PSMA-617 radioligands to
LNCaP cells.
Time

[43,44,47Sc]Sc-PSMA-617 [177Lu]Lu-PSMA-617

[68Ga]Ga-PSMA-617

[PSMA-617]

2 nM

20 nM

2 hr (LNCaP)

(0.3 ± 0.1)%

(1.3 ± 0.4)%

*

(0.33 ± 0.04)%

(1.0 ± 0.2)%

*

(0.3 ± 0.1)%

(1.2 ± 0.3)%

†

(1.5 ± 0.2)%

(0.27 ± 0.03)%

(0.9 ± 0.1)%

†

(1.6 ± 0.3)%

2 hr (PC3)
4 hr (LNCaP)
4 hr (PC3)
*1

20 nM
(0.5 ± 0.1)%
(0.3 ± 0.2)%

hr, †2 hr

The cell uptake values for each radioligand under both conditions (no-inhibitor and inhibitor) at
both time points were than plotted to show the specific uptake of PSMA-617 labeled with Sc
radionuclides, 68Ga, and 177Lu (Figure 5-8).

Figure 5-8. The average cell uptake of [43,44,47Sc]Sc-PSMA-617, [177Lu]Lu-PSMA-617, and
[68Ga]Ga-PSMA-617 to LNCaP cells
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Cell Internalization
The internalization of receptor-bound [43,44,47Sc]Sc-PSMA-617 and [177Lu]Lu-PSMA-617 into
LNCaP cells was investigated. Table 5-3 shows the percent of membrane-bound [43,44,47Sc]ScPSMA-617 and internalized [43,44,47Sc]Sc-PSMA-617 on LNCaP cells at time points out to 24 hr.
Table 5-3. The average (n = 6, 1σ) percent of membrane-bound or internalized [43,44,47Sc]ScPSMA-617 and [177Lu]Lu-PSMA-617
[43,44,47Sc]Sc-PSMA-617

[177Lu]Lu-PSMA-617

Times (h)

Internalized

Receptor-bound

Internalized

Receptor-bound

0.167

(37.3 ± 2.8)%

(62.7 ± 2.8)%

(66.8 ± 3.2)%

(33.2 ± 3.2)%

0.5

(82.0 ± 2.1)%

(18.0 ± 2.1)%

(80.5 ± 0.8)%

(19.5 ± 0.8)%

0.8

(79.1 ± 1.7)%

(20.9 ± 1.7)%

(85.5 ± 2.0)%

(14.5 ± 2.0)%

1.0

(82.4 ± 2.1)%

(17.6 ± 0.7)%

(85.5 ± 2.0)%

(14.5 ± 2.0)%

2.0

(91.5 ± 1.3)%

(9.0 ± 1.3)%

(91.2 ± 0.4)%

(8.8 ± 0.4)%

4.0

(94.8 ± 0.7)%

(5.2 ± 0.7)%

(92.8 ± 1.0)%

(7.2 ± 1.0)%

8.0

(95.2 ± 1.7)%

(4.8 ± 1.7)%

(93.2 ± 0.8)%

(6.8 ± 0.8)%

24.0

(95.6 ± 1.6)%

(4.4 ± 1.6)%

(95.0 ± 2.1)%

(5.0 ± 2.1)%

Figure 5-9 shows the fraction of membrane-bound [43,44,47Sc]Sc-PSMA-617 and [177Lu]LuPSMA-617 internalized into LNCaP cells as a function of time.
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Figure 5-9. The rate of internalized (◊) PSMA-617 labeled with Sc radionuclides and 177Lu

5.4

Discussion

PSMA-617 was labeled with

43

Sc,

44

Sc, and

47

Sc produced via proton irradiation of Ti target

material using methods detailed in Chapter 4. The [43,44,47Sc]Sc-PSMA-617 yield, based on
radiolabeling conditions employed in this work, was greater than 99% measured by radio-TLC
and radio-HPLC at ligand masses as low as 1 nmol in 50 µL of 0.5 M ammonium acetate (pH 4.7).
Similar to other published methods to label DOTA-functionalized compounds, all synthesis
reactions were carried out at 95°C. The effect of time on radiochemical yield was studied and
reproducible yields greater than 99% were obtained at incubation times greater than or equal to 30
min. At shorter reaction times, 10 min, 15 min, and 20 min, reaction yields less than 90% were
obtained. PSMA-617 was labeled with 177Lu using similar conditions by dissolving 177Lu-chloride
solution (0.05 M HCl) in 0.5 M ammonium acetate (pH 4.7). The [177Lu]Lu-PSMA-617 yield was
greater than 99% measured by radio-TLC and radio-HPLC at ligand masses low as 1 nmol in 50
µL of 0.5 M ammonium acetate (pH 4.7).
These reaction conditions were than adjusted to carry out batch labeling of larger quantities of
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43

Sc, 44Sc, and 47Sc, and 177Lu. The reaction volume and PSMA ligand mass was increased from

50 µL to 100 µL and 1 nmol to 2 nmol, respectively. At these conditions, the radiochemical yield
of [43,44,47Sc]Sc-PSMA-617 and [177Lu]Lu-PSMA-617 was greater than 99%. A specific activity
for [43,44,47Sc]Sc-PSMA-617 was not measured due to the mixture of Sc radionuclides with
different half-lives; however, the [177Lu]Lu-PSMA-617 specific activity was between 10-20
MBq/nmol for all reactions. The [177Lu]Lu-PSMA-617 specific activity was similar to or greater
than specific activities (approximately 10 MBq/nmol) reported using similar labeling conditions.
PSMA-617 was labeled with 68Ga by adding 25 nmol of aqueous PSMA-617 to 3 mL of 0.1 M
HCl containing 259-296 MBq

68

Ga obtained by fractionating the eluate from a

68

Ge/68Ga

generator. The [68Ga]Ga-PSMA-617 yield and specific activity were greater than 98% and
approximately 10 MBq/nmol, respectively. For each radioligand, the radiochemical purity,
confirmed by radio-HPLC, was greater than 99% and each trivalent radiometal was chelated by
DOTA at acidic pH. Unlike the mixture of 43Sc, 44Sc, and 47Sc and 177Lu, which labeled PSMA617 in low molarity ammonium acetate buffer with an approximate pH of 4.7, 68Ga was directly
labeled in 0.1 M HCl; however, previously published methods exist to concentrate

68

Ga onto a

strong cation exchange cartridge followed by collection of purified 68Ga in a small solvent volume.
Once concentrated, purified 68Ga could be used to label PSMA-617 under conditions identical to
the 43Sc, 44Sc, and 47Sc, and 177Lu in 0.5 M ammonium acetate (pH 4.7).
The affinity of PSMA-617 for PSMA receptors on LNCaP cells was studied to determine the
ligand concentration that minimized self-competition for available receptor sites. The experimental
EC50 for [43,44,47Sc]Sc-PSMA-617 associated with LNCaP cells was 2.0 ± 0.1 nM. This ligand
concentration was used to investigate the specific targeting of PSMA receptors on LNCaP cells by
[43,44,47Sc]Sc-PSMA-617. For these preliminary studies, a PSMA-617 concentration of 20 nM was
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used to show specific targeting of PSMA receptors on LNCaP cells by [177Lu]Lu-PSMA-617 and
[68Ga]Ga-PSMA-617 and the known PSMA inhibitor 2-PMPA was used to block PSMA receptors
and confirm specific targeting by PSMA-617. At 2 hr and 4 hr, after addition of [43,44,47Sc]ScPSMA-617 to LNCaP cells, the cell uptake was (16.6 ± 1.6)% and (21.9 ± 1.7)%, respectively.
The [43,44,47Sc]Sc-PSMA-617 cell uptake values were similar to the experimental uptake of
[177Lu]Lu-PSMA-617 and [68Ga]Ga-PSMA-617 (Table 5-1 and Table 5-2) to LNCaP cells at 2 hr
and 4 hr (1 hr and 2 hr for PSMA-617 labeled with

68

Ga). These results confirmed that

[43,44,47Sc]Sc-PSMA-617 was selectively associated with PSMA receptors on LNCaP cells.
Moreover, [43,44,47Sc]Sc-PSMA-617 had cell uptake values similar to those of [177Lu]Lu-PSMA617. However, increased non-specific uptake was observed in PSMA-617 labeled with 177Lu and
68

Ga (20 nM); thus, the cell uptake values of both compounds should be measured at 2 nM.
The rates at which [43,44,47Sc]Sc-PSMA-617 and [177Lu]Lu-PSMA-617 was internalized into

LNCaP cells were studied at different time points up to 24 hours. These data may predict the in
vivo characteristics of PSMA-617. Figure 5-9 showed that within 4 h the fraction of receptorbound [43,44,47Sc]Sc-PSMA-617 and [177Lu]Lu-PSMA-617 internalized into LNCaP cells was
approximately 95% and 93%, respectively. At 24 hr, the fraction internalized into LNCaP cells
was (95.6 ± 1.6)% and (95.0 ± 2.1)%. This in vitro model using LNCaP cells indicated successful
targeting of PSMA receptors with [43,44,47Sc]Sc-PSMA-617, [177Lu]Lu-PSMA-617, and [68Ga]GaPSMA-617.
The cell uptake studies indicated that a significant fraction of PSMA-617 labeled with Sc
radionuclides will target PSMA receptors. After receptor mediated uptake to LNCaP cells, up to
93% of PSMA-617 was then transported into the cell within 4 h. These preliminary data may
predict in vivo characteristics. The findings suggest that in vivo imaging may be carried out at
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time-points up to 24 hr and the continuation of the work described herein will include studies that
investigate the in vivo properties of PSMA-617 labeled with the matched-pair radionuclides of Sc.

5.5

Conclusion

Scandium-43, 44Sc, and 47Sc were produced using natTiO2 and the in vitro properties of PSMA-617
labeled with these radionuclides was investigated. The radiochemical yield of [43,44,47Sc]ScPSMA-617 was greater than 99%. The in vitro properties of [43,44,47Sc]Sc-PSMA-617 were
investigated and the radioligand was used to show cell associated uptake to LNCaP prostate cancer
cells. These data were directly compared to the cell associated uptake of [177Lu]Lu-PSMA-617
and [68Ga]Ga-PSMA-617 in the same prostate cancer cell line. These findings showed that PSMA617 labeled with Sc radionuclides has similar in vitro properties to PSMA-617 labeled with 177Lu
and

68

Ga. Future work should repeat these studies using radioisotopically pure

(produced using enriched

46,50

43

Sc and

47

Sc

TiO2) to assess the in vivo biodistribution of [43Sc]Sc-PSMA-617

and [47Sc]Sc-PSMA-617. Additionally, the in vitro and in vivo therapeutic efficacy of [47Sc]ScPSMA-617 should be investigated along with the in vivo imaging of LNCaP tumors in tumorbearing animal models. Overall, these results in this work show that cyclotron produced 43Sc and
47

Sc obtained using enriched TiO2 targets can be used in future preclinical investigations to study

the in vitro and in vivo characteristics of PSMA-617 labeled with the matched-pair theranostic
radionuclides 43Sc and 47Sc.
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Chapter 6: Conclusion
6.1

Research Summary

This work investigated the production, purification, and potential medical applications of

43

Sc,

44

Sc, and 47Sc. These radionuclides of Sc have properties that can be used for molecular imaging

and targeted radionuclide therapy (TRNT) in nuclear medicine. The diagnostic radionuclides, 43Sc
and 44Sc (see Figure 2-2 and Figure 2-3), undergo positron decay and emit annihilation photons
that can be detected by a positron emission tomography (PET) scanner. The third radionuclide,
47

Sc (see Figure 2-7), undergoes beta decay and emits a beta particle which deposits ionizing

radiation in tissue that can kill cells. When these radionuclides are incorporated into a molecular
compound that targets a disease, they can be used as a pair (i.e., 43Sc/47Sc and 44Sc/47Sc). In this
case, 43Sc or 44Sc can be used for diagnostic imaging followed by 47Sc for TRNT. These matchedpair Sc radionuclides enable a theranostic strategy that uses a diagnostic compound to identify and
profile disease and a therapeutic compound to provide patient specific treatment. An example of
this personalized approach in nuclear medicine is the FDA-approved compound DOTATE labeled
with

68

Ga and

177

Lu. The diagnostic, [68Ga]Ga-DOTATATE is clinically used to detect

neuroendocrine tumors (NETs), monitor NETs progression, and profile patient response to
targeted radionuclide therapy (TRNT) with [177Lu]Lu-DOTATATE. The aim of this work was to
identify and develop methods to produce these matched-pair radionuclides of Sc for pre-clinical
investigation of novel theranostic agents at the University of Alabama at Birmingham (UAB).
Unlike many FDA-approved radiopharmaceuticals that use radionuclides of different elements
(e.g. 68Ga and 177Lu) that require different instruments and infrastructure (e.g. particle accelerator
and a nuclear reactor) for their production, the production of these Sc radionuclides via proton
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induced nuclear reactions on enriched Ti in the oxide form (i.e. TiO2) would represent a robust
and unified production route that uses similar target material and target processing methods to
supply 43Sc, 44Sc, and 47Sc. The findings detailed in Chapter 3 and Chapter 4, taken together, show
that methods developed in this work can provide useful quantities of these Sc radionuclides for
pre-clinical studies. However, these methods will require further optimization and development of
additional steps to reduce the time required to process irradiated targets and isolate 43Sc, 44Sc, and
47

Sc in a small volume suitable for direct radiolabeling of theranostic compounds. As optimization

continues at UAB, the processes detailed in this work will allow onsite production of 43Sc/47Sc or
44

Sc/47Sc. A reliable source of these radionuclides will enable future studies that investigate the

diagnostic efficacy of 43Sc and 44Sc and the therapeutic efficacy of 47Sc. The key findings detailed
in this work are summarized below.
Scandium-43, 44Sc, and 47Sc Production
Naturally isotopic Ti foils were irradiated to produce a mixture of Sc radionuclides (including coproduced

46

Sc and

48

Sc). These targets were digested, and the experimental yield of each

radioactive product (43Sc,

44

Sc, and

47

Sc) was measured using gamma-ray spectroscopy. The

experimental end-of-bombardment (EOB) yield was compared to theoretical EOB yields for each
Sc radionuclide. The theoretical EOB yields were calculated using published cross-section data or
theoretical cross-section data obtained from the TENDL database.1 The experimental and
theoretical EOB yields agreed, and the modeling methodology was used to predict EOB yields for
43

Sc,

47

44

Sc, and

47

Sc using enriched

Sc and tens of GBqs of

43

Sc and

46,47,48,50
44

TiO2. These data showed that hundreds of MBqs of

Sc could be produced using 24 MeV protons at low beam

currents (20-30 µA) to irradiate enriched Ti targets (46Ti, 47Ti, 48Ti, and 50Ti).
Target Processing
Naturally isotopic TiO2 (natTiO2) was used to develop methods that enabled the irradiation of Ti in
152

its oxide form at beam currents up to 30 µA to produce 43Sc, 44Sc, and 47Sc. Firstly, durable Ta
target holders were developed and tested that held pressed natTiO2 targets. The Ta target holder was
designed to enclose the powdery oxide target material to prevent radiological contamination during
irradiation and transfer of irradiated targets. These Ta target holders were durable under all
conditions tested and tolerated heat buildup in the

nat

TiO2 due to its poor thermal conductivity.

Further, no radiological contamination was detected after EOB or during transfer of the irradiated
targets. Next, a method to digest natTiO2, known for its resistance to attack by acids, was developed
since previously reported methods required hours to achieve total digestion of this target material.
The digestion method developed in this work used inexpensive and widely available PFA vials
(threaded with caps) that contained natTiO2 in a mixture of ammonium bifluoride digested in 12.1
M HCl (see Figure 4-2). The vial was tightly capped and heated at 255°C for approximately 60
min to completely digest natTiO2. Last, a method to chemically separate and purify 43Sc, 44Sc, and
47

Sc from co-produced radionuclides (like 47V and 48V, see Figure 2-11 and Figure 2-12) using

the cation exchange resin BDGA was developed. The average (n = 3, 1σ) percent recovery of Sc
using the separation method was greater than 90%. Typically, the separation (see Figure 4-3),
included a vacuum evaporation step to concentrate the Sc radionuclides collected in 10 mL of the
eluate. The complete digestion and processing of an irradiated natTiO2 target and concentration of
the 43Sc, 44Sc, and 47Sc in the separation column eluate required approximately 4 h.
Target Material Recycling
Non-radioactive TiO2 was used to develop an alkali-based precipitation of Ti collected in 20 mL
of 7.0 M HCl. This method was needed to recycle costly enriched TiO2 after reach irradiation to
produce 43Sc, 44Sc, and 47Sc using enriched TiO2 targets and represents an important element of
this work. It was developed by preparing multiple pressed TiO2 targets and digesting them using
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the digestion method. For each sample, the digestant was diluted to 20 mL with HCl to reach a
final concentration of 7.0 M HCl. These samples were then diluted to 500 mL with water and the
alkali precipitation was carried out by dropwise addition of ammonia solution (see Section 4.3.5).
The Ti precipitate that formed at pH 8 was isolated by gravity filtration onto ashless filter paper
and thoroughly rinsed with ethanol to dry each sample. The dried precipitate was combusted and
the initial mass and final mass of target material (measured via mass balance) were compared to
determine the percent recovery of TiO2. The average (n = 4, 1σ) recovery of TiO2 was equal to or
greater than 100% and these data suggest added mass in the precipitate may be due to contributions
from incomplete ashing. Additionally, the concentration of Ti in the final filtrate was measured
via ICP-MS and no Ti was detected (n = 4, 1σ). This result indicated that Ti in the filtrate was
below the ICP-MS detection limit (approximately 100 µg/L). Therefore, the Ti mass would be less
than 50 µg which shows that the alkali precipitation is effective.
Preliminary Study of the In Vitro Properties of [43,44,47Sc]Sc-PSMA-617
Radionuclides of Sc were produced using natTi targets irradiated with 24 MeV and 30 µA of beam
current. Irradiated targets were processed using the methods described in this work. The 43Sc, 44Sc,
and 47Sc collected in the final purified Sc product was used to investigate conditions to radiolabel
PSMA-617. A radiochemical yield of greater than 99% (measured via radio-TLC) was obtained
for [43,44,47Sc]Sc-PSMA-617 when aqueous PSMA-617 was labeled with Sc radionuclides in 0.5
M ammonium acetate (pH 4.7). Additionally, a radiochemical purity greater than 99% was
confirmed by radio-HPLC. PSMA-617 was also labeled with 68Ga and 177Lu (see Section 5.3.2).
The PSMA-617 labeled with Sc radionuclides, 68Ga, and 177Lu was then used in cell uptake studies
to show specific uptake to LNCaP cells for each radioligand. At 4 h (2 h for

68

Ga) after each

radioligand was added to LNCaP cells, the amount of added radioactivity associated with LNCaP
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cells for [43,44,47Sc]Sc-PSMA-617, [177Lu]Lu-PSMA-617, and [68Ga]Ga-PSMA-617 was (21.9 ±
1.7)%, (27.0 ± 1.2 )%, and (15.5 ± 1.2)%, respectively. These results indicated that Sc
radionuclides produced and purified using the methods in this work can be used to label PSMA617 to investigate its in vitro properties. Furthermore, results from the proof-of-concept cell uptake
study (see Section 5.3.3) showed agreement in cell uptake values between PSMA labeled with Sc
radionuclides produced in this work, 68Ga obtained from a 68Ge/68Ga generator, and 177Lu produced
in a nuclear reactor.

6.2

Future Work

Continuation of studies detailed in this work should focus on two areas: (1) optimization of the
existing methods and development of methods to improve the production and chemical separation
of 43Sc, 44Sc, and 47Sc, and (2) development of a 44Ti/44Sc generator.
The methods described herein demonstrated that relevant quantities of Sc radionuclides were
prepared for pre-clinical evaluations of [43,44,47Sc]Sc-PSMA-617; however, optimization of
processing steps (e.g. target digestion) should be investigated to improve overall yields.
Suggestions for optimization (or improvement) to the existing methods are detailed below.
TiO2 Target Material
The Ta-backed targets developed in this work allowed irradiation of natTiO2 with 24 MeV protons
at beam currents up to 40 µA; however, the temperature increase in the target material (due to heat
deposition and poor thermal conductivity of the target material) resulted in a distinct change in
color (white to gray-blue) of the pressed

nat

TiO2 targets between 30 and 40 µA. Upon digestion

(see Figure 4-2), these targets (n = 2) did not fully dissolve, and it was hypothesized that the
nat

TiO2 may have undergone a phase change from the anatase to rutile form (600 to 700°C) during

bombardment. For pressed natTiO2 targets that were irradiated at beam currents at or under 25 µA,
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this effect was either not observed or the change in color was faint. To better understand the
downstream process effects caused by the color change, multiple pressed TiO2 targets should be
subject to different temperatures using a furnace and processed using the methods in this work.
The TiO2 targets should be divided into at least three groups (control, low-heat, and high-heat).
The low-heat and high-heat groups should be heated at 400°C and 1000°C, and the control group
kept at room temperature. Each target should then be digested, purified as if it had been
bombarded, and the Ti target material recovered via alkali precipitation (see Section 4.3.5).
Measurements of the initial and recovered masses of Ti can be performed using a mass balance,
and the mass of Ti measured in the digestant can be determined using an inductively-coupled mass
spectrometer (ICP-MS). The phase and morphology of the

nat

TiO2 can be characterized before

digestion and after combustion by surface analysis with a scanning electron microscope (SEM).
The proposed experiment may be helpful in determining how to modify the digestion method to
fully dissolve targets irradiated at beam currents greater than 25 µA. An emphasis on irradiating
Ti targets at higher beam currents would increase the EOB yields of

43

Sc,

44

Sc, and

47

Sc.

Additionally, the current targetry could be modified to decrease the amount of energy (i.e., heat)
deposited in the

nat

TiO2 by modifying the target holder design to promote better thermal

conductivity throughout the target-target holder, improving the cooling efficiency of the target
station, or by irradiating targets using the 20° target station to spread the beam over a greater
region.
Target Digestion
The method to digest TiO2 developed herein uses a mixture of ammonium bifluoride and HCl and
requires approximately 60 min for full dissolution. During development of the dissolution method,
the dependence of the mass of ammonium bifluoride and dissolution temperature, on digestion
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times was investigated but the sample size was limited (n = 1 or n = 2). Additional experiments to
assess the effects that the volume of 12.1 M HCl have on dissolution may be beneficial. Results
from these studies were reproducible and showed that TiO2 could be dissolved in two 30 min steps
(see Section 4.3.2). In some cases, total digestion was observed after heating for 15 to 20 min per
step; however, faster dissolution times caused more variable results. Therefore, the impact of each
parameter should be systematically investigated to ascertain whether total digestion of TiO2 can
be reliably performed in less than 60 min. Optimizing the time required to digest irradiated targets
will reduce the amount of 43Sc, 44Sc, or 47Sc that is lost to decay during target processing. These
optimization studies could be carried out with non-radioactive TiO2. The degree of dissolution can
be determined by measuring the ratio of dissolved Ti in the digestant (via ICP-MS analysis) to the
initial Ti mass (via mass balance measurement).
BDGA Separation
The Ti/Sc separation method using BDGA resin used 10 mL of 0.1 M HCl to collect the purified
Sc material. The volume of the Sc fraction was reduced by heating the fraction at 95°C under
vacuum to remove the eluant. The remaining radioactive Sc was reconstituted in 0.5 M ammonium
acetate (pH 4.7). While this approach was successful, the steps required to evaporate the eluate
could be a potential source of chemical contamination.
Two studies could be conducted to investigate improvements in the separation process. First,
data from a preliminary investigation of the disassociation constant (e.g., kD) for the adsorption of
Sc onto BDGA resin at different concentrations of HNO3 showed that Sc ions have a similar
affinity for the resin at 7 M and 2 M HNO3. Based on this observation, the HNO3 fraction (collected
just prior to the Sc fraction) was adjusted to 2 M HNO3. This modification reduced the
concentration of HNO3 on the column and allowed collection of the purified Sc material in 5 mL
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of 0.1 M HCl (instead of 10 mL). This modification will need further validation to prove that 43Sc,
44

Sc, and

47

Sc purified using the modified method is of comparable or better quality to that

prepared using the original method (i.e., 7 M HNO3 followed by 10 mL of 0.1 M HCl). Secondly,
an alternative concentration method could be explored. The purified Sc fraction in 0.1 M HCl
could be absorbed onto a cartridge containing strong cation exchange resin cartridge and eluted by
a small volume (hundreds of µLs) of suitable solvent or buffer. This approach could be pursued
by identifying multiple chromatographic resin cartridges that have affinity for Sc in 0.1 M HCl.
Each cartridge could be systematically investigated using different eluents buffered to an
approximate pH of 4.0 to 4.7. These experiments could be carried out with radiotracer quantities
of

43

Sc,

44

Sc, and

47

Sc produced using

nat

Ti targets, and the fate of radioactive Sc could be

quantitatively determined via gamma-ray spectroscopy using an HPGe detector.
Ti Recycling
The Ti/Sc separation method using BDGA resin used 10 mL of 0.1 M HCl to collect the purified
Sc material. The volume of the Sc fraction was reduced by heating the fraction at 95°C under
vacuum to remove the eluant. The remaining radioactive Sc was reconstituted in 0.5 M ammonium
acetate (pH 4.7). While this approach was successful, the steps required to evaporate the eluate
could be a potential source of chemical contamination.
Two studies could be conducted to investigate improvements in the separation process. First,
data from a preliminary investigation of the disassociation constant (e.g., kD) for the adsorption of
Sc onto BDGA resin at different concentrations of HNO3 showed that Sc ions have a similar
affinity for the resin at 7 M and 2 M HNO3. Based on this observation, the HNO3 fraction (collected
just prior to the Sc fraction) was adjusted to 2 M HNO3. This modification reduced the
concentration of HNO3 on the column and allowed collection of the purified Sc material in 5 mL
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of 0.1 M HCl (instead of 10 mL). This modification will need further validation to prove that 43Sc,
44

Sc, and

47

Sc purified using the modified method is of comparable or better quality to that

prepared using the original method (i.e., 7 M HNO3 followed by 10 mL of 0.1 M HCl). Secondly,
an alternative concentration method could be explored. The purified Sc fraction in 0.1 M HCl
could be absorbed onto a cartridge containing strong cation exchange resin cartridge and eluted by
a small volume (hundreds of µLs) of suitable solvent or buffer. This approach could be pursued
by identifying multiple chromatographic resin cartridges that have affinity for Sc in 0.1 M HCl.
Each cartridge could be systematically investigated using different eluents buffered to an
approximate pH of 4.0 to 4.7. These experiments could be carried out with radiotracer quantities
43

of

Sc,

44

Sc, and

47

Sc produced using

nat

Ti targets, and the fate of radioactive Sc could be

quantitatively determined via gamma-ray spectroscopy using an HPGe detector.
Ti-44 Production
Unlike 43Sc and 47Sc, which can be produced in their ground states via proton bombardment on
enriched Ti nuclei,

44

Sc produced via proton-induced reactions on

47

Ti will always result in a

mixture of 44mSc and 44Sc (see Figure 2-3 and Figure 2-4). Due to the relatively long half-life of
44m

Sc (in comparison to 44Sc), using a mixture of these two radionuclides would complicate patient

dosimetry and adoption into a clinical setting. Therefore, the more desirable method for producing
44

Sc is indirectly via the

45

Sc(p,2n)44Ti 

44

Sc reaction pathway. The decay of the

44

Ti parent

offers an alternative production route where 44Sc can be obtained from a 44Ti/44Sc generator as the
radiopure ground state isomer.
Previous investigations have shown that a

44

Ti/44Sc generator capable of supplying

approximately 185 MBq of 44Sc can be produced.2-5 The generator operated by adsorbing 44Ti in
the 4+ oxidation state onto an AG 1-X8 strong anion exchange resin. After allowed the adsorbed
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44

Ti to reach secular equilibrium with the 44Sc daughter, approximately 185 MBq was eluted in 20

mL of 0.005 M H2C2O4 in 0.07 M HCl (aq) at a flow rate of 1 mL/min. The reported generator
design resulted in 97% recovery of 44Sc with 44Ti breakthrough of (5 x 10-5)%. An additional step
to concentrate and further purify the 44Sc eluate was also reported.5 The 44Sc generator fraction
was loaded onto 53 mg of AG 50W-X8, a strong cation exchange resin, and the resin was rinsed
with water, dried with air, and 44Sc was collected in 3 mL of 0.25 M ammonium acetate (pH 4.0).
A flow rate of 1 mL/min was used for each step in this process. The quantity of 44Ti in the final
recovered product was further reduced by a factor of 10 with a final 44Ti breakthrough of less than
(2 x 10-7)%.
In the future, a well-designed commercial

44

Ti/44Sc generator capable of supplying clinical

quantities of 44Sc could potentially be used for several years due to the approximately 60 y halflife of

44

Ti. Furthermore, a

44

Ti/44Sc generator that incorporated 700-800 MBq of

44

Ti could

provide as much as 370 MBq of 44Sc every 4 hrs, which indicates multiple patient doses could be
eluted per day to support clinical imaging with

44

Sc-labeled compounds. However, multiple

technical challenges exist that must be addressed in order to make these generators widely
available. Firstly, few published studies exist that investigate alternative

44

Ti/44Sc generator

designs to the Rosch generator described earlier; thus, a method to produce and supply 44Ti isolated
from irradiated 45Sc targets should be developed.3, 4 Next, the magnitude of the cross section for
the 45Sc(p,2n)44Ti reaction is small (tens of mb) between proton energies of 13 and 24 MeV, and
due to the half-life of 44Ti, production of useful quantities of 44Ti may require months of dedicated
beam time at high beam currents. The resource cost (i.e., beam time), can be reduced by developing
targetry that allows bombardment of 45Sc at currents of up to 300 µA and by utilizing the dualbeam capability of the TR-24 proton accelerator at UAB. Bombardment at high currents and the
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ability to continuously irradiate Sc targets concurrent with routine production of clinical
radionuclides presents opportunities for production of significant quantities of 44Ti that could be
used to investigate alternative generator designs and supply isomerically pure 44Sc at UAB and at
other institutions. Lastly, long-lived

44

Ti represents a hazard with respect to radiological

contamination. All experiments that involve cyclotron produced 44Ti should be carefully planned
and executed to avoid contamination of equipment and surfaces.
As part of this initial work, calculations were performed to predict the theoretical

44

Ti

production rate using 24 MeV protons at different beam currents up to 200 µA. The predicted
production rate was approximately 0.05 MBq/µA⸱d and a thick Sc target was assumed for this
model. At this rate, 185 MBq of 44Ti could be produced in 39 days using 24 MeV protons and a
beam current of 100 µA. Further, small quantities (up to 10 MBq) of 44Ti could be produced within
a reasonable timeframe of 2 to 3 months using beam currents of up to 60 to 80 µA and a thick Sc
target periodically.
To produce quantities greater than 10 MBq it is more feasible to design targetry capable of
withstanding much higher beam currents. Therefore, an additional focus of this preliminary work
was target design. To bombard thick Sc targets at high-current, two target holders were proposed
that could be used to bombard targets at a grazing angle of either 7° or 20°. The target stations can
mount each Sc target-target holder assemblies and were described in Chapter 2 (see Section 2.4.5).
By using a slant angle, the profile of the beam elongates and adopts an oval-shape. Thus, the slant
angle targets will have an increased region where the beam deposits energy in the target material
and can therefore be cooled more efficiently, increasing the amount of beam current the target can
withstand. The angle also means that thick target yields can be achieved with a thin layer of 45Sc
target material. The production of

44

Ti at UAB using a slant angle could be developed in two
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phases.
Phase one would involve developing production of 44Ti using the 20° target station. This station
mounts an oval shaped Ta target holder with a maximum thickness of 3 mm. For 44Ti production,
a 650 µm thick 45Sc foil could be heat-pressed into an oval shaped inset centered on a Ta base
(Figure 6-1).

Figure 6-1. The 20° target holder and a carton illustrating the heat-pressing of a Sc foil
Figure 6-1 demonstrates the straightforward design of this proposed target holder. For this design,
the 45Sc foil can be machined to achieve a tight-fit with the oval shaped inset. The 45Sc foil can be
mounted into the Ta target holder by heating the Ta base with an acetylene torch to induce thermal
expansion. At this point, the 45Sc foil can be pressed into oval shaped inset by using a machined
punch with geometry similar to the oval shaped inset. The feasibility of this proposed method was
confirmed by heat-pressing a circular 250 µm 45Sc foil into a circular bore (∅ = 260 to 265 µm)
centered in a 2 mm thick Ta disc (∅ = 24 mm). This proof-of-concept experiment validated the
machinability of Sc metal, and the target-target holder assembly is currently being used to produce
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small quantities (less than 10 MBq) of 44Ti using 24 MeV protons and beam currents up to 35 µA.
These results suggest that the proposed design for the 20° target holder could be implemented for
production of greater quantities of 44Ti using 60 to 80 µA of beam current. The predicted EOB
yield of 44Ti as a function of time are shown in Figure 6-2 for those conditions (24 MeV protons
at 60 and 80 µA of beam current).

Figure 6-2. The predicted EOB yield of 44Ti as a function of time at 60 and 80 µA of beam
current.
Phase two would involve developing production of 44Ti using the 7° target station. This station
was specifically designed for high-current irradiations of solid targets at beam currents up to 300
µA (Figure 6-3).
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Figure 6-3. A drawing of the stock high-current solid target geometry.. Not shown in this
cartoon is a top plate that is secured by six fasteners. It can be removed and imaged to profile the
proton beam strike. Alternatively, target material can be electrodeposited onto the top plate for
radionuclide production.
Figure 6-3 shows a stock Al target holder, designed for the 7° station, which has a specific
geometry that must be maintained to achieve a vacuum seal (via a gasket seal that sits upon the
gasket base) in the beam line and proper cooling of the target material (via the cooling ports which
circulate water across the bottom of the top plate) during irradiation. The proposed modifications
to allow bombardment of thick Sc targets are shown in Figure 6-4.
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Figure 6-4. A drawing of the unmodified target holder base and a modified top plate. The top
plate contains an oval-shaped inset for the 45Sc foil
The modifications shown in Figure 6-4 include an oval-shaped inset and a thinner top plate, which
was adjusted to reduce the material thickness between the 45Sc foil and the water cooling fins. The
reduction in thickness is expected to promote better conductive cooling of the Sc target during
irradiation. Moreover, the top plate material was changed to Nb, which was selected as a
machinable corrosion-resistant alternative to Ta. Similarly, to preparing the target for the 20° target
station, a 45Sc foil can be machined to achieve a tight-fit with the oval-shaped inset in the Nb top
plate and heat-pressed into the target holder. After development and preparation of a proof-ofconcept target-target holder assembly, the target should be tested by increasing beam current
incrementally over a series of irradiations to determine the maximum tolerated beam current. The
proposed design for the 7° 45Sc target holder may tolerate 24 MeV protons at beam currents up to
300 µA. At these conditions, Figure 6-5 shows the predicted EOB yield of 44Ti as a function of
time.
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Figure 6-5. The predicted EOB yield of 44Ti as a function of time at 100, 200, and 300 µA of
beam current.
Figure 6-5 indicates that 370 MBq of 44Ti could be produced at 300 µA in approximately 20 days
of beam time.
To prepare 45Sc targets using the target holder designs proposed in this work, the 45Sc foil will
need to be mechanically fixed into the oval-shaped inset, and the irradiated targets must be digested
while fixed in the target holder. Therefore, an apparatus for achieving dissolution of the 45Sc foil
was designed.

Figure 6-6. The proposed design for a perfluoroalkoxy alkane (PFA) collar
Figure 6-6 illustrates the proposed design for a corrosion resistant addition to the target holder
that creates a reservoir. An irradiated Sc target could be digested while mounted into the target
holder. that allows acid digestion of a Sc target. The PFA reservoir could be secured with cclamps. This apparatus will allow testing of different mineral acids to determine the best method
to digest irradiated Sc targets. The proposed designs may enable 44Ti production at beam currents
between 60 and 300 µA for continued investigation of 44Ti/44Sc generator designs.
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6.3

Conclusion

This work investigated the production and supply of

43

Sc,

44

Sc, and

47

Sc using proton-induced

reactions on titanium nuclei. Compounds can be labeled with these Sc radionuclides to allow a
theranostic approach using the diagnostic and therapeutic matched-pairs, 43Sc/47Sc and 44Sc/47Sc.
The theranostic approach uses a diagnostic compound to identify and profile disease followed by
treatment with a therapeutic compound. Unlike other common diagnostic and therapeutic pairs
(e.g.,

68

Ga and

177

Lu), a compound labeled with a Sc matched-pair could be prepared using

identical methods and would be expected to have an identical pharmacokinetic profile. This work
showed, based on the use of naturally isotopic TiO2, that enriched TiO2 targets (i.e., 46Ti, 47Ti, 48Ti,
and 50Ti) could be used to produce small quantities of radiopure 43Sc, 44Sc, and 47Sc.
Production of these Sc radionuclides was carried out at 24 MeV and at beam currents up to 40
µA using naturally isotopic Ti foil and Ti in the oxide form (TiO2). Irradiated targets were digested
in less than 60 min. and separated from non-radioactive target material via cation-exchange
chromatography using BDGA resin. The eluate containing 43Sc, 44Sc, and 47Sc was evaporated and
reconstituted in 0.5 M ammonium acetate (pH 4.7). The Sc radionuclides were then used to label
PSMA-617, a compound that targets PSMA receptors on prostate cancer cells. The in vitro
properties of [43,44,47Sc]Sc-PSMA-617 were then evaluated and compared to the in vitro properties
of PSMA-617 labeled with 68Ga and 177Lu. These studies were carried out using the LNCaP cell
line (PSMA+) and PC3 cell line (PSMA-). Cell uptake studies that used the known PSMA inhibitor
2-PMPA were carried out using [43,44,47Sc]Sc-PSMA-617, [177Lu]Lu-PSMA-617, and [68Ga]GaPSMA-617, and these studies showed specific uptake of each radioligand to LNCaP cells.
Collectively, the results in this work show that small quantities of these matched-pair Sc
radionuclides can be produced at UAB. The methods developed herein can be further optimized
167

and used to supply radiopure 43Sc, 44Sc, and 47Sc using a combination of enriched Ti target material
and a future

44

Ti/44Sc generator. A reliable supply of each radionuclide will support future

preclinical investigations of different compounds that enable theranostic strategies in nuclear
medicine.
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